Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
≤,27738089,minimal inhibitory concentration (MIC),"Plasma cefazolin and ceftazidime exceeded the minimal inhibitory concentration (MIC) for susceptible organisms (≤ 8 mg/L) within 2 hours (cefazolin 28.5 ± 8.0 and ceftazidime 12.5 ± 3.4 mg/L), peak at 10 hours (51.1 ± 14.1 and 23.0 ± 5.2 mg/L) and sustained well above the MIC at 24 hours (42.0 ± 9.6 and 17.1 ± 3.1 mg/L).",Short-Dwell Cycling Intraperitoneal Cefazolin Plus Ceftazidime in Peritoneal Dialysis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27738089/),[mg] / [l],8,1508,DB01327,Cefazolin
,27738089,minimal inhibitory concentration (MIC),"Plasma cefazolin and ceftazidime exceeded the minimal inhibitory concentration (MIC) for susceptible organisms (≤ 8 mg/L) within 2 hours (cefazolin 28.5 ± 8.0 and ceftazidime 12.5 ± 3.4 mg/L), peak at 10 hours (51.1 ± 14.1 and 23.0 ± 5.2 mg/L) and sustained well above the MIC at 24 hours (42.0 ± 9.6 and 17.1 ± 3.1 mg/L).",Short-Dwell Cycling Intraperitoneal Cefazolin Plus Ceftazidime in Peritoneal Dialysis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27738089/),[mg] / [l],51.1,1509,DB01327,Cefazolin
,27738089,minimal inhibitory concentration (MIC),"Plasma cefazolin and ceftazidime exceeded the minimal inhibitory concentration (MIC) for susceptible organisms (≤ 8 mg/L) within 2 hours (cefazolin 28.5 ± 8.0 and ceftazidime 12.5 ± 3.4 mg/L), peak at 10 hours (51.1 ± 14.1 and 23.0 ± 5.2 mg/L) and sustained well above the MIC at 24 hours (42.0 ± 9.6 and 17.1 ± 3.1 mg/L).",Short-Dwell Cycling Intraperitoneal Cefazolin Plus Ceftazidime in Peritoneal Dialysis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27738089/),[mg] / [l],23.0,1510,DB01327,Cefazolin
,27738089,MIC,"Plasma cefazolin and ceftazidime exceeded the minimal inhibitory concentration (MIC) for susceptible organisms (≤ 8 mg/L) within 2 hours (cefazolin 28.5 ± 8.0 and ceftazidime 12.5 ± 3.4 mg/L), peak at 10 hours (51.1 ± 14.1 and 23.0 ± 5.2 mg/L) and sustained well above the MIC at 24 hours (42.0 ± 9.6 and 17.1 ± 3.1 mg/L).",Short-Dwell Cycling Intraperitoneal Cefazolin Plus Ceftazidime in Peritoneal Dialysis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27738089/),[mg] / [l],42.0,1511,DB01327,Cefazolin
,27738089,MIC,"Plasma cefazolin and ceftazidime exceeded the minimal inhibitory concentration (MIC) for susceptible organisms (≤ 8 mg/L) within 2 hours (cefazolin 28.5 ± 8.0 and ceftazidime 12.5 ± 3.4 mg/L), peak at 10 hours (51.1 ± 14.1 and 23.0 ± 5.2 mg/L) and sustained well above the MIC at 24 hours (42.0 ± 9.6 and 17.1 ± 3.1 mg/L).",Short-Dwell Cycling Intraperitoneal Cefazolin Plus Ceftazidime in Peritoneal Dialysis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27738089/),[mg] / [l],17.1,1512,DB01327,Cefazolin
,6456890,peak serum level,"After intramuscular injection of 2 g of cefoperazone, the mean peak serum level was 111 microgram/ml at 1.5 hours.",Pharmacokinetics of cefoperazone: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6456890/),[μg] / [ml],111,2631,DB01327,Cefazolin
,6456890,apparent volume of distribution,The apparent volume of distribution was 10 to 13L.,Pharmacokinetics of cefoperazone: a review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6456890/),l,10 to 13,2632,DB01327,Cefazolin
,6456890,half-life,The half-life of the drug varied from 1.6 to 2.4 hours; serum clearance was between 75 and 96 ml/min.,Pharmacokinetics of cefoperazone: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6456890/),h,1.6 to 2.4,2633,DB01327,Cefazolin
,6456890,serum clearance,The half-life of the drug varied from 1.6 to 2.4 hours; serum clearance was between 75 and 96 ml/min.,Pharmacokinetics of cefoperazone: a review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6456890/),[ml] / [min],75 and 96,2634,DB01327,Cefazolin
,6456890,Renal clearance,Renal clearance ranged from 14 to 25 ml/min.,Pharmacokinetics of cefoperazone: a review. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6456890/),[ml] / [min],14 to 25,2635,DB01327,Cefazolin
,6456890,peak bile concentrations,Biliary levels of cefoperazone were many-fold higher than serum levels; peak bile concentrations from 675 to 6000 microgram/ml were obtained.,Pharmacokinetics of cefoperazone: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6456890/),[μg] / [ml],675 to 6000,2636,DB01327,Cefazolin
,1580051,peak serum concentrations,"The mean peak serum concentrations (+/- SEM) were 387.79 +/- 27.56 micrograms/mL, 521.71 +/- 28.00 micrograms/mL, and 542.20 +/- 30.91 micrograms/mL, respectively.",Pharmacokinetic disposition of cefazolin in serum and tissue during canine total hip replacement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1580051/),[μg] / [ml],387.79,5361,DB01327,Cefazolin
,1580051,peak serum concentrations,"The mean peak serum concentrations (+/- SEM) were 387.79 +/- 27.56 micrograms/mL, 521.71 +/- 28.00 micrograms/mL, and 542.20 +/- 30.91 micrograms/mL, respectively.",Pharmacokinetic disposition of cefazolin in serum and tissue during canine total hip replacement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1580051/),[μg] / [ml],521.71,5362,DB01327,Cefazolin
,1580051,peak serum concentrations,"The mean peak serum concentrations (+/- SEM) were 387.79 +/- 27.56 micrograms/mL, 521.71 +/- 28.00 micrograms/mL, and 542.20 +/- 30.91 micrograms/mL, respectively.",Pharmacokinetic disposition of cefazolin in serum and tissue during canine total hip replacement. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1580051/),[μg] / [ml],542.20,5363,DB01327,Cefazolin
less,1580051,minimum inhibitory concentration,The minimum inhibitory concentration of cefazolin for 90% of the common contaminants (MIC90) in this clinic is less than or equal to 2 micrograms/mL or per gram of tissue.,Pharmacokinetic disposition of cefazolin in serum and tissue during canine total hip replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1580051/),[μg] / [ml],2,5364,DB01327,Cefazolin
less,1580051,MIC90,The minimum inhibitory concentration of cefazolin for 90% of the common contaminants (MIC90) in this clinic is less than or equal to 2 micrograms/mL or per gram of tissue.,Pharmacokinetic disposition of cefazolin in serum and tissue during canine total hip replacement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1580051/),[μg] / [ml],2,5365,DB01327,Cefazolin
,1580051,lowest,"Serum concentrations never fell below 15 times the MIC90 (lowest trough, 35.93 micrograms/mL), and the lowest tissue concentration (6.57 micrograms/mL in cancellous bone from the acetabulum) was still more than 3 times the MIC90.",Pharmacokinetic disposition of cefazolin in serum and tissue during canine total hip replacement. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1580051/),[μg] / [ml],35.93,5366,DB01327,Cefazolin
,1580051,trough,"Serum concentrations never fell below 15 times the MIC90 (lowest trough, 35.93 micrograms/mL), and the lowest tissue concentration (6.57 micrograms/mL in cancellous bone from the acetabulum) was still more than 3 times the MIC90.",Pharmacokinetic disposition of cefazolin in serum and tissue during canine total hip replacement. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1580051/),[μg] / [ml],35.93,5367,DB01327,Cefazolin
>,20570290,time above minimal inhibitory concentration,"For 9 of 10 (90%) patients in the continuous infusion group, the targeted pharmacokinetic and pharmacodynamic goal (time above minimal inhibitory concentration >90%) was achieved, whereas the goal was met for only 3 of 10 (30%) in the intermittent group (P < .05).",Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570290/),%,90,7910,DB01327,Cefazolin
,7571387,MIC90,"Cephalothin and cefazolin were similarly very effective in vitro against staphylococcal isolates, with an MIC90 of 0.12 microgram/mL and 0.25 microgram/mL, respectively.",Cephalothin and cefazolin in vitro antibacterial activity and pharmacokinetics in dogs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571387/),[μg] / [ml],0.12,9805,DB01327,Cefazolin
,7571387,MIC90,"Cephalothin and cefazolin were similarly very effective in vitro against staphylococcal isolates, with an MIC90 of 0.12 microgram/mL and 0.25 microgram/mL, respectively.",Cephalothin and cefazolin in vitro antibacterial activity and pharmacokinetics in dogs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571387/),[μg] / [ml],0.25,9806,DB01327,Cefazolin
,7571387,MIC90,"In contrast, cefazolin was more effective than cephalothin against E coli isolates; the cefazolin MIC90 for E coli was 16 micrograms/mL and for cephalothin 64 micrograms/mL.",Cephalothin and cefazolin in vitro antibacterial activity and pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571387/),[μg] / [ml],16,9807,DB01327,Cefazolin
,7571387,MIC90,"In contrast, cefazolin was more effective than cephalothin against E coli isolates; the cefazolin MIC90 for E coli was 16 micrograms/mL and for cephalothin 64 micrograms/mL.",Cephalothin and cefazolin in vitro antibacterial activity and pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7571387/),[μg] / [ml],64,9808,DB01327,Cefazolin
,26103528,area under the plasma concentration vs time curve,The median area under the plasma concentration vs time curve was significantly greater in the 3 g group than in the 2 g group (27204 μg/mL per minute vs 14058 μg/mL per minute; P = .001).,Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26103528/),[μg] / [min·ml],27204,10128,DB01327,Cefazolin
,26103528,area under the plasma concentration vs time curve,The median area under the plasma concentration vs time curve was significantly greater in the 3 g group than in the 2 g group (27204 μg/mL per minute vs 14058 μg/mL per minute; P = .001).,Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26103528/),[μg] / [min·ml],14058,10129,DB01327,Cefazolin
,10201343,absorption rate constant,The cefazolin absorption rate constant from dialysate to serum was 0.21+/-0.1/hr (absorption half-life 3.5+/-0.8 hr).,Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),1/[h],0.21,11071,DB01327,Cefazolin
,10201343,absorption half-life,The cefazolin absorption rate constant from dialysate to serum was 0.21+/-0.1/hr (absorption half-life 3.5+/-0.8 hr).,Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),h,3.5,11072,DB01327,Cefazolin
,10201343,serum concentrations,"The mean serum concentrations reached at 24 and 48 hours were 52.4+/-3.7 mg/L and 30.3+/-5.9 mg/L, respectively.",Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),[mg] / [l],52.4,11073,DB01327,Cefazolin
,10201343,serum concentrations,"The mean serum concentrations reached at 24 and 48 hours were 52.4+/-3.7 mg/L and 30.3+/-5.9 mg/L, respectively.",Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),[mg] / [l],30.3,11074,DB01327,Cefazolin
,10201343,concentrations,"The mean dialysate cefazolin concentrations reached at 24 and 48 hours were 15.1+/-3.4 mg/L and 7.9+/-1.4 mg/L, respectively.",Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),[mg] / [l],15.1,11075,DB01327,Cefazolin
,10201343,concentrations,"The mean dialysate cefazolin concentrations reached at 24 and 48 hours were 15.1+/-3.4 mg/L and 7.9+/-1.4 mg/L, respectively.",Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),[mg] / [l],7.9,11076,DB01327,Cefazolin
,10201343,serum elimination rate constant,The cefazolin serum elimination rate constant was 0.02+/-0.01/hr (elimination half-life 31.5+/-8.8 hr).,Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),1/[h],0.02,11077,DB01327,Cefazolin
,10201343,elimination half-life,The cefazolin serum elimination rate constant was 0.02+/-0.01/hr (elimination half-life 31.5+/-8.8 hr).,Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),h,31.5,11078,DB01327,Cefazolin
,10201343,total cefazolin body clearance,The total cefazolin body clearance was 3.4+/-0.6 ml/min.,Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),[ml] / [min],3.4,11079,DB01327,Cefazolin
,10201343,renal clearance,In the 3 nonanuric patients the mean renal clearance of cefazolin was 0.6+/-0.4 ml/min.,Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),[ml] / [min],0.6,11080,DB01327,Cefazolin
,10201343,peritoneal clearance,The peritoneal clearance of cefazolin was 1.0+/-0.3 mL/min.,Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),[ml] / [min],1.0,11081,DB01327,Cefazolin
,10201343,systemic volume of distribution,The systemic volume of distribution of cefazolin was 0.2+/-0.05 L/kg.,Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201343/),[l] / [kg],0.2,11082,DB01327,Cefazolin
below,7699834,Minimum inhibitory concentration (MIC),"Minimum inhibitory concentration (MIC) values of SY5555 were below 0.39 micrograms/ml for all strains examined, thus the drug showed an excellent activities against benzylpenicillin (PCG)-resistant strains as well.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),[μg] / [ml],0.39,13719,DB01327,Cefazolin
,7699834,Peak plasma levels,"Peak plasma levels were reached at 1 hour after administration in the two groups, and they were 0.93 +/- 0.25 and 2.44 +/- 1.25 micrograms/ml, respectively.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),[μg] / [ml],0.93,13720,DB01327,Cefazolin
,7699834,Peak plasma levels,"Peak plasma levels were reached at 1 hour after administration in the two groups, and they were 0.93 +/- 0.25 and 2.44 +/- 1.25 micrograms/ml, respectively.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),[μg] / [ml],2.44,13721,DB01327,Cefazolin
,7699834,half-lives,"The plasma levels then decreased gradually with half-lives of 1.95 +/- 1.09 and 0.72 +/- 0.21 hours, respectively.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),h,1.95,13722,DB01327,Cefazolin
,7699834,half-lives,"The plasma levels then decreased gradually with half-lives of 1.95 +/- 1.09 and 0.72 +/- 0.21 hours, respectively.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),h,0.72,13723,DB01327,Cefazolin
,7699834,Urinary recovery rates,"Urinary recovery rates in the first 6 hours after administration were 1.98 +/- 0.82 and 4.13 +/- 1.40%, respectively.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),%,1.98,13724,DB01327,Cefazolin
,7699834,Urinary recovery rates,"Urinary recovery rates in the first 6 hours after administration were 1.98 +/- 0.82 and 4.13 +/- 1.40%, respectively.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),%,4.13,13725,DB01327,Cefazolin
,7699834,peak,"In 3 cases (6-9 years) treated with the drug at a dose of 10 mg/kg after meal, a peak of 1.58 +/- 0.81 micrograms/ml appeared 1 hour after administration with a half-life of 1.08 +/- 0.30 hours and with the urinary recovery rate in the first 6 hours after administration of 3.46 +/- 1.03%.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),[μg] / [ml],1.58,13726,DB01327,Cefazolin
,7699834,half-life,"In 3 cases (6-9 years) treated with the drug at a dose of 10 mg/kg after meal, a peak of 1.58 +/- 0.81 micrograms/ml appeared 1 hour after administration with a half-life of 1.08 +/- 0.30 hours and with the urinary recovery rate in the first 6 hours after administration of 3.46 +/- 1.03%.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),h,1.08,13727,DB01327,Cefazolin
,7699834,urinary recovery rate,"In 3 cases (6-9 years) treated with the drug at a dose of 10 mg/kg after meal, a peak of 1.58 +/- 0.81 micrograms/ml appeared 1 hour after administration with a half-life of 1.08 +/- 0.30 hours and with the urinary recovery rate in the first 6 hours after administration of 3.46 +/- 1.03%.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),%,3.46,13728,DB01327,Cefazolin
,7699834,peak plasma level,"When the drug at a dose of 10 mg/kg was administered to 2 infants (2-3 months post partum) after meal, a peak plasma level of 3.74 micrograms/ml appeared 1 hour after administration with a half-life of 1.19 hours.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),[μg] / [ml],3.74,13729,DB01327,Cefazolin
,7699834,half-life,"When the drug at a dose of 10 mg/kg was administered to 2 infants (2-3 months post partum) after meal, a peak plasma level of 3.74 micrograms/ml appeared 1 hour after administration with a half-life of 1.19 hours.",[Laboratory and clinical studies on SY5555 in pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699834/),h,1.19,13730,DB01327,Cefazolin
,30410768,Plasma concentrations,Plasma concentrations of unbound cefazolin exceeded the assumed target thresholds of 2 μg mL-1 in all samples and of 8 μg mL-1 in all but one of 199 samples.,Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30410768/),[μg] / [ml],2,15203,DB01327,Cefazolin
,30410768,Plasma concentrations,Plasma concentrations of unbound cefazolin exceeded the assumed target thresholds of 2 μg mL-1 in all samples and of 8 μg mL-1 in all but one of 199 samples.,Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30410768/),[μg] / [ml],8,15204,DB01327,Cefazolin
,6979591,maximal concentrations,"Levels in the aqueous humor rose more slowly; the respective maximal concentrations of methicillin, oxacillin, and cefazolin were 72, 1,180, and 111 micrograms/ml.","Ocular penetration of subconjunctival oxacillin, methicillin, and cefazolin in rabbits with staphylococcal endophthalmitis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6979591/),[μg] / [ml],72,15881,DB01327,Cefazolin
,6979591,maximal concentrations,"Levels in the aqueous humor rose more slowly; the respective maximal concentrations of methicillin, oxacillin, and cefazolin were 72, 1,180, and 111 micrograms/ml.","Ocular penetration of subconjunctival oxacillin, methicillin, and cefazolin in rabbits with staphylococcal endophthalmitis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6979591/),[μg] / [ml],1,15882,DB01327,Cefazolin
,6979591,maximal concentrations,"Levels in the aqueous humor rose more slowly; the respective maximal concentrations of methicillin, oxacillin, and cefazolin were 72, 1,180, and 111 micrograms/ml.","Ocular penetration of subconjunctival oxacillin, methicillin, and cefazolin in rabbits with staphylococcal endophthalmitis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6979591/),[μg] / [ml],180,15883,DB01327,Cefazolin
,6979591,maximal concentrations,"Levels in the aqueous humor rose more slowly; the respective maximal concentrations of methicillin, oxacillin, and cefazolin were 72, 1,180, and 111 micrograms/ml.","Ocular penetration of subconjunctival oxacillin, methicillin, and cefazolin in rabbits with staphylococcal endophthalmitis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6979591/),[μg] / [ml],111,15884,DB01327,Cefazolin
,32360445,clearance,"The PK was ascribed to a one-compartment model, where typical clearance and volume of distribution estimations were 1.4 L/h and 3.3 L respectively.",Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32360445/),[l] / [h],1.4,16467,DB01327,Cefazolin
,32360445,volume of distribution,"The PK was ascribed to a one-compartment model, where typical clearance and volume of distribution estimations were 1.4 L/h and 3.3 L respectively.",Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32360445/),l,3.3,16468,DB01327,Cefazolin
,352636,serum half-life,"In 9 patients the mean serum half-life was 2.7 h, whereas in 4 patients--all over 60 years of age--it was significantly above this value.","Absorption, distribution and elimination of cefazolin in patients with normal renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/352636/),h,2.7,17146,DB01327,Cefazolin
,6945066,plasma half-lives,"Mean plasma levels of YM09330 at 30 min after intravenous administration of 20 mg/kg were 5.5 micrograms/ml for mice, 17 micrograms/ml for rats, 24 micrograms/ml for rabbits, 42 micrograms/ml for dogs, and 76 micrograms/ml for monkeys; plasma half-lives were 13.0, 15.9, 30.5, 55.5, and 75.6 min, respectively.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),min,13.0,17221,DB01327,Cefazolin
,6945066,plasma half-lives,"Mean plasma levels of YM09330 at 30 min after intravenous administration of 20 mg/kg were 5.5 micrograms/ml for mice, 17 micrograms/ml for rats, 24 micrograms/ml for rabbits, 42 micrograms/ml for dogs, and 76 micrograms/ml for monkeys; plasma half-lives were 13.0, 15.9, 30.5, 55.5, and 75.6 min, respectively.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),min,15.9,17222,DB01327,Cefazolin
,6945066,plasma half-lives,"Mean plasma levels of YM09330 at 30 min after intravenous administration of 20 mg/kg were 5.5 micrograms/ml for mice, 17 micrograms/ml for rats, 24 micrograms/ml for rabbits, 42 micrograms/ml for dogs, and 76 micrograms/ml for monkeys; plasma half-lives were 13.0, 15.9, 30.5, 55.5, and 75.6 min, respectively.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),min,30.5,17223,DB01327,Cefazolin
,6945066,plasma half-lives,"Mean plasma levels of YM09330 at 30 min after intravenous administration of 20 mg/kg were 5.5 micrograms/ml for mice, 17 micrograms/ml for rats, 24 micrograms/ml for rabbits, 42 micrograms/ml for dogs, and 76 micrograms/ml for monkeys; plasma half-lives were 13.0, 15.9, 30.5, 55.5, and 75.6 min, respectively.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),min,55.5,17224,DB01327,Cefazolin
,6945066,plasma half-lives,"Mean plasma levels of YM09330 at 30 min after intravenous administration of 20 mg/kg were 5.5 micrograms/ml for mice, 17 micrograms/ml for rats, 24 micrograms/ml for rabbits, 42 micrograms/ml for dogs, and 76 micrograms/ml for monkeys; plasma half-lives were 13.0, 15.9, 30.5, 55.5, and 75.6 min, respectively.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),min,75.6,17225,DB01327,Cefazolin
,6945066,Urinary excretion,"Urinary excretion of YM09330 within 48 h of intravenous administrations was 67% of the dose in mice, 52% in rats, 74% in rabbits, 53% in dogs, and 60% in monkeys.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,67,17226,DB01327,Cefazolin
,6945066,Urinary excretion,"Urinary excretion of YM09330 within 48 h of intravenous administrations was 67% of the dose in mice, 52% in rats, 74% in rabbits, 53% in dogs, and 60% in monkeys.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,52,17227,DB01327,Cefazolin
,6945066,Urinary excretion,"Urinary excretion of YM09330 within 48 h of intravenous administrations was 67% of the dose in mice, 52% in rats, 74% in rabbits, 53% in dogs, and 60% in monkeys.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,74,17228,DB01327,Cefazolin
,6945066,Urinary excretion,"Urinary excretion of YM09330 within 48 h of intravenous administrations was 67% of the dose in mice, 52% in rats, 74% in rabbits, 53% in dogs, and 60% in monkeys.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,53,17229,DB01327,Cefazolin
,6945066,Urinary excretion,"Urinary excretion of YM09330 within 48 h of intravenous administrations was 67% of the dose in mice, 52% in rats, 74% in rabbits, 53% in dogs, and 60% in monkeys.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,60,17230,DB01327,Cefazolin
,6945066,Serum protein binding,"Serum protein binding of YM09330 was 30% of rats, 51% for rabbits, 39% for dogs, 87% for monkeys, and 91% for humans.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,30,17231,DB01327,Cefazolin
,6945066,Serum protein binding,"Serum protein binding of YM09330 was 30% of rats, 51% for rabbits, 39% for dogs, 87% for monkeys, and 91% for humans.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,51,17232,DB01327,Cefazolin
,6945066,Serum protein binding,"Serum protein binding of YM09330 was 30% of rats, 51% for rabbits, 39% for dogs, 87% for monkeys, and 91% for humans.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,39,17233,DB01327,Cefazolin
,6945066,Serum protein binding,"Serum protein binding of YM09330 was 30% of rats, 51% for rabbits, 39% for dogs, 87% for monkeys, and 91% for humans.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,87,17234,DB01327,Cefazolin
,6945066,Serum protein binding,"Serum protein binding of YM09330 was 30% of rats, 51% for rabbits, 39% for dogs, 87% for monkeys, and 91% for humans.","Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6945066/),%,91,17235,DB01327,Cefazolin
,18955527,instrument,The instrument run time was approximately 3.50 min per sample.,Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18955527/),[min] / [sample],3.50,18628,DB01327,Cefazolin
,18955527,run time,The instrument run time was approximately 3.50 min per sample.,Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18955527/),[min] / [sample],3.50,18629,DB01327,Cefazolin
,6459759,peak serum concentration,Cefazolin was found to produce a significantly greater peak serum concentration (105 +/- 14 versus 81 +/- 21 microgram/ml) and a significantly greater area under the curve (218 +/- 42 versus 157 +/- 19 . microgram h/ml).,Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6459759/),[μg] / [ml],105,18653,DB01327,Cefazolin
,6459759,peak serum concentration,Cefazolin was found to produce a significantly greater peak serum concentration (105 +/- 14 versus 81 +/- 21 microgram/ml) and a significantly greater area under the curve (218 +/- 42 versus 157 +/- 19 . microgram h/ml).,Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6459759/),[μg] / [ml],81,18654,DB01327,Cefazolin
,6459759,area under the curve,Cefazolin was found to produce a significantly greater peak serum concentration (105 +/- 14 versus 81 +/- 21 microgram/ml) and a significantly greater area under the curve (218 +/- 42 versus 157 +/- 19 . microgram h/ml).,Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6459759/),[h·μg] / [ml],218,18655,DB01327,Cefazolin
,6459759,area under the curve,Cefazolin was found to produce a significantly greater peak serum concentration (105 +/- 14 versus 81 +/- 21 microgram/ml) and a significantly greater area under the curve (218 +/- 42 versus 157 +/- 19 . microgram h/ml).,Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6459759/),[h·μg] / [ml],157,18656,DB01327,Cefazolin
,6459759,terminal half-life,"The terminal half-life of moxalactam was not significantly longer than for cefazolin (2.2 +/- 0.6 versus 2.0 +/- 0.6 h, respectively).",Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6459759/),h,2.2,18657,DB01327,Cefazolin
,6459759,terminal half-life,"The terminal half-life of moxalactam was not significantly longer than for cefazolin (2.2 +/- 0.6 versus 2.0 +/- 0.6 h, respectively).",Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6459759/),h,2.0,18658,DB01327,Cefazolin
,24733461,distribution volume,The distribution volume of cefazolin was 9.44 liters.,Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733461/),l,9.44,19092,DB01327,Cefazolin
,24733461,clearance,"[corrected] The values for pre- and postdelivery clearance were 7.18 and 4.12 liters/h, respectively.",Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733461/),[l] / [h],7.18,19093,DB01327,Cefazolin
,24733461,clearance,"[corrected] The values for pre- and postdelivery clearance were 7.18 and 4.12 liters/h, respectively.",Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24733461/),[l] / [h],4.12,19094,DB01327,Cefazolin
,833342,peak serum levels,"The mean peak serum levels obtained after 30 minutes were 25.2, 17.2, and 62.3 mug/ml, respectively, for cefazaflur, cephalothin, and cefazolin.",Pharmacokinetic study of cefazaflur compared to cephalothin and cefazolin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833342/),[μg] / [ml],25.2,19640,DB01327,Cefazolin
,833342,peak serum levels,"The mean peak serum levels obtained after 30 minutes were 25.2, 17.2, and 62.3 mug/ml, respectively, for cefazaflur, cephalothin, and cefazolin.",Pharmacokinetic study of cefazaflur compared to cephalothin and cefazolin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833342/),[μg] / [ml],17.2,19641,DB01327,Cefazolin
,833342,peak serum levels,"The mean peak serum levels obtained after 30 minutes were 25.2, 17.2, and 62.3 mug/ml, respectively, for cefazaflur, cephalothin, and cefazolin.",Pharmacokinetic study of cefazaflur compared to cephalothin and cefazolin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833342/),[μg] / [ml],62.3,19642,DB01327,Cefazolin
,833342,percentage of total administered dose recovered,"The percentage of total administered dose recovered in urine in a microbiologically active form for the 0-24-hour collection was, respectively, 92.7, 59.2, and 94.9 per cent with cefazaflur, cephalothin, and cefazolin, the largest part being excreted during the first 6 hours.",Pharmacokinetic study of cefazaflur compared to cephalothin and cefazolin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833342/),%,92.7,19643,DB01327,Cefazolin
,833342,percentage of total administered dose recovered,"The percentage of total administered dose recovered in urine in a microbiologically active form for the 0-24-hour collection was, respectively, 92.7, 59.2, and 94.9 per cent with cefazaflur, cephalothin, and cefazolin, the largest part being excreted during the first 6 hours.",Pharmacokinetic study of cefazaflur compared to cephalothin and cefazolin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833342/),%,59.2,19644,DB01327,Cefazolin
,833342,percentage of total administered dose recovered,"The percentage of total administered dose recovered in urine in a microbiologically active form for the 0-24-hour collection was, respectively, 92.7, 59.2, and 94.9 per cent with cefazaflur, cephalothin, and cefazolin, the largest part being excreted during the first 6 hours.",Pharmacokinetic study of cefazaflur compared to cephalothin and cefazolin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833342/),%,94.9,19645,DB01327,Cefazolin
,1854250,Bioavailability,Bioavailability after topical administration was 95%.,Pharmacokinetics of cefazolin applied topically to the surgical wound. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854250/),%,95,21950,DB01327,Cefazolin
,1854250,time above the su,"In wound fluid, the mean time above the susceptibility break point minimum inhibitory concentration after topical administration of cefazolin was 5.76 hours compared with the estimated time above the minimum inhibitory concentration of 2.55 hours after intravenous administration.",Pharmacokinetics of cefazolin applied topically to the surgical wound. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854250/),h,5.76,21951,DB01327,Cefazolin
,1854250,time above the minimum inhibitory concentration,"In wound fluid, the mean time above the susceptibility break point minimum inhibitory concentration after topical administration of cefazolin was 5.76 hours compared with the estimated time above the minimum inhibitory concentration of 2.55 hours after intravenous administration.",Pharmacokinetics of cefazolin applied topically to the surgical wound. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1854250/),h,2.55,21952,DB01327,Cefazolin
,25817353,half-life of the beta phase,The half-life of the beta phase of cefazolin is 2.46 h and that of piperacillin is 0.7 h according to their manufacturers.,Serum antimicrobial concentrations for surgical antimicrobial prophylaxis in radical nephrectomy and radical prostatectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25817353/),h,2.46,22167,DB01327,Cefazolin
,25817353,half-life of the beta phase,The half-life of the beta phase of cefazolin is 2.46 h and that of piperacillin is 0.7 h according to their manufacturers.,Serum antimicrobial concentrations for surgical antimicrobial prophylaxis in radical nephrectomy and radical prostatectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25817353/),h,0.7,22168,DB01327,Cefazolin
,25817353,serum concentration,The average serum concentration of cefazolin at 30 min was 144 μg/mL in the prostatectomy group and 175 μg/mL in the nephrectomy group.,Serum antimicrobial concentrations for surgical antimicrobial prophylaxis in radical nephrectomy and radical prostatectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25817353/),[μg] / [ml],144,22169,DB01327,Cefazolin
,25817353,serum concentration,The average serum concentration of cefazolin at 30 min was 144 μg/mL in the prostatectomy group and 175 μg/mL in the nephrectomy group.,Serum antimicrobial concentrations for surgical antimicrobial prophylaxis in radical nephrectomy and radical prostatectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25817353/),[μg] / [ml],175,22170,DB01327,Cefazolin
,27609113,Cp(0),"Results Initial plasma concentrations were high (Cp(0), 134.80 ± 40.54 µg/ml), with fast and moderately wide distribution (distribution half-life [t½(d)] 0.16 ± 0.15 h; volume of distribution at steady state [V(d[ss])] 0.29 ± 0.10 l/kg) and rapid elimination (body clearance [ClB], 0.21 ± 0.06 l/h/kg; elimination half-life [t½], 1.18 ± 0.27 h; mean residence time 1.42 ± 0.36 h).",Cefazolin pharmacokinetics in cats under surgical conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),[μg] / [ml],134.80,22661,DB01327,Cefazolin
,27609113,distribution half-life [t½(d)],"Results Initial plasma concentrations were high (Cp(0), 134.80 ± 40.54 µg/ml), with fast and moderately wide distribution (distribution half-life [t½(d)] 0.16 ± 0.15 h; volume of distribution at steady state [V(d[ss])] 0.29 ± 0.10 l/kg) and rapid elimination (body clearance [ClB], 0.21 ± 0.06 l/h/kg; elimination half-life [t½], 1.18 ± 0.27 h; mean residence time 1.42 ± 0.36 h).",Cefazolin pharmacokinetics in cats under surgical conditions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),h,0.16,22662,DB01327,Cefazolin
,27609113,volume of distribution at steady state [V(d[ss]),"Results Initial plasma concentrations were high (Cp(0), 134.80 ± 40.54 µg/ml), with fast and moderately wide distribution (distribution half-life [t½(d)] 0.16 ± 0.15 h; volume of distribution at steady state [V(d[ss])] 0.29 ± 0.10 l/kg) and rapid elimination (body clearance [ClB], 0.21 ± 0.06 l/h/kg; elimination half-life [t½], 1.18 ± 0.27 h; mean residence time 1.42 ± 0.36 h).",Cefazolin pharmacokinetics in cats under surgical conditions. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),[l] / [kg],0.29,22663,DB01327,Cefazolin
,27609113,body clearance [ClB],"Results Initial plasma concentrations were high (Cp(0), 134.80 ± 40.54 µg/ml), with fast and moderately wide distribution (distribution half-life [t½(d)] 0.16 ± 0.15 h; volume of distribution at steady state [V(d[ss])] 0.29 ± 0.10 l/kg) and rapid elimination (body clearance [ClB], 0.21 ± 0.06 l/h/kg; elimination half-life [t½], 1.18 ± 0.27 h; mean residence time 1.42 ± 0.36 h).",Cefazolin pharmacokinetics in cats under surgical conditions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),[l] / [h·kg],0.21,22664,DB01327,Cefazolin
,27609113,elimination half-life [t½],"Results Initial plasma concentrations were high (Cp(0), 134.80 ± 40.54 µg/ml), with fast and moderately wide distribution (distribution half-life [t½(d)] 0.16 ± 0.15 h; volume of distribution at steady state [V(d[ss])] 0.29 ± 0.10 l/kg) and rapid elimination (body clearance [ClB], 0.21 ± 0.06 l/h/kg; elimination half-life [t½], 1.18 ± 0.27 h; mean residence time 1.42 ± 0.36 h).",Cefazolin pharmacokinetics in cats under surgical conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),h,1.18,22665,DB01327,Cefazolin
,27609113,mean residence time,"Results Initial plasma concentrations were high (Cp(0), 134.80 ± 40.54 µg/ml), with fast and moderately wide distribution (distribution half-life [t½(d)] 0.16 ± 0.15 h; volume of distribution at steady state [V(d[ss])] 0.29 ± 0.10 l/kg) and rapid elimination (body clearance [ClB], 0.21 ± 0.06 l/h/kg; elimination half-life [t½], 1.18 ± 0.27 h; mean residence time 1.42 ± 0.36 h).",Cefazolin pharmacokinetics in cats under surgical conditions. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),h,1.42,22666,DB01327,Cefazolin
,27609113,tissue concentrations,"Thirty to 60 mins after intravenous administration, cefazolin tissue concentrations ranged from 9.24 µg/ml (subcutaneous tissue) to 26.44 µg/ml (ovary).",Cefazolin pharmacokinetics in cats under surgical conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),,9.24,22667,DB01327,Cefazolin
,27609113,tissue concentrations,"Thirty to 60 mins after intravenous administration, cefazolin tissue concentrations ranged from 9.24 µg/ml (subcutaneous tissue) to 26.44 µg/ml (ovary).",Cefazolin pharmacokinetics in cats under surgical conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),μg,26.44,22668,DB01327,Cefazolin
,27609113,tissue/plasma concentration ratio,The tissue/plasma concentration ratio ranged from 0.18 (muscle) to 0.58 (ovary).,Cefazolin pharmacokinetics in cats under surgical conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),,0.18,22669,DB01327,Cefazolin
,27609113,tissue/plasma concentration ratio,The tissue/plasma concentration ratio ranged from 0.18 (muscle) to 0.58 (ovary).,Cefazolin pharmacokinetics in cats under surgical conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),,0.58,22670,DB01327,Cefazolin
,27609113,minimum inhibitory concentration,Conclusions and relevance Cefazolin plasma concentrations remained above a minimum inhibitory concentration of ⩽2 µg/ml up to 4 h in all the studied cats.,Cefazolin pharmacokinetics in cats under surgical conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27609113/),[μg] / [ml],⩽2,22671,DB01327,Cefazolin
,3210156,Vdss/BW,The Vdss/BW values ranged from 0.212 to 0.373 L/kg for cefazolin and from 0.384 to 0.541 L/kg for tobramycin.,Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210156/),[l] / [kg],0.212 to 0.373,24325,DB01327,Cefazolin
,3210156,Vdss/BW,The Vdss/BW values ranged from 0.212 to 0.373 L/kg for cefazolin and from 0.384 to 0.541 L/kg for tobramycin.,Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210156/),[l] / [kg],0.384 to 0.541,24326,DB01327,Cefazolin
,3210156,unbound fraction of cefazolin in plasma (fp),"The unbound fraction of cefazolin in plasma (fp) fluctuated widely, from 0.22 to 0.83, among patients.",Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210156/),,0.22,24327,DB01327,Cefazolin
,3210156,unbound fraction of cefazolin in plasma (fp),"The unbound fraction of cefazolin in plasma (fp) fluctuated widely, from 0.22 to 0.83, among patients.",Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210156/),,0.83,24328,DB01327,Cefazolin
,3802300,peak average serum concentration,"The peak average serum concentration, reached 2 h after injection, was 22.5 micrograms/ml, and the t1/2 beta was 1.5 h; urinary recovery was over 80% within 24 h, the majority of injected ceftezole being excreted within 3 hours.",Pharmacokinetic studies on ceftezole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802300/),[μg] / [ml],22.5,24597,DB01327,Cefazolin
,3802300,t1/2 beta,"The peak average serum concentration, reached 2 h after injection, was 22.5 micrograms/ml, and the t1/2 beta was 1.5 h; urinary recovery was over 80% within 24 h, the majority of injected ceftezole being excreted within 3 hours.",Pharmacokinetic studies on ceftezole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802300/),h,1.5,24598,DB01327,Cefazolin
,12212035,Analytical recovery,"Analytical recovery of cefazolin was 107.9%, the limit of detection was 1.5 micrograms/ml, the limit of quantitation was 3.6 micrograms/ml.",[Rapid determination of cefazolin in porcine serum by high performance capillary electrophoresis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12212035/),%,107.9,28373,DB01327,Cefazolin
,12212035,clearance,Cefazolin metabolism in adult pigs appeared to be a typical two-compartment model with a clearance of 8.43 ml/(kg.min).,[Rapid determination of cefazolin in porcine serum by high performance capillary electrophoresis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12212035/),[ml] / [kg·min],8.43,28374,DB01327,Cefazolin
,10588308,AUC,"We assessed the cephalosporin concentration-time curve area (AUC), peak concentration, maintained concentration and duration of exposure on in-vitro bactericidal effects on Escherichia coli NCTC 10418, using exposures modelling cephazolin clinical profiles after 1 g and 2 g i.m. injection, equal AUC exposures (288 mg x h/L, 576 mg x h/L; 48 h) and constant exposures to 6, 12 and 24 mg/L.",Cephalosporin clinical concentration-time profile modelling and in-vitro bactericidal effects on Escherichia coli. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10588308/),[h·mg] / [l],288,34216,DB01327,Cefazolin
,10588308,AUC,"We assessed the cephalosporin concentration-time curve area (AUC), peak concentration, maintained concentration and duration of exposure on in-vitro bactericidal effects on Escherichia coli NCTC 10418, using exposures modelling cephazolin clinical profiles after 1 g and 2 g i.m. injection, equal AUC exposures (288 mg x h/L, 576 mg x h/L; 48 h) and constant exposures to 6, 12 and 24 mg/L.",Cephalosporin clinical concentration-time profile modelling and in-vitro bactericidal effects on Escherichia coli. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10588308/),[h·mg] / [l],576,34217,DB01327,Cefazolin
,8034522,half-life,"From April 1988 to December 1990 we randomly assigned 429 patients with gastro-intestinal operations to a defined protocol: 210 patients (5 drop-outs) with elective operations of the upper GI-tract were given Ceftriaxone (half-life 8 hours, 102 patients) or Cefazolin (half-life 2 hours, 103 patients).","[""Single shot"" prevention in abdominal surgery. Antibiotics with long half-life (ceftriaxone, ornidazole) vs. antibiotics with short half-life (cefazolin, metronidazole, clindamycin)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8034522/),h,8,34312,DB01327,Cefazolin
,8034522,half-life,"From April 1988 to December 1990 we randomly assigned 429 patients with gastro-intestinal operations to a defined protocol: 210 patients (5 drop-outs) with elective operations of the upper GI-tract were given Ceftriaxone (half-life 8 hours, 102 patients) or Cefazolin (half-life 2 hours, 103 patients).","[""Single shot"" prevention in abdominal surgery. Antibiotics with long half-life (ceftriaxone, ornidazole) vs. antibiotics with short half-life (cefazolin, metronidazole, clindamycin)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8034522/),h,2,34313,DB01327,Cefazolin
,8034522,half-life,"117 (12 drop-outs) patients with operations of the lower GI-tract were given Ceftriaxone/Ornidazole (half-life 13 hours, 50 patients) or Cefazolin/Metronidazole (half-life 8 hours, 55 patients).","[""Single shot"" prevention in abdominal surgery. Antibiotics with long half-life (ceftriaxone, ornidazole) vs. antibiotics with short half-life (cefazolin, metronidazole, clindamycin)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8034522/),h,13,34314,DB01327,Cefazolin
,8034522,half-life,"117 (12 drop-outs) patients with operations of the lower GI-tract were given Ceftriaxone/Ornidazole (half-life 13 hours, 50 patients) or Cefazolin/Metronidazole (half-life 8 hours, 55 patients).","[""Single shot"" prevention in abdominal surgery. Antibiotics with long half-life (ceftriaxone, ornidazole) vs. antibiotics with short half-life (cefazolin, metronidazole, clindamycin)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8034522/),h,8,34315,DB01327,Cefazolin
,30944398,clearance,The median (range) individual Bayesian estimates were 0.03 L/h/kg (0.01-0.08) for clearance and 0.39 L/kg (0.31-0.52) for volume.,Cefazolin pharmacokinetics in premature infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30944398/),[l] / [h·kg],0.03,34537,DB01327,Cefazolin
,30944398,volume,The median (range) individual Bayesian estimates were 0.03 L/h/kg (0.01-0.08) for clearance and 0.39 L/kg (0.31-0.52) for volume.,Cefazolin pharmacokinetics in premature infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30944398/),[l] / [kg],0.39,34538,DB01327,Cefazolin
,8017411,volume of distribution,"In healthy adults, the volume of distribution is 13-22 L and the elimination half-life is 2-2.3 hours.",Cefepime: a new fourth-generation cephalosporin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017411/),l,13-22,35239,DB01327,Cefazolin
,8017411,elimination half-life,"In healthy adults, the volume of distribution is 13-22 L and the elimination half-life is 2-2.3 hours.",Cefepime: a new fourth-generation cephalosporin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017411/),h,2-2.3,35240,DB01327,Cefazolin
,400257,half-lives,"Preliminary studies were carried out with cefazolin against an E. coli strain simulating initial concentrations of 5, 10 and 20 micrograms/ml that decreased exponentially with half-lives of 30, 60 and 120 min.","[Correlation between antibacterial activity of some cephalosporins and pharmacokinetic properties ""in vitro"" (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/400257/),min,30,40406,DB01327,Cefazolin
,400257,half-lives,"Preliminary studies were carried out with cefazolin against an E. coli strain simulating initial concentrations of 5, 10 and 20 micrograms/ml that decreased exponentially with half-lives of 30, 60 and 120 min.","[Correlation between antibacterial activity of some cephalosporins and pharmacokinetic properties ""in vitro"" (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/400257/),min,60,40407,DB01327,Cefazolin
,400257,half-lives,"Preliminary studies were carried out with cefazolin against an E. coli strain simulating initial concentrations of 5, 10 and 20 micrograms/ml that decreased exponentially with half-lives of 30, 60 and 120 min.","[Correlation between antibacterial activity of some cephalosporins and pharmacokinetic properties ""in vitro"" (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/400257/),min,120,40408,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],39.6,41983,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],29.1,41984,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],21.2,41985,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],10.3,41986,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],6.4,41987,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],2.7,41988,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],38.3,41989,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],53.3,41990,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],46.4,41991,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],31.7,41992,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],19.1,41993,DB01327,Cefazolin
,28541147,concentration,"RESULTS Mean cefazolin concentration in the interstitial fluid at 1, 1.5, 2, 3, 4, and 5 hours after injection was 39.6, 29.1, 21.2, 10.3, 6.4, and 2.7 μg/mL, respectively, for the IV group and 38.3, 53.3, 46.4, 31.7, 19.1, and 8.9 μg/mL, respectively, for the IV + IM group.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],8.9,41994,DB01327,Cefazolin
,28541147,area under the concentration-time curve extrapolated to infinity,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[h·μg] / [ml],74.99,41995,DB01327,Cefazolin
,28541147,area under the concentration-time curve extrapolated to infinity,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[h·μg] / [ml],154.16,41996,DB01327,Cefazolin
,28541147,maximum concentration,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[h·μg] / [ml],154.16,41997,DB01327,Cefazolin
,28541147,maximum concentration,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],37.3,41998,DB01327,Cefazolin
,28541147,maximum concentration,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),h,0.96,41999,DB01327,Cefazolin
,28541147,half-life,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[h·μg] / [ml],154.16,42000,DB01327,Cefazolin
,28541147,half-life,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),[μg] / [ml],37.3,42001,DB01327,Cefazolin
,28541147,half-life,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),h,0.96,42002,DB01327,Cefazolin
,28541147,time to maximum concentration,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),h,1.11,42003,DB01327,Cefazolin
,28541147,time to maximum concentration,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),h,1.28,42004,DB01327,Cefazolin
,28541147,time to maximum concentration,"Mean area under the concentration-time curve extrapolated to infinity, maximum concentration, half-life, and time to maximum concentration was 74.99 and 154.16 h·μg/mL, 37.3 and 51.5 μg/mL, 0.96 and 1.11 hours, and 1.28 and 1.65 hours, respectively, for the IV and IV + IM groups.",Pharmacokinetics of cefazolin for prophylactic administration to dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541147/),h,1.65,42005,DB01327,Cefazolin
,6961888,half-life,The half-life (3 h) of cefotetan was longer than that of cefazolin.,Pharmacokinetics of cefotetan (YM09330) in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6961888/),h,3,48251,DB01327,Cefazolin
,6961888,recoveries,"Mean recoveries of cefotetan in urine within a 24-h period were 74.5 to 88.4% of the dose, regardless of the route of administration and the dosage.",Pharmacokinetics of cefotetan (YM09330) in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6961888/),%,74.5 to 88.4,48252,DB01327,Cefazolin
,3946913,half-life,Probenecid given IV was characterized by a rapid disposition phase with a mean half-life of 14.0 minutes and a subsequent slower elimination phase with a mean half-life of 87.8 minutes in 5 of 6 mares.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,14.0,48431,DB01327,Cefazolin
,3946913,half-life,Probenecid given IV was characterized by a rapid disposition phase with a mean half-life of 14.0 minutes and a subsequent slower elimination phase with a mean half-life of 87.8 minutes in 5 of 6 mares.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,87.8,48432,DB01327,Cefazolin
,3946913,half-life of the elimination phase,"In the remaining mare, a rapid disposition phase was not observed, and the half-life of the elimination phase was slower (172 minutes).",Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,172,48433,DB01327,Cefazolin
,3946913,mean residence time,The mean residence time of probenecid averaged 116 minutes for all 6 mares and 89.2 minutes for the 5 mares with biphasic disposition.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,116,48434,DB01327,Cefazolin
,3946913,mean residence time,The mean residence time of probenecid averaged 116 minutes for all 6 mares and 89.2 minutes for the 5 mares with biphasic disposition.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,89.2,48435,DB01327,Cefazolin
,3946913,total plasma clearance,"The total plasma clearance of probenecid averaged 1.18 +/- 0.49 ml/min/kg, whereas renal clearance accounted for 42.6 +/- 9.3% of the total clearance.",Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),[ml] / [kg·min],1.18,48436,DB01327,Cefazolin
,3946913,steady-state volume of distribution,The steady-state volume of distribution of probenecid averaged 116 +/- 28.2 ml/kg.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),[ml] / [kg],116,48437,DB01327,Cefazolin
,3946913,maximum plasma probenecid concentration,The maximum plasma probenecid concentration after 10 mg/kg orally averaged nearly 30 micrograms/ml.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),[μg] / [ml],30,48438,DB01327,Cefazolin
,3946913,half-life,The half-life of probenecid after oral administration was approximately 120 minutes.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),min,120,48439,DB01327,Cefazolin
greater,3946913,Oral bioavailability,Oral bioavailability was good with greater than 90% of the dose absorbed.,Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946913/),%,90,48440,DB01327,Cefazolin
,11273877,dialytic clearance,"Mean dialytic clearance values for cefazolin were significantly greater in the high-flux group compared with the high-efficiency group (30.9 +/- 6.52 versus 18.0 +/- 6.26 mL/min, respectively; P: < 0.05).",Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11273877/),[ml] / [min],30.9,48940,DB01327,Cefazolin
,11273877,dialytic clearance,"Mean dialytic clearance values for cefazolin were significantly greater in the high-flux group compared with the high-efficiency group (30.9 +/- 6.52 versus 18.0 +/- 6.26 mL/min, respectively; P: < 0.05).",Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11273877/),[ml] / [min],18.0,48941,DB01327,Cefazolin
,11273877,reduction ratios,Cefazolin reduction ratios were significantly greater (0.62 +/- 0.08 versus 0.50 +/- 0.07; P: < 0.005) in the high-flux group compared with the high-efficiency group and correlated well with equilibrated urea reduction.,Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11273877/),,0.62,48942,DB01327,Cefazolin
,11273877,reduction ratios,Cefazolin reduction ratios were significantly greater (0.62 +/- 0.08 versus 0.50 +/- 0.07; P: < 0.005) in the high-flux group compared with the high-efficiency group and correlated well with equilibrated urea reduction.,Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11273877/),,0.50,48943,DB01327,Cefazolin
,8196091,elimination half-life,"After tourniquet removal, synovial fluid concentration-time curves followed first-order one-compartment model decay in most of the animals with an elimination half-life of 0.82 h (harmonic mean).",Single-dose pharmacokinetics of cefazolin in bovine synovial fluid after intravenous regional injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196091/),h,0.82,49062,DB01327,Cefazolin
,12708933,serum peak,"In patients who received cefazolin once daily, the average serum peak and trough concentrations on day 1 were 146.53 and 2.02 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],146.53,49393,DB01327,Cefazolin
,12708933,trough concentrations,"In patients who received cefazolin once daily, the average serum peak and trough concentrations on day 1 were 146.53 and 2.02 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],2.02,49394,DB01327,Cefazolin
,12708933,Peak,"Peak and trough concentrations on day 5 were 148.30 and 2.67 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],148.30,49395,DB01327,Cefazolin
,12708933,trough concentrations,"Peak and trough concentrations on day 5 were 148.30 and 2.67 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],2.67,49396,DB01327,Cefazolin
,12708933,peak,"In patients who received cefazolin every 8 hours, peak and trough concentrations were 122.15 and 18.65 mg/L on day 1 and, on day 5, 136.51 and 16.98 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],122.15,49397,DB01327,Cefazolin
,12708933,trough concentrations,"In patients who received cefazolin every 8 hours, peak and trough concentrations were 122.15 and 18.65 mg/L on day 1 and, on day 5, 136.51 and 16.98 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],18.65,49398,DB01327,Cefazolin
,12708933,trough concentrations,"In patients who received cefazolin every 8 hours, peak and trough concentrations were 122.15 and 18.65 mg/L on day 1 and, on day 5, 136.51 and 16.98 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],136.51,49399,DB01327,Cefazolin
,12708933,trough concentrations,"In patients who received cefazolin every 8 hours, peak and trough concentrations were 122.15 and 18.65 mg/L on day 1 and, on day 5, 136.51 and 16.98 mg/L, respectively.",Effect of chronic probenecid therapy on cefazolin serum concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12708933/),[mg] / [l],16.98,49400,DB01327,Cefazolin
,11775826,valley serum concentration,"The mean serum concentration of netilmicin was 27.23 mg/L, the valley serum concentration was 0.23 mg/L, T1/2 beta was 5.059 h, AUC was 70 micrograms.h-1.ml-1.netilmicin at concentrations 0.5, 1.0 and 4 times the MIC showed different degrees of PAE against 4 strains of bacterium.",[A series of clinical study on netilmicin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11775826/),[mg] / [l],0.23,50324,DB01327,Cefazolin
,11775826,T1/2 beta,"The mean serum concentration of netilmicin was 27.23 mg/L, the valley serum concentration was 0.23 mg/L, T1/2 beta was 5.059 h, AUC was 70 micrograms.h-1.ml-1.netilmicin at concentrations 0.5, 1.0 and 4 times the MIC showed different degrees of PAE against 4 strains of bacterium.",[A series of clinical study on netilmicin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11775826/),h,5.059,50325,DB01327,Cefazolin
,11775826,AUC,"The mean serum concentration of netilmicin was 27.23 mg/L, the valley serum concentration was 0.23 mg/L, T1/2 beta was 5.059 h, AUC was 70 micrograms.h-1.ml-1.netilmicin at concentrations 0.5, 1.0 and 4 times the MIC showed different degrees of PAE against 4 strains of bacterium.",[A series of clinical study on netilmicin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11775826/),[μg] / [h·ml],70,50326,DB01327,Cefazolin
,28505360,Protein binding,Protein binding varied with time [mean (range) 69 (44-80)%] with a fixed 21% unbound value of cefazolin used for the simulations (120 min post-initial dosing).,Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28505360/),%,69,51420,DB01327,Cefazolin
,28505360,central volume of distribution,"Mean ( sd ) central volume of distribution was 5.73 (2.42) litres, and total cefazolin clearance was 4.72 (1.1) litres h -1 .",Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28505360/),l,5.73,51421,DB01327,Cefazolin
,28505360,total cefazolin clearance,"Mean ( sd ) central volume of distribution was 5.73 (2.42) litres, and total cefazolin clearance was 4.72 (1.1) litres h -1 .",Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28505360/),-1·h·l,4.72,51422,DB01327,Cefazolin
,2810728,MIC,"Most frequent MIC values of R-3746 to S. aureus, E. coli, K. pneumoniae and P. mirabilis were 1.56, 0.39, less than or equal to 0.10 and less than or equal to 0.10 microgram/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],1.56,51476,DB01327,Cefazolin
,2810728,MIC,"Most frequent MIC values of R-3746 to S. aureus, E. coli, K. pneumoniae and P. mirabilis were 1.56, 0.39, less than or equal to 0.10 and less than or equal to 0.10 microgram/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],0.39,51477,DB01327,Cefazolin
less,2810728,MIC,"Most frequent MIC values of R-3746 to S. aureus, E. coli, K. pneumoniae and P. mirabilis were 1.56, 0.39, less than or equal to 0.10 and less than or equal to 0.10 microgram/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],0.10,51478,DB01327,Cefazolin
higher,2810728,MICs,"Against isolated strains of MRSA, MICs of R-3746 were higher than 25 micrograms/ml with 23 strains (77%), which were similar to MIC values of CCL and AMPC against these organisms.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],25,51479,DB01327,Cefazolin
,2810728,MIC50,"MIC values of R-3746 against CEZ resistant E. coli and K. pneumoniae were superior to MICs of other antibiotics, and the MIC50 value was 0.20 micrograms/ml.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],0.20,51480,DB01327,Cefazolin
,2810728,MIC,Against many isolated strains of E. cloacae MIC values of R-3746 were relatively high ranging 0.78 to greater than 100 micrograms/ml.,"[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],0.78 to greater,51481,DB01327,Cefazolin
,2810728,MIC,Against many isolated strains of E. cloacae MIC values of R-3746 were relatively high ranging 0.78 to greater than 100 micrograms/ml.,"[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],100,51482,DB01327,Cefazolin
,2810728,MIC50,MIC50 of R-3746 against E. cloacae was 12.5 micrograms/ml.,"[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],12.5,51483,DB01327,Cefazolin
,2810728,peak of serum concentration,"The peak of serum concentration of CPDX was attained in 1-6 hours 1-4 hours and 2-6 hours after administration of CPDX-PR at the 3 different dosage levels, and they were 0.99-2.99 micrograms/ml, 4.30-7.05 micrograms/ml and 1.65-2.93 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],0.99-2.99,51484,DB01327,Cefazolin
,2810728,peak of serum concentration,"The peak of serum concentration of CPDX was attained in 1-6 hours 1-4 hours and 2-6 hours after administration of CPDX-PR at the 3 different dosage levels, and they were 0.99-2.99 micrograms/ml, 4.30-7.05 micrograms/ml and 1.65-2.93 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],4.30-7.05,51485,DB01327,Cefazolin
,2810728,peak of serum concentration,"The peak of serum concentration of CPDX was attained in 1-6 hours 1-4 hours and 2-6 hours after administration of CPDX-PR at the 3 different dosage levels, and they were 0.99-2.99 micrograms/ml, 4.30-7.05 micrograms/ml and 1.65-2.93 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[μg] / [ml],1.65-2.93,51486,DB01327,Cefazolin
,2810728,concentrations,"At 8 hours after administration, mean concentrations of CPDX for the 3 groups were 0.31, 0.83 and 0.66 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),,0.83,51487,DB01327,Cefazolin
,2810728,concentrations,"At 8 hours after administration, mean concentrations of CPDX for the 3 groups were 0.31, 0.83 and 0.66 micrograms/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),,0.66,51488,DB01327,Cefazolin
,2810728,AUC's,"As the average AUC's for the 3 groups were 8.16, 25.97 and 10.79 micrograms.hr/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[h·μg] / [ml],8.16,51489,DB01327,Cefazolin
,2810728,AUC's,"As the average AUC's for the 3 groups were 8.16, 25.97 and 10.79 micrograms.hr/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[h·μg] / [ml],25.97,51490,DB01327,Cefazolin
,2810728,AUC's,"As the average AUC's for the 3 groups were 8.16, 25.97 and 10.79 micrograms.hr/ml, respectively.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),[h·μg] / [ml],10.79,51491,DB01327,Cefazolin
,2810728,Urinary recovery rates,"Urinary recovery rates of CPDX for the 3 groups were 20.9-56.2, 28.3-49.7 and 35.1-50.4%, respectively in the first 8 hours after administration.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),%,20.9-56.2,51492,DB01327,Cefazolin
,2810728,Urinary recovery rates,"Urinary recovery rates of CPDX for the 3 groups were 20.9-56.2, 28.3-49.7 and 35.1-50.4%, respectively in the first 8 hours after administration.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),%,28.3-49.7,51493,DB01327,Cefazolin
,2810728,Urinary recovery rates,"Urinary recovery rates of CPDX for the 3 groups were 20.9-56.2, 28.3-49.7 and 35.1-50.4%, respectively in the first 8 hours after administration.","[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field]. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810728/),%,35.1-50.4,51494,DB01327,Cefazolin
,32250982,minimum inhibitory concentration,"Total and unbound cefazolin concentrations in plasma and ISF were compared with the minimum inhibitory concentration at which 90% of isolates are inhibited (MIC90) of cefazolin for Staphylococcus aureus, 2 mg·L.",Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250982/),l·mg,2,53992,DB01327,Cefazolin
,32250982,MIC90),"Total and unbound cefazolin concentrations in plasma and ISF were compared with the minimum inhibitory concentration at which 90% of isolates are inhibited (MIC90) of cefazolin for Staphylococcus aureus, 2 mg·L.",Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250982/),l·mg,2,53993,DB01327,Cefazolin
>,32250982,95% unbound,The fractional target attainment (FTA) of dosing regimens to achieve a pre-established target of 95% unbound ISF concentrations >2 mg·L throughout a 3-hour duration of the surgery was calculated.,Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250982/),,2,53994,DB01327,Cefazolin
above,32250982,total,"For each timepoint up to 180 minutes, the median across subjects of total and unbound plasma concentration of cefazolin remained above 2 mg·L.",Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250982/),l·mg,2,53995,DB01327,Cefazolin
above,32250982,unbound plasma concentration,"For each timepoint up to 180 minutes, the median across subjects of total and unbound plasma concentration of cefazolin remained above 2 mg·L.",Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250982/),l·mg,2,53996,DB01327,Cefazolin
,32250982,minimum observed total plasma concentration,The minimum observed total plasma concentration was 31.7 mg·L and plasma unbound concentration was 7.7 mg·L (observed in the same participant).,Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250982/),l·mg,31.7,53997,DB01327,Cefazolin
,32250982,plasma unbound concentration,The minimum observed total plasma concentration was 31.7 mg·L and plasma unbound concentration was 7.7 mg·L (observed in the same participant).,Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250982/),l·mg,7.7,53998,DB01327,Cefazolin
above,32250982,unbound,"For each timepoint up to 150 minutes, the median across subjects of unbound ISF concentrations remained above 2 mg·L.",Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250982/),mg,2,53999,DB01327,Cefazolin
,32250982,minimum observed unbound ISF concentration,The minimum observed unbound ISF concentration was 0.7 mg·L (observed in 1 participant).,Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250982/),l·mg,0.7,54000,DB01327,Cefazolin
,6848301,half-life (t 1/2),"CFZ led to serum concentrations of 25 microgram/ml at 24 hr, with a half-life (t 1/2) of 33 hr.",Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848301/),h,33,54169,DB01327,Cefazolin
,6848301,serum t 1/2,"CPX, on the other hand, had a serum t 1/2 of 8.6 hr and resulted in much lower peritoneal concentrations than CFZ.",Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848301/),h,8.6,54170,DB01327,Cefazolin
,6848301,steady-state plasma concentrations,"The model predicts that a 10-mg/kg intraperitoneal loading dose, followed by 5-mg/kg doses in each exchange the first day and 2.5-mg/kg doses thereafter, will lead to steady-state plasma concentrations of 50 to 65 microgram/ml.",Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848301/),[μg] / [ml],50 to 65,54171,DB01327,Cefazolin
,580023,Peak serum concentrations,"Peak serum concentrations occurred 45 min after the administration and were 31.52 microgram/ml for cephazolin, 17.32 microgram/ml for cephaloridine, 13.98 microgram/ml for cephapirin, 9.51 microgram/ml for cephradine and 8.60 microgram/ml for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),[μg] / [ml],31.52,54474,DB01327,Cefazolin
,580023,Peak serum concentrations,"Peak serum concentrations occurred 45 min after the administration and were 31.52 microgram/ml for cephazolin, 17.32 microgram/ml for cephaloridine, 13.98 microgram/ml for cephapirin, 9.51 microgram/ml for cephradine and 8.60 microgram/ml for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),[μg] / [ml],17.32,54475,DB01327,Cefazolin
,580023,Peak serum concentrations,"Peak serum concentrations occurred 45 min after the administration and were 31.52 microgram/ml for cephazolin, 17.32 microgram/ml for cephaloridine, 13.98 microgram/ml for cephapirin, 9.51 microgram/ml for cephradine and 8.60 microgram/ml for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),[μg] / [ml],13.98,54476,DB01327,Cefazolin
,580023,Peak serum concentrations,"Peak serum concentrations occurred 45 min after the administration and were 31.52 microgram/ml for cephazolin, 17.32 microgram/ml for cephaloridine, 13.98 microgram/ml for cephapirin, 9.51 microgram/ml for cephradine and 8.60 microgram/ml for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),[μg] / [ml],9.51,54477,DB01327,Cefazolin
,580023,Peak serum concentrations,"Peak serum concentrations occurred 45 min after the administration and were 31.52 microgram/ml for cephazolin, 17.32 microgram/ml for cephaloridine, 13.98 microgram/ml for cephapirin, 9.51 microgram/ml for cephradine and 8.60 microgram/ml for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),[μg] / [ml],8.60,54478,DB01327,Cefazolin
,580023,half-lives,"The average half-lives were found to be 2.07, 1.80, 0.98, 1.24 and 0.97 h, respectively.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),h,2.07,54479,DB01327,Cefazolin
,580023,half-lives,"The average half-lives were found to be 2.07, 1.80, 0.98, 1.24 and 0.97 h, respectively.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),h,1.80,54480,DB01327,Cefazolin
,580023,half-lives,"The average half-lives were found to be 2.07, 1.80, 0.98, 1.24 and 0.97 h, respectively.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),h,0.98,54481,DB01327,Cefazolin
,580023,half-lives,"The average half-lives were found to be 2.07, 1.80, 0.98, 1.24 and 0.97 h, respectively.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),h,1.24,54482,DB01327,Cefazolin
,580023,half-lives,"The average half-lives were found to be 2.07, 1.80, 0.98, 1.24 and 0.97 h, respectively.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),h,0.97,54483,DB01327,Cefazolin
,580023,percentage of protein binding,"The percentage of protein binding was found to be 82 for cephazolin, 59 for cephalothin, 51 for cephapirin, 31 for cephaloridine and only 10 for cephradine, half an hour after drug administration.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),,82,54484,DB01327,Cefazolin
,580023,percentage of protein binding,"The percentage of protein binding was found to be 82 for cephazolin, 59 for cephalothin, 51 for cephapirin, 31 for cephaloridine and only 10 for cephradine, half an hour after drug administration.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),,59,54485,DB01327,Cefazolin
,580023,percentage of protein binding,"The percentage of protein binding was found to be 82 for cephazolin, 59 for cephalothin, 51 for cephapirin, 31 for cephaloridine and only 10 for cephradine, half an hour after drug administration.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),,51,54486,DB01327,Cefazolin
,580023,percentage of protein binding,"The percentage of protein binding was found to be 82 for cephazolin, 59 for cephalothin, 51 for cephapirin, 31 for cephaloridine and only 10 for cephradine, half an hour after drug administration.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),,31,54487,DB01327,Cefazolin
,580023,percentage of protein binding,"The percentage of protein binding was found to be 82 for cephazolin, 59 for cephalothin, 51 for cephapirin, 31 for cephaloridine and only 10 for cephradine, half an hour after drug administration.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),,10,54488,DB01327,Cefazolin
,580023,total urine recovery,"The total urine recovery of the above cephalosporins, within 24 h, was 91.9% for cephradine, 81.9% for cephaloridine, 73.3% for cephazolin, 69.5% for cephapirin and 51.2% for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),%,91.9,54489,DB01327,Cefazolin
,580023,total urine recovery,"The total urine recovery of the above cephalosporins, within 24 h, was 91.9% for cephradine, 81.9% for cephaloridine, 73.3% for cephazolin, 69.5% for cephapirin and 51.2% for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),%,81.9,54490,DB01327,Cefazolin
,580023,total urine recovery,"The total urine recovery of the above cephalosporins, within 24 h, was 91.9% for cephradine, 81.9% for cephaloridine, 73.3% for cephazolin, 69.5% for cephapirin and 51.2% for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),%,73.3,54491,DB01327,Cefazolin
,580023,total urine recovery,"The total urine recovery of the above cephalosporins, within 24 h, was 91.9% for cephradine, 81.9% for cephaloridine, 73.3% for cephazolin, 69.5% for cephapirin and 51.2% for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),%,69.5,54492,DB01327,Cefazolin
,580023,total urine recovery,"The total urine recovery of the above cephalosporins, within 24 h, was 91.9% for cephradine, 81.9% for cephaloridine, 73.3% for cephazolin, 69.5% for cephapirin and 51.2% for cephalothin.",Pharmacokinetics of five cephalosporins in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580023/),%,51.2,54493,DB01327,Cefazolin
,30689931,total body CL,"The mean ± standard deviation (SD) total body CL for the birth-6 month cohort was 0.009 ± 0.006 mL/min/kg with a mean ± SD Vd of 0.59 ± 0.26 L/kg, the mean ± SD total body CL for the 7 month-3 year cohort was 0.01 ± 0.005 mL/min/kg with a mean ± SD Vd of 0.79 ± 0.15 L/kg, and the mean ± SD total body CL for the 4-16 year cohort was 0.007 ± 0.004 mL/min/kg with a mean ± SD Vd of 3.4 ± 0.94 L/kg.",Pharmacokinetics of cefazolin delivery via the cardiopulmonary bypass circuit priming solution in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689931/),[ml] / [kg·min],0.009,54653,DB01327,Cefazolin
,30689931,Vd,"The mean ± standard deviation (SD) total body CL for the birth-6 month cohort was 0.009 ± 0.006 mL/min/kg with a mean ± SD Vd of 0.59 ± 0.26 L/kg, the mean ± SD total body CL for the 7 month-3 year cohort was 0.01 ± 0.005 mL/min/kg with a mean ± SD Vd of 0.79 ± 0.15 L/kg, and the mean ± SD total body CL for the 4-16 year cohort was 0.007 ± 0.004 mL/min/kg with a mean ± SD Vd of 3.4 ± 0.94 L/kg.",Pharmacokinetics of cefazolin delivery via the cardiopulmonary bypass circuit priming solution in infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689931/),[l] / [kg],0.59,54654,DB01327,Cefazolin
,30689931,total body CL,"The mean ± standard deviation (SD) total body CL for the birth-6 month cohort was 0.009 ± 0.006 mL/min/kg with a mean ± SD Vd of 0.59 ± 0.26 L/kg, the mean ± SD total body CL for the 7 month-3 year cohort was 0.01 ± 0.005 mL/min/kg with a mean ± SD Vd of 0.79 ± 0.15 L/kg, and the mean ± SD total body CL for the 4-16 year cohort was 0.007 ± 0.004 mL/min/kg with a mean ± SD Vd of 3.4 ± 0.94 L/kg.",Pharmacokinetics of cefazolin delivery via the cardiopulmonary bypass circuit priming solution in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689931/),[ml] / [kg·min],0.01,54655,DB01327,Cefazolin
,30689931,Vd,"The mean ± standard deviation (SD) total body CL for the birth-6 month cohort was 0.009 ± 0.006 mL/min/kg with a mean ± SD Vd of 0.59 ± 0.26 L/kg, the mean ± SD total body CL for the 7 month-3 year cohort was 0.01 ± 0.005 mL/min/kg with a mean ± SD Vd of 0.79 ± 0.15 L/kg, and the mean ± SD total body CL for the 4-16 year cohort was 0.007 ± 0.004 mL/min/kg with a mean ± SD Vd of 3.4 ± 0.94 L/kg.",Pharmacokinetics of cefazolin delivery via the cardiopulmonary bypass circuit priming solution in infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689931/),[l] / [kg],0.79,54656,DB01327,Cefazolin
,30689931,total body CL,"The mean ± standard deviation (SD) total body CL for the birth-6 month cohort was 0.009 ± 0.006 mL/min/kg with a mean ± SD Vd of 0.59 ± 0.26 L/kg, the mean ± SD total body CL for the 7 month-3 year cohort was 0.01 ± 0.005 mL/min/kg with a mean ± SD Vd of 0.79 ± 0.15 L/kg, and the mean ± SD total body CL for the 4-16 year cohort was 0.007 ± 0.004 mL/min/kg with a mean ± SD Vd of 3.4 ± 0.94 L/kg.",Pharmacokinetics of cefazolin delivery via the cardiopulmonary bypass circuit priming solution in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689931/),[ml] / [kg·min],0.007,54657,DB01327,Cefazolin
,30689931,Vd,"The mean ± standard deviation (SD) total body CL for the birth-6 month cohort was 0.009 ± 0.006 mL/min/kg with a mean ± SD Vd of 0.59 ± 0.26 L/kg, the mean ± SD total body CL for the 7 month-3 year cohort was 0.01 ± 0.005 mL/min/kg with a mean ± SD Vd of 0.79 ± 0.15 L/kg, and the mean ± SD total body CL for the 4-16 year cohort was 0.007 ± 0.004 mL/min/kg with a mean ± SD Vd of 3.4 ± 0.94 L/kg.",Pharmacokinetics of cefazolin delivery via the cardiopulmonary bypass circuit priming solution in infants and children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689931/),[l] / [kg],3.4,54658,DB01327,Cefazolin
,25410773,Clearance,"The final model resulted in the mean ± SD parameter values: Clearance = 3.8 ± 2.1 L/h, volume of distribution in central compartment = 8.6 ± 6.4 L and volume of distribution in ISF = 36.6 ± 17.9 L.",Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410773/),[l] / [h],3.8,56000,DB01327,Cefazolin
,25410773,volume of distribution in central compartment,"The final model resulted in the mean ± SD parameter values: Clearance = 3.8 ± 2.1 L/h, volume of distribution in central compartment = 8.6 ± 6.4 L and volume of distribution in ISF = 36.6 ± 17.9 L.",Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410773/),l,8.6,56001,DB01327,Cefazolin
,25410773,volume of distribution,"The final model resulted in the mean ± SD parameter values: Clearance = 3.8 ± 2.1 L/h, volume of distribution in central compartment = 8.6 ± 6.4 L and volume of distribution in ISF = 36.6 ± 17.9 L.",Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410773/),l,36.6,56002,DB01327,Cefazolin
,25410773,penetration ratios,"The mean ± SD and median penetration ratios were 1.36 ± 4.57 and 0.80, respectively.",Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25410773/),,0.80,56003,DB01327,Cefazolin
,2795860,MICs,"MICs of CDZM against 1 strain each of Streptococcus pneumoniae, Escherichia coli and Klebsiella pneumoniae were 0.05 micrograms/ml to 0.10 micrograms/ml.",[Clinical and pharmacokinetic evaluation of cefodizime in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795860/),[μg] / [ml],0.05,58502,DB01327,Cefazolin
,2795860,MICs,"MICs of CDZM against 1 strain each of Streptococcus pneumoniae, Escherichia coli and Klebsiella pneumoniae were 0.05 micrograms/ml to 0.10 micrograms/ml.",[Clinical and pharmacokinetic evaluation of cefodizime in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795860/),[μg] / [ml],0.10,58503,DB01327,Cefazolin
less,2795860,MIC,"Especially, MIC against all 6 strains of Haemophilus influenzae was less than or equal to 0.024 micrograms/ml.",[Clinical and pharmacokinetic evaluation of cefodizime in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795860/),[μg] / [ml],0.024,58504,DB01327,Cefazolin
,2795860,peak value of serum concentration,The peak value of serum concentration of CDZM was 207.80 micrograms/ml at the end of the infusion.,[Clinical and pharmacokinetic evaluation of cefodizime in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795860/),[μg] / [ml],207.80,58505,DB01327,Cefazolin
,2795860,half-life,The half-life was 2.15 hours.,[Clinical and pharmacokinetic evaluation of cefodizime in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795860/),h,2.15,58506,DB01327,Cefazolin
,2795860,urinary excretion rate,"The mean urinary excretion rate was 68.5% in the first 4 hours, 79.2% in 6 hours and 76.5% in 8 hours after the 30-minute drip infusion.",[Clinical and pharmacokinetic evaluation of cefodizime in children]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795860/),%,68.5,58507,DB01327,Cefazolin
,2795860,urinary excretion rate,"The mean urinary excretion rate was 68.5% in the first 4 hours, 79.2% in 6 hours and 76.5% in 8 hours after the 30-minute drip infusion.",[Clinical and pharmacokinetic evaluation of cefodizime in children]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795860/),%,79.2,58508,DB01327,Cefazolin
,2795860,urinary excretion rate,"The mean urinary excretion rate was 68.5% in the first 4 hours, 79.2% in 6 hours and 76.5% in 8 hours after the 30-minute drip infusion.",[Clinical and pharmacokinetic evaluation of cefodizime in children]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795860/),%,76.5,58509,DB01327,Cefazolin
,2795860,eradication rate,Bacteriological effects were investigated in 13 cases and the eradication rate was 85%.,[Clinical and pharmacokinetic evaluation of cefodizime in children]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795860/),%,85,58510,DB01327,Cefazolin
,21859939,terminal volume of distribution,"The median (interquartile range) terminal volume of distribution was 0.14 (0.11 to 0.15) liter/kg, total clearance was 0.05 (0.03 to 0.06) liter/h, and minimum observed unbound concentration was 5.7 (5.4 to 8.1) mg/liter.",Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21859939/),[l] / [kg],0.14,58586,DB01327,Cefazolin
,21859939,total clearance,"The median (interquartile range) terminal volume of distribution was 0.14 (0.11 to 0.15) liter/kg, total clearance was 0.05 (0.03 to 0.06) liter/h, and minimum observed unbound concentration was 5.7 (5.4 to 8.1) mg/liter.",Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21859939/),[l] / [h],0.05,58587,DB01327,Cefazolin
,21859939,minimum observed unbound concentration,"The median (interquartile range) terminal volume of distribution was 0.14 (0.11 to 0.15) liter/kg, total clearance was 0.05 (0.03 to 0.06) liter/h, and minimum observed unbound concentration was 5.7 (5.4 to 8.1) mg/liter.",Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21859939/),[mg] / [l],5.7,58588,DB01327,Cefazolin
,21859939,penetration of unbound drug,The penetration of unbound drug from plasma to ISF was 85% (78% to 106%).,Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21859939/),%,85,58589,DB01327,Cefazolin
,3695403,half-life,"For Streptococcus and Staphylococcus sp., the drug half-life was 0.5 hours with peak concentrations occurring within 0.25 hours of injection.",Pharmacokinetics of cefazolin in guinea pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695403/),h,0.5,59632,DB01327,Cefazolin
,3695403,volume of distribution,The volume of distribution of 0.5 l/kg indicated that there was extensive tissue distribution.,Pharmacokinetics of cefazolin in guinea pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695403/),[l] / [kg],0.5,59633,DB01327,Cefazolin
,3695403,Serum protein binding,Serum protein binding was approximately 85%.,Pharmacokinetics of cefazolin in guinea pigs. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695403/),%,85,59634,DB01327,Cefazolin
,3695403,plasma clearance rate,The short half-life and rapid plasma clearance rate (10.4 ml/min/kg) indicated that cefazolin is eliminated very rapidly from the guinea pig and may be of questionable therapeutic value.,Pharmacokinetics of cefazolin in guinea pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695403/),[ml] / [kg·min],10.4,59635,DB01327,Cefazolin
,1164008,serum half-life,"In patients on dialysis, the mean serum half-life of cefazolin was 4.05 h during (or after) hemodialysis, and 32.1 h during (or after) peritoneal dialysis.",Effects of renal failure and dialysis on cefazolin pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164008/),h,4.05,65079,DB01327,Cefazolin
,1164008,serum half-life,"In patients on dialysis, the mean serum half-life of cefazolin was 4.05 h during (or after) hemodialysis, and 32.1 h during (or after) peritoneal dialysis.",Effects of renal failure and dialysis on cefazolin pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164008/),h,32.1,65080,DB01327,Cefazolin
,12080793,peak time (Tmax),"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),min,58.8,66742,DB01327,Cefazolin
,12080793,peak time (Tmax),"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),min,19.7,66743,DB01327,Cefazolin
,12080793,peak time (Tmax),"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),min,18.2,66744,DB01327,Cefazolin
,12080793,T1/2 alpha,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),min,42.3,66745,DB01327,Cefazolin
,12080793,T1/2 alpha,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),min,19.0,66746,DB01327,Cefazolin
,12080793,T1/2 alpha,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),min,9.3,66747,DB01327,Cefazolin
,12080793,peak concentration (Cmax),"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),[mg] / [l],101.6,66748,DB01327,Cefazolin
,12080793,peak concentration (Cmax),"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),[mg] / [l],28.7,66749,DB01327,Cefazolin
,12080793,peak concentration (Cmax),"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),[mg] / [l],23.5,66750,DB01327,Cefazolin
,12080793,Vd,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),[l] / [kg],0.096,66751,DB01327,Cefazolin
,12080793,Vd,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),[l] / [kg],0.374,66752,DB01327,Cefazolin
,12080793,Vd,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),[l] / [kg],0.386,66753,DB01327,Cefazolin
,12080793,T1/2ka,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),min,22.5,66754,DB01327,Cefazolin
,12080793,T1/2ka,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),min,8.6,66755,DB01327,Cefazolin
,12080793,T1/2ka,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),min,10.6,66756,DB01327,Cefazolin
,12080793,T1/2 beta,"In normal men, 8-month pigs and 4-month pigs, the peak time (Tmax) was (58.8 +/- 13.0), (19.7 +/- 9.9) and (18.2 +/- 8.6) min respectively, T1/2 alpha was (42.3 +/- 19.7), (19.0 +/- 7.7) and (9.3 +/- 1.9) min, the peak concentration (Cmax) was (101.6 +/- 14.6), (28.7 +/- 9.0) and (23.5 +/- 4.6) mg/L; Vd was (0.096 +/- 0.016), (0.374 +/- 0.184) and (0.386 +/- 0.211) L/kg; T1/2ka was (22.5 +/- 6.8), (8.6 +/- 4.8) and (10.6 +/- 10.2) min; T1/2 beta was (117.3 +/- 8.6), (84.2 +/- 9.8) and (45.1 +/- 11.5) min; clean rate of plasma Cl was (0.8 +/- 0.1), (6.8 +/- 1.2) and (11.0 +/- 3.0) ml/kg.min; AUC was (21,803 +/- 4,145), (2,407 +/- 443) and (1,636 +/- 685) mg.min/L.",[Comparative study of the character of cefazolin pharmacokinetics between Neijiang pig and human]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12080793/),,117.3,66757,DB01327,Cefazolin
,1102452,serum half-lives,"In normal subjects, serum half-lives averaged 1.75 hour after intravenous injection (Ke = 0.395) and 2.22 hours after intra-muscular injection (Ke = 0.312); urinary recovery of cefazolin over a six hours period amounted to 61% after intra-venous injection and to 47.5% after intra-muscular injection.",Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102452/),h,1.75,69496,DB01327,Cefazolin
,1102452,serum half-lives,"In normal subjects, serum half-lives averaged 1.75 hour after intravenous injection (Ke = 0.395) and 2.22 hours after intra-muscular injection (Ke = 0.312); urinary recovery of cefazolin over a six hours period amounted to 61% after intra-venous injection and to 47.5% after intra-muscular injection.",Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102452/),h,2.22,69497,DB01327,Cefazolin
,1102452,Ke,"In normal subjects, serum half-lives averaged 1.75 hour after intravenous injection (Ke = 0.395) and 2.22 hours after intra-muscular injection (Ke = 0.312); urinary recovery of cefazolin over a six hours period amounted to 61% after intra-venous injection and to 47.5% after intra-muscular injection.",Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102452/),,0.395,69498,DB01327,Cefazolin
,1102452,Ke,"In normal subjects, serum half-lives averaged 1.75 hour after intravenous injection (Ke = 0.395) and 2.22 hours after intra-muscular injection (Ke = 0.312); urinary recovery of cefazolin over a six hours period amounted to 61% after intra-venous injection and to 47.5% after intra-muscular injection.",Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102452/),h,2.22,69499,DB01327,Cefazolin
,1102452,Ke,"In normal subjects, serum half-lives averaged 1.75 hour after intravenous injection (Ke = 0.395) and 2.22 hours after intra-muscular injection (Ke = 0.312); urinary recovery of cefazolin over a six hours period amounted to 61% after intra-venous injection and to 47.5% after intra-muscular injection.",Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102452/),,0.312,69500,DB01327,Cefazolin
,1102452,urinary recovery,"In normal subjects, serum half-lives averaged 1.75 hour after intravenous injection (Ke = 0.395) and 2.22 hours after intra-muscular injection (Ke = 0.312); urinary recovery of cefazolin over a six hours period amounted to 61% after intra-venous injection and to 47.5% after intra-muscular injection.",Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102452/),%,61,69501,DB01327,Cefazolin
,1102452,urinary recovery,"In normal subjects, serum half-lives averaged 1.75 hour after intravenous injection (Ke = 0.395) and 2.22 hours after intra-muscular injection (Ke = 0.312); urinary recovery of cefazolin over a six hours period amounted to 61% after intra-venous injection and to 47.5% after intra-muscular injection.",Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102452/),%,47.5,69502,DB01327,Cefazolin
,1102452,renal clearance,The renal clearance of the drug approximated 40 ml/mn.,Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102452/),[ml] / [mn],40,69503,DB01327,Cefazolin
,3994100,half-life,The disposition of cefazolin given by IV route was characterized by a rapid disposition phase with a half-life of 5 to 10 minutes and a subsequent slower elimination phase with a half-life of 35 to 46 minutes.,Pharmacokinetics and bioavailability of cefazolin in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994100/),min,5 to 10,69677,DB01327,Cefazolin
,3994100,half-life,The disposition of cefazolin given by IV route was characterized by a rapid disposition phase with a half-life of 5 to 10 minutes and a subsequent slower elimination phase with a half-life of 35 to 46 minutes.,Pharmacokinetics and bioavailability of cefazolin in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994100/),min,35 to 46,69678,DB01327,Cefazolin
,3994100,total plasma clearance,The total plasma clearance of cefazolin averaged 5.51 ml/min/kg and was due mainly to renal clearance (5.39 ml/min/kg) of unchanged drug.,Pharmacokinetics and bioavailability of cefazolin in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994100/),[ml] / [kg·min],5.51,69679,DB01327,Cefazolin
,3994100,renal clearance,The total plasma clearance of cefazolin averaged 5.51 ml/min/kg and was due mainly to renal clearance (5.39 ml/min/kg) of unchanged drug.,Pharmacokinetics and bioavailability of cefazolin in horses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994100/),[ml] / [kg·min],5.39,69680,DB01327,Cefazolin
,3994100,volume of distribution at steady-state,The volume of distribution at steady-state averaged 188 ml/kg.,Pharmacokinetics and bioavailability of cefazolin in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994100/),[ml] / [kg],188,69681,DB01327,Cefazolin
,3994100,Plasma protein binding,Plasma protein binding of cefazolin at a concentration of 10 micrograms/ml averaged 8.1 +/- 1.9%.,Pharmacokinetics and bioavailability of cefazolin in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994100/),%,8.1,69682,DB01327,Cefazolin
,3994100,bioavailability,"Given by the IM route, cefazolin was rapidly absorbed; the extent of bioavailability was 78.4 +/- 18.8%, and the terminal half-life ranged from 49 to 99 minutes.",Pharmacokinetics and bioavailability of cefazolin in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994100/),%,78.4,69683,DB01327,Cefazolin
,3994100,terminal half-life,"Given by the IM route, cefazolin was rapidly absorbed; the extent of bioavailability was 78.4 +/- 18.8%, and the terminal half-life ranged from 49 to 99 minutes.",Pharmacokinetics and bioavailability of cefazolin in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994100/),min,49 to 99,69684,DB01327,Cefazolin
,8723889,alpha,"Mean pharmacokinetic constants (SEM) were 0.146 (0.013) min-1 for alpha, 4.47 min for t1/2 alpha 0.015 (0.004) min-1 for beta, 46.83 min for t1/2 beta.",Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723889/),1/[min],0.146,69723,DB01327,Cefazolin
,8723889,t1/2 alpha,"Mean pharmacokinetic constants (SEM) were 0.146 (0.013) min-1 for alpha, 4.47 min for t1/2 alpha 0.015 (0.004) min-1 for beta, 46.83 min for t1/2 beta.",Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723889/),min,4.47,69724,DB01327,Cefazolin
,8723889,t1/2 alpha,"Mean pharmacokinetic constants (SEM) were 0.146 (0.013) min-1 for alpha, 4.47 min for t1/2 alpha 0.015 (0.004) min-1 for beta, 46.83 min for t1/2 beta.",Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723889/),1/[min],0.015,69725,DB01327,Cefazolin
,8723889,beta,"Mean pharmacokinetic constants (SEM) were 0.146 (0.013) min-1 for alpha, 4.47 min for t1/2 alpha 0.015 (0.004) min-1 for beta, 46.83 min for t1/2 beta.",Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723889/),1/[min],0.015,69726,DB01327,Cefazolin
,8723889,t1/2 beta,"Mean pharmacokinetic constants (SEM) were 0.146 (0.013) min-1 for alpha, 4.47 min for t1/2 alpha 0.015 (0.004) min-1 for beta, 46.83 min for t1/2 beta.",Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723889/),min,46.83,69727,DB01327,Cefazolin
,20813593,recovery,The average recovery of cefazedone was 90.8-91.0%.,Determination of cefazedone in human plasma by high performance liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20813593/),%,90.8-91.0,73937,DB01327,Cefazolin
,22833246,unbound CFZ fraction,The median unbound CFZ fraction was 0.39 (0.10-0.73).,Cefazolin plasma protein binding and its covariates in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22833246/),,0.39,75044,DB01327,Cefazolin
,22833246,unbound CFZ fraction at the peak concentration,"The median unbound CFZ fraction at the peak concentration (0.46, range 0.28-0.69) was significantly higher compared to the trough level (0.36, range 0.17-0.73) (p < 0.001).",Cefazolin plasma protein binding and its covariates in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22833246/),,0.46,75045,DB01327,Cefazolin
,22833246,unbound CFZ fraction at the peak concentration,"The median unbound CFZ fraction at the peak concentration (0.46, range 0.28-0.69) was significantly higher compared to the trough level (0.36, range 0.17-0.73) (p < 0.001).",Cefazolin plasma protein binding and its covariates in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22833246/),,0.36,75046,DB01327,Cefazolin
,825020,half-life,"The half-life in serum under the same conditions was 56 min, i.e., about one-half that of cefazolin.","In vitro and in vivo evaluation of ceftezole, a new cephalosporin derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/825020/),min,56,79952,DB01327,Cefazolin
,825020,24-h,The 24-h urinary recovery rate was 87.5%.,"In vitro and in vivo evaluation of ceftezole, a new cephalosporin derivative. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/825020/),%,87.5,79953,DB01327,Cefazolin
,825020,urinary recovery rate,The 24-h urinary recovery rate was 87.5%.,"In vitro and in vivo evaluation of ceftezole, a new cephalosporin derivative. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/825020/),%,87.5,79954,DB01327,Cefazolin
,825020,biliary excretion rate,The biliary excretion rate in SD strain rats after intramuscular injection of 20 mg/kg was about 4.4%.,"In vitro and in vivo evaluation of ceftezole, a new cephalosporin derivative. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/825020/),%,4.4,79955,DB01327,Cefazolin
,2810536,serum half-life,The serum half-life (hr +/- SEM) was 1.43 +/- 0.36 for cefamandole and 2.22 +/- 0.40 for cefazolin.,Efficacy of prophylactic antibiotics in vascular surgery: an arterial wall microbiologic and pharmacokinetic perspective. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810536/),h,1.43,81289,DB01327,Cefazolin
,2810536,serum half-life,The serum half-life (hr +/- SEM) was 1.43 +/- 0.36 for cefamandole and 2.22 +/- 0.40 for cefazolin.,Efficacy of prophylactic antibiotics in vascular surgery: an arterial wall microbiologic and pharmacokinetic perspective. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2810536/),h,2.22,81290,DB01327,Cefazolin
,4004190,elimination rate constants,"The mean elimination rate constants were 0.41 and 0.50 h-1 for total and free ceforanide, respectively.",Intraoperative ceforanide pharmacokinetics and protein binding. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4004190/),1/[h],0.41,85280,DB01327,Cefazolin
,4004190,elimination rate constants,"The mean elimination rate constants were 0.41 and 0.50 h-1 for total and free ceforanide, respectively.",Intraoperative ceforanide pharmacokinetics and protein binding. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4004190/),1/[h],0.50,85281,DB01327,Cefazolin
,4004190,association constant,"The data were fit to double-reciprocal and half-reciprocal relationships with good agreement, showing one binding site and an association constant range of 1.6 X 10(7) to 1.9 X 10(7) at these in vivo concentrations.",Intraoperative ceforanide pharmacokinetics and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4004190/),,1.6 X 10(7),85282,DB01327,Cefazolin
,4004190,association constant,"The data were fit to double-reciprocal and half-reciprocal relationships with good agreement, showing one binding site and an association constant range of 1.6 X 10(7) to 1.9 X 10(7) at these in vivo concentrations.",Intraoperative ceforanide pharmacokinetics and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4004190/),,1.9 X 10(7),85283,DB01327,Cefazolin
,4004190,volume of distribution,"The mean volume of distribution and mean systemic clearance of total drug were 100 ml/kg and 45.9 ml/min per 1.73 m2, respectively.",Intraoperative ceforanide pharmacokinetics and protein binding. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4004190/),[ml] / [kg],100,85284,DB01327,Cefazolin
,4004190,systemic clearance,"The mean volume of distribution and mean systemic clearance of total drug were 100 ml/kg and 45.9 ml/min per 1.73 m2, respectively.",Intraoperative ceforanide pharmacokinetics and protein binding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4004190/),[ml] / [1.73·m2·min],45.9,85285,DB01327,Cefazolin
,28483961,MIC,"No InE was observed for CPT or NAF, whereas a marked InE was detected for CFZ (MIC, 8 to ≥128 μg/ml).",Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28483961/),[μg] / [ml],8 to ≥128,85637,DB01327,Cefazolin
,697350,Binding,"Binding of the cephalosporins to dog serum ranged from 31% for cephaloridine to 46% for cephalothin, considerably lower than human serum binding for cefazolin, cephalothin, and cefamandole.",Ascitic fluid cephalosporin concentrations: influence of protein binding and serum pharmacokinetics. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697350/),%,31,85675,DB01327,Cefazolin
,697350,Binding,"Binding of the cephalosporins to dog serum ranged from 31% for cephaloridine to 46% for cephalothin, considerably lower than human serum binding for cefazolin, cephalothin, and cefamandole.",Ascitic fluid cephalosporin concentrations: influence of protein binding and serum pharmacokinetics. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/697350/),%,46,85676,DB01327,Cefazolin
above,30995208,plasma concentrations,"Simulations demonstrated that a 1-hour vancomycin infusion (15 mg·kg), repeated every 12 hours and a 10-minute infusion of cefazolin (30 mg·kg), repeated every 4 hours maintained plasma concentrations above 4 μg·mL and 16 μg·mL, for vancomycin and cefazolin, respectively.",Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30995208/),ml·μg,4,85903,DB01327,Cefazolin
,30995208,plasma concentrations,"Simulations demonstrated that a 1-hour vancomycin infusion (15 mg·kg), repeated every 12 hours and a 10-minute infusion of cefazolin (30 mg·kg), repeated every 4 hours maintained plasma concentrations above 4 μg·mL and 16 μg·mL, for vancomycin and cefazolin, respectively.",Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30995208/),ml·μg,16,85904,DB01327,Cefazolin
,7387141,Plasma half-lives,"Plasma half-lives for ceforanide and cefazolin were 1.1 and 0.5 h in the rat, 5 and 0.3 h in the rabbit, 1 and 0.8 h in the dog, and 2.6 and 2 h in humans, respectively.",Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387141/),h,1.1,87668,DB01327,Cefazolin
,7387141,Plasma half-lives,"Plasma half-lives for ceforanide and cefazolin were 1.1 and 0.5 h in the rat, 5 and 0.3 h in the rabbit, 1 and 0.8 h in the dog, and 2.6 and 2 h in humans, respectively.",Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387141/),h,0.5,87669,DB01327,Cefazolin
,7387141,Plasma half-lives,"Plasma half-lives for ceforanide and cefazolin were 1.1 and 0.5 h in the rat, 5 and 0.3 h in the rabbit, 1 and 0.8 h in the dog, and 2.6 and 2 h in humans, respectively.",Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387141/),h,5,87670,DB01327,Cefazolin
,7387141,Plasma half-lives,"Plasma half-lives for ceforanide and cefazolin were 1.1 and 0.5 h in the rat, 5 and 0.3 h in the rabbit, 1 and 0.8 h in the dog, and 2.6 and 2 h in humans, respectively.",Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387141/),h,0.3,87671,DB01327,Cefazolin
,7387141,Plasma half-lives,"Plasma half-lives for ceforanide and cefazolin were 1.1 and 0.5 h in the rat, 5 and 0.3 h in the rabbit, 1 and 0.8 h in the dog, and 2.6 and 2 h in humans, respectively.",Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387141/),h,1,87672,DB01327,Cefazolin
,7387141,Plasma half-lives,"Plasma half-lives for ceforanide and cefazolin were 1.1 and 0.5 h in the rat, 5 and 0.3 h in the rabbit, 1 and 0.8 h in the dog, and 2.6 and 2 h in humans, respectively.",Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387141/),h,0.8,87673,DB01327,Cefazolin
,7387141,Plasma half-lives,"Plasma half-lives for ceforanide and cefazolin were 1.1 and 0.5 h in the rat, 5 and 0.3 h in the rabbit, 1 and 0.8 h in the dog, and 2.6 and 2 h in humans, respectively.",Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387141/),h,2.6,87674,DB01327,Cefazolin
,7387141,Plasma half-lives,"Plasma half-lives for ceforanide and cefazolin were 1.1 and 0.5 h in the rat, 5 and 0.3 h in the rabbit, 1 and 0.8 h in the dog, and 2.6 and 2 h in humans, respectively.",Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7387141/),h,2,87675,DB01327,Cefazolin
,10861740,flow rate,"Chromatographic conditions consisted of a mobile phase of methanol-acetonitrile-100 mM monosodium phosphoric acid (20:10:70, v/v, pH 4.5) pumped through a microbore reversed-phase column at a flow rate of 0.05 mL/min.",Simultaneous determination of cefazolin in rat blood and brain by microdialysis and microbore liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10861740/),[ml] / [min],0.05,88696,DB01327,Cefazolin
,10861740,area under the concentration (AUC) vs time ratio,"According to a non-compartmental pharmacokinetics model, the area under the concentration (AUC) vs time ratio of cefazolin in rat brain and blood was 6%.",Simultaneous determination of cefazolin in rat blood and brain by microdialysis and microbore liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10861740/),%,6,88697,DB01327,Cefazolin
,22249886,protein binding,Pharmacokinetics and duration above the minimum inhibitory concentration (MIC) were determined using a protein binding value of 15% and a MIC threshold of 8 μg/mL.,Cefepime dosing in the morbidly obese patient population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249886/),%,15,88879,DB01327,Cefazolin
,22249886,MIC,Pharmacokinetics and duration above the minimum inhibitory concentration (MIC) were determined using a protein binding value of 15% and a MIC threshold of 8 μg/mL.,Cefepime dosing in the morbidly obese patient population. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249886/),[μg] / [ml],8,88880,DB01327,Cefazolin
,22249886,concentrations,"Mean free cefepime concentrations for t = 30, 120, and 360 min were 69.6, 31.6, and 9.2 μg/mL, respectively.",Cefepime dosing in the morbidly obese patient population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249886/),[μg] / [ml],69.6,88881,DB01327,Cefazolin
,22249886,concentrations,"Mean free cefepime concentrations for t = 30, 120, and 360 min were 69.6, 31.6, and 9.2 μg/mL, respectively.",Cefepime dosing in the morbidly obese patient population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249886/),[μg] / [ml],31.6,88882,DB01327,Cefazolin
,22249886,concentrations,"Mean free cefepime concentrations for t = 30, 120, and 360 min were 69.6, 31.6, and 9.2 μg/mL, respectively.",Cefepime dosing in the morbidly obese patient population. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22249886/),[μg] / [ml],9.2,88883,DB01327,Cefazolin
,9124823,MICs,"The corresponding values in neutropenic mice, also for the MICs obtained with the large inoculum, were 0.54, 0.68, and 0.64, respectively, at 24 h.",Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124823/),,0.54,89489,DB01327,Cefazolin
,9124823,MICs,"The corresponding values in neutropenic mice, also for the MICs obtained with the large inoculum, were 0.54, 0.68, and 0.64, respectively, at 24 h.",Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124823/),,0.68,89490,DB01327,Cefazolin
,9124823,MICs,"The corresponding values in neutropenic mice, also for the MICs obtained with the large inoculum, were 0.54, 0.68, and 0.64, respectively, at 24 h.",Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124823/),,0.64,89491,DB01327,Cefazolin
≤,29644481,MICs,CFZ 2 g warrant up to 5 h SSI prophylaxis for bacteria with MICs ≤1 mg/L such as Escherichia coli and Staphylococcus aureus.,Efficacious Cefazolin Prophylactic Dose for Morbidly Obese Women Undergoing Bariatric Surgery Based on Evidence from Subcutaneous Microdialysis and Populational Pharmacokinetic Modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29644481/),[mg] / [l],1,89763,DB01327,Cefazolin
,29644481,MIC distribution frequency,"For species such as Klebsiella pneumoniae, which present MIC distribution frequency of 2 mg/L, the maintenance of PTA ≥ 90% occurs with a 3 g dose for surgeries lasting up to 5 h, and 2 g dose provide an adequate response up to 4 h (PTA of 89%).",Efficacious Cefazolin Prophylactic Dose for Morbidly Obese Women Undergoing Bariatric Surgery Based on Evidence from Subcutaneous Microdialysis and Populational Pharmacokinetic Modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29644481/),[mg] / [l],2,89764,DB01327,Cefazolin
up to,29644481,MIC,"Effectiveness of CFZ 2 g is similar to 3 g against bacteria with a MIC up to 2 mg/L, especially if the surgery does not last for more than 4 h.",Efficacious Cefazolin Prophylactic Dose for Morbidly Obese Women Undergoing Bariatric Surgery Based on Evidence from Subcutaneous Microdialysis and Populational Pharmacokinetic Modeling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29644481/),[mg] / [l],2,89765,DB01327,Cefazolin
,649639,serum half-life,"The serum half-life of the antibiotic was 1.8 hours, the same value found in normal volunteers.",Cefazolin concentrations in bone and synovial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/649639/),h,1.8,91318,DB01327,Cefazolin
,34231117,Cmax,"The mean measured daptomycin Cmax and Ctrough were 54.1 μg/mL (CV: 0.32) and 8.7 μg/mL (CV: 0.59), respectively; the mean calculated AUC0-24 was 742.7 μg × h/mL (CV: 0.31).",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[μg] / [ml],54.1,92817,DB01327,Cefazolin
,34231117,Ctrough,"The mean measured daptomycin Cmax and Ctrough were 54.1 μg/mL (CV: 0.32) and 8.7 μg/mL (CV: 0.59), respectively; the mean calculated AUC0-24 was 742.7 μg × h/mL (CV: 0.31).",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[μg] / [ml],8.7,92818,DB01327,Cefazolin
,34231117,AUC0-24,"The mean measured daptomycin Cmax and Ctrough were 54.1 μg/mL (CV: 0.32) and 8.7 μg/mL (CV: 0.59), respectively; the mean calculated AUC0-24 was 742.7 μg × h/mL (CV: 0.31).",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[h·μg] / [ml],742.7,92819,DB01327,Cefazolin
,34231117,"volume of distribution at the steady state (Vd,ss)","The estimated average volume of distribution at the steady state (Vd,ss) and the half-life (t1/2) were 316.5 mL/kg (CV: 0.53) and 14.4 h (CV: 0.30), respectively.",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[ml] / [kg],316.5,92820,DB01327,Cefazolin
,34231117,half-life (t1/2),"The estimated average volume of distribution at the steady state (Vd,ss) and the half-life (t1/2) were 316.5 mL/kg (CV: 0.53) and 14.4 h (CV: 0.30), respectively.",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),h,14.4,92821,DB01327,Cefazolin
,34231117,clearance,The mean daptomycin clearance from plasma normalized for body weight (CLwp) was 17.3 mL/(h × kg) (CV: 0.33).,Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[ml] / [h·kg],17.3,92822,DB01327,Cefazolin
,34231117,Cmax,"The calculated average Cmax and AUC0-24 (183.7 µg/mL and 1277.4 µg × h/mL, respectively) were lower than and statistically significantly different from (p < 0.001 and p = 0.001, respectively) those expected for healthy volunteers.",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[μg] / [ml],183.7,92823,DB01327,Cefazolin
,34231117,AUC0-24,"The calculated average Cmax and AUC0-24 (183.7 µg/mL and 1277.4 µg × h/mL, respectively) were lower than and statistically significantly different from (p < 0.001 and p = 0.001, respectively) those expected for healthy volunteers.",Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34231117/),[h·μg] / [ml],1277.4,92824,DB01327,Cefazolin
,16175313,MIC,"Using a fixed MIC of 2 microg ml(-1) against potentially encountered bacteria, it was concluded that the recommended dosing schedule was suitable in all tested populations, including obese patients, although prolongation of the interval between injections appeared advisable for renal insufficiency patients.",Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175313/),[μg] / [ml],2,92912,DB01327,Cefazolin
,16175313,MIC,"Furthermore, when a MIC of 3 microg ml(-1) was considered, the recommended cefazolin-dosing regimen failed to maintain sufficient free cefazolin concentrations in the interstitial fluids during surgery in all tested populations except renal insufficiency patients (GFR < 50 ml min(-1)).",Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175313/),[μg] / [ml],3,92913,DB01327,Cefazolin
,21422859,adipose concentration,The mean adipose concentration was 9.4 plus or minus 2.7 micrograms/g in the lean group of women compared with 6.4 plus or minus 2.3 micrograms/g in the obese group (P=.009) and 4.4 plus or minus 1.2 micrograms/g in the extremely obese group (P<.001).,Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422859/),[μg] / [g],9.4,94202,DB01327,Cefazolin
,21422859,adipose concentration,The mean adipose concentration was 9.4 plus or minus 2.7 micrograms/g in the lean group of women compared with 6.4 plus or minus 2.3 micrograms/g in the obese group (P=.009) and 4.4 plus or minus 1.2 micrograms/g in the extremely obese group (P<.001).,Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422859/),[μg] / [g],6.4,94203,DB01327,Cefazolin
,21422859,adipose concentration,The mean adipose concentration was 9.4 plus or minus 2.7 micrograms/g in the lean group of women compared with 6.4 plus or minus 2.3 micrograms/g in the obese group (P=.009) and 4.4 plus or minus 1.2 micrograms/g in the extremely obese group (P<.001).,Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422859/),[μg] / [g],4.4,94204,DB01327,Cefazolin
greater,21422859,minimal inhibitory concentrations,"Although all specimens demonstrated therapeutic cefazolin levels for gram-positive cocci (greater than 1 microgram/g), a considerable portion of obese and extremely obese did not achieve minimal inhibitory concentrations of greater than 4 micrograms/g for Gram-negative rods in adipose samples at skin incision (20% and 33.3%, respectively) or closure (20.0% and 44.4%, respectively).",Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422859/),[μg] / [g],4,94205,DB01327,Cefazolin
≤,29501602,MIC,"For Staphylococcus spp. and Streptococcus spp., which are the most frequent species isolated from post-surgical infections in bariatric surgery (MIC usually ≤2 mg/L), PTA remains greater than 0.9 until 2 h after administration of 4000 mg of cefazolin.",Prophylactic cefazolin concentrations in morbidly obese patients undergoing sleeve gastrectomy: do we achieve targets? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29501602/),[mg] / [l],2,94569,DB01327,Cefazolin
up to,29501602,MIC,"For MIC up to 4 mg/L, efficient prophylaxis was checked until 1 h after the initial administration.",Prophylactic cefazolin concentrations in morbidly obese patients undergoing sleeve gastrectomy: do we achieve targets? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29501602/),[mg] / [l],4,94570,DB01327,Cefazolin
,6218568,peak serum level,"After intravenous bolus injection of 1 g of moxalactam, the peak serum level was 201.0 micrograms/ml, the half-life (beta-phase) was 126 min, and the cumulative urinary excretion during a 10-hr period was 90.5% of the dose.","Moxalactam--absorption, excretion, distribution, and metabolism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6218568/),[μg] / [ml],201.0,96743,DB01327,Cefazolin
,6218568,half-life (beta-phase),"After intravenous bolus injection of 1 g of moxalactam, the peak serum level was 201.0 micrograms/ml, the half-life (beta-phase) was 126 min, and the cumulative urinary excretion during a 10-hr period was 90.5% of the dose.","Moxalactam--absorption, excretion, distribution, and metabolism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6218568/),min,126,96744,DB01327,Cefazolin
,6218568,Concentrations,Concentrations in sputum were 1.84-2.11 micrograms/ml in individuals given 1 g by intravenous slow bolus injection.,"Moxalactam--absorption, excretion, distribution, and metabolism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6218568/),[μg] / [ml],1.84-2.11,96745,DB01327,Cefazolin
,24672799,baseline clearance (CL),"Estimates for baseline clearance (CL) were 0.119 L/min (RSE 58%) and 0.142 L/min (RSE 44%) for the empirical and semiphysiological models, respectively.",Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672799/),[l] / [min],0.119,98282,DB01327,Cefazolin
,24672799,baseline clearance (CL),"Estimates for baseline clearance (CL) were 0.119 L/min (RSE 58%) and 0.142 L/min (RSE 44%) for the empirical and semiphysiological models, respectively.",Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24672799/),[l] / [min],0.142,98283,DB01327,Cefazolin
,3119555,peak concentrations,"The peak concentrations of imipenem, ceftizoxime, cefazolin, and cefsulodin in exudates ranged from 10.1 to 12.3 mg/l, except that ampicillin achieved only 5.4 mg/l.",Penetration of imipenem and other antibiotics into inflammatory exudate and their efficacy in pseudomonas infection in the rat granuloma pouch model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3119555/),[mg] / [l],10.1 to 12.3,102188,DB01327,Cefazolin
,3119555,peak concentrations,"The peak concentrations of imipenem, ceftizoxime, cefazolin, and cefsulodin in exudates ranged from 10.1 to 12.3 mg/l, except that ampicillin achieved only 5.4 mg/l.",Penetration of imipenem and other antibiotics into inflammatory exudate and their efficacy in pseudomonas infection in the rat granuloma pouch model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3119555/),[mg] / [l],5.4,102189,DB01327,Cefazolin
,3119555,half life for elimination,"Imipenem rapidly reached peak concentration after injection, but the half life for elimination of imipenem from exudate was 77.7 min, which was shorter than that of other beta-lactam antibiotics.",Penetration of imipenem and other antibiotics into inflammatory exudate and their efficacy in pseudomonas infection in the rat granuloma pouch model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3119555/),min,77.7,102190,DB01327,Cefazolin
,6455787,peak serum concentrations,"In studies of the intramuscular (i.m.) administration of cefoperazone at doses of 0.25, 0.5, and 1 g, mean peak serum concentrations were 22, 33, and 67 micrograms/ml at 1 hr.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[μg] / [ml],22,106110,DB01327,Cefazolin
,6455787,peak serum concentrations,"In studies of the intramuscular (i.m.) administration of cefoperazone at doses of 0.25, 0.5, and 1 g, mean peak serum concentrations were 22, 33, and 67 micrograms/ml at 1 hr.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[μg] / [ml],33,106111,DB01327,Cefazolin
,6455787,peak serum concentrations,"In studies of the intramuscular (i.m.) administration of cefoperazone at doses of 0.25, 0.5, and 1 g, mean peak serum concentrations were 22, 33, and 67 micrograms/ml at 1 hr.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[μg] / [ml],67,106112,DB01327,Cefazolin
,6455787,half-life,The mean half-life after intramuscular injection was 108-154 min.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),min,108-154,106113,DB01327,Cefazolin
,6455787,Urinary recovery,Urinary recovery ranged from 14 to 18% of an administered dose.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),%,14 to 18,106114,DB01327,Cefazolin
,6455787,Concentrations,"Concentrations of cefoperazone at 8 hr were 2.4, 6.5, and 11.8 micrograms/ml after these respective doses.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),,2.4,106115,DB01327,Cefazolin
,6455787,Concentrations,"Concentrations of cefoperazone at 8 hr were 2.4, 6.5, and 11.8 micrograms/ml after these respective doses.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),,6.5,106116,DB01327,Cefazolin
,6455787,Concentrations,"Concentrations of cefoperazone at 8 hr were 2.4, 6.5, and 11.8 micrograms/ml after these respective doses.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),,11.8,106117,DB01327,Cefazolin
,6455787,Serum half-life,"Serum half-life was 115-120 min and urinary recovery, 29-33%.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),min,115-120,106118,DB01327,Cefazolin
,6455787,urinary recovery,"Serum half-life was 115-120 min and urinary recovery, 29-33%.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),%,29-33,106119,DB01327,Cefazolin
,6455787,half-life,The half-life found in these studies ranged from 1.6 to 2.38 hr.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),h,1.6 to 2.38,106120,DB01327,Cefazolin
,6455787,Urinary recovery,Urinary recovery was 25-30%.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),%,25-30,106121,DB01327,Cefazolin
,6455787,Serum clearances,"Serum clearances have been 80-90 ml/min and renal clearances, 18-30 ml/min.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[ml] / [min],80-90,106122,DB01327,Cefazolin
,6455787,renal clearances,"Serum clearances have been 80-90 ml/min and renal clearances, 18-30 ml/min.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),[ml] / [min],18-30,106123,DB01327,Cefazolin
,6455787,apparent volume of distribution,The apparent volume of distribution of the compound has ranged from 10 to 16 liters.,"A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),l,10 to 16,106124,DB01327,Cefazolin
,6455787,serum half-life,"In the presence of renal failure there is a minimal increase in serum half-life; but in the presence of biliary obstruction, serum half-life may reach 11 hr, depending on the degree of biliary obstruction.","A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6455787/),h,11,106125,DB01327,Cefazolin
,6573314,biological half-lives,"In animal pharmacokinetic studies the biological half-lives of cefotetan were 13.0 min in mice, 15.9 min in rats, 30.5 min in rabbits, 55.5 min in dogs and 77.9 min in rhesus monkeys.",Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573314/),min,13.0,107010,DB01327,Cefazolin
,6573314,biological half-lives,"In animal pharmacokinetic studies the biological half-lives of cefotetan were 13.0 min in mice, 15.9 min in rats, 30.5 min in rabbits, 55.5 min in dogs and 77.9 min in rhesus monkeys.",Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573314/),min,15.9,107011,DB01327,Cefazolin
,6573314,biological half-lives,"In animal pharmacokinetic studies the biological half-lives of cefotetan were 13.0 min in mice, 15.9 min in rats, 30.5 min in rabbits, 55.5 min in dogs and 77.9 min in rhesus monkeys.",Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573314/),min,30.5,107012,DB01327,Cefazolin
,6573314,biological half-lives,"In animal pharmacokinetic studies the biological half-lives of cefotetan were 13.0 min in mice, 15.9 min in rats, 30.5 min in rabbits, 55.5 min in dogs and 77.9 min in rhesus monkeys.",Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573314/),min,55.5,107013,DB01327,Cefazolin
,6573314,biological half-lives,"In animal pharmacokinetic studies the biological half-lives of cefotetan were 13.0 min in mice, 15.9 min in rats, 30.5 min in rabbits, 55.5 min in dogs and 77.9 min in rhesus monkeys.",Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573314/),min,77.9,107014,DB01327,Cefazolin
,6573314,LD50,"The acute intravenous LD50 values (g/kg) were 6.4 and 5.0 in male and female mice, respectively, and 8.5 and 6.8 in male and female rats, respectively.",Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573314/),[g] / [kg],6.4,107015,DB01327,Cefazolin
,6573314,LD50,"The acute intravenous LD50 values (g/kg) were 6.4 and 5.0 in male and female mice, respectively, and 8.5 and 6.8 in male and female rats, respectively.",Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573314/),[g] / [kg],5.0,107016,DB01327,Cefazolin
,6573314,LD50,"The acute intravenous LD50 values (g/kg) were 6.4 and 5.0 in male and female mice, respectively, and 8.5 and 6.8 in male and female rats, respectively.",Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573314/),[g] / [kg],8.5,107017,DB01327,Cefazolin
,6573314,LD50,"The acute intravenous LD50 values (g/kg) were 6.4 and 5.0 in male and female mice, respectively, and 8.5 and 6.8 in male and female rats, respectively.",Animal pharmacokinetics and toxicology of cefotetan--a new cephamycin antibiotic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6573314/),[g] / [kg],6.8,107018,DB01327,Cefazolin
,3531130,blood half-life,"Potent in vivo activity of SF-2103A was related to good pharmacokinetic properties, with blood half-life of 30 minutes and urinary recovery of 55.2% after parenteral administration to rats.","Therapeutic effect of SF-2103A, a novel carbapenem antibiotic, in combination with cefotaxime, cefoperazone and other cephalosporins. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3531130/),min,30,107156,DB01327,Cefazolin
,3531130,urinary recovery,"Potent in vivo activity of SF-2103A was related to good pharmacokinetic properties, with blood half-life of 30 minutes and urinary recovery of 55.2% after parenteral administration to rats.","Therapeutic effect of SF-2103A, a novel carbapenem antibiotic, in combination with cefotaxime, cefoperazone and other cephalosporins. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3531130/),%,55.2,107157,DB01327,Cefazolin
greater,24814000,Recovery,Recovery was greater than 96% for all analytes except for ertapenem (78%).,Simultaneous determination of seven β-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814000/),%,96,108719,DB01327,Cefazolin
,24814000,Recovery,Recovery was greater than 96% for all analytes except for ertapenem (78%).,Simultaneous determination of seven β-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24814000/),%,78,108720,DB01327,Cefazolin
,3813510,constant of the process rate,"In the first case the value of this parameter systematically lowered with time (the constant of the process rate amounted to 0.89 h-1), while in the second case it was constant.",[Pharmacokinetics of cefazolin during hemosorption and hemodialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3813510/),1/[h],0.89,108921,DB01327,Cefazolin
,24717822,serum half-life,Cefazolin achieves highest peak bone concentrations 40 min after parenteral application with serum half-life of 108 min and bone half-life of 42 min.,Cefazolin should be administered maximum 30 min before incision in total knee arthroplasty when tourniquet is used. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24717822/),min,108,109098,DB01327,Cefazolin
,24717822,bone half-life,Cefazolin achieves highest peak bone concentrations 40 min after parenteral application with serum half-life of 108 min and bone half-life of 42 min.,Cefazolin should be administered maximum 30 min before incision in total knee arthroplasty when tourniquet is used. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24717822/),min,42,109099,DB01327,Cefazolin
,1147591,bioavailability,The bioavailability was calculated to be 100% for cefazolin and cephalothin.,Pharmacokinetic interpretation of blood levels and urinary excretion data for cefazolin and cephalothin after intravenous and intramuscular administration in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1147591/),%,100,109339,DB01327,Cefazolin
,34081795,retention times,"The retention times of CFX and cephazolin (internal standard) were 9.8 and 7.4 min, respectively.","A fast, cost-saving and sensitive method for determination of cefuroxime in plasma by HPLC with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34081795/),min,9.8,110093,DB01327,Cefazolin
,34081795,retention times,"The retention times of CFX and cephazolin (internal standard) were 9.8 and 7.4 min, respectively.","A fast, cost-saving and sensitive method for determination of cefuroxime in plasma by HPLC with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34081795/),min,7.4,110094,DB01327,Cefazolin
,34081795,limits of detection,"The limits of detection and quantification were 0.1 μg/ml and 0.25 μg/ml, respectively.","A fast, cost-saving and sensitive method for determination of cefuroxime in plasma by HPLC with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34081795/),[μg] / [ml],0.1,110095,DB01327,Cefazolin
,34081795,limits of detection,"The limits of detection and quantification were 0.1 μg/ml and 0.25 μg/ml, respectively.","A fast, cost-saving and sensitive method for determination of cefuroxime in plasma by HPLC with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34081795/),[μg] / [ml],0.25,110096,DB01327,Cefazolin
,34081795,recovery,The mean recovery was 93.52%.,"A fast, cost-saving and sensitive method for determination of cefuroxime in plasma by HPLC with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34081795/),%,93.52,110097,DB01327,Cefazolin
,6454387,clearance,"For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin.",Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),[ml] / [70·kg·min],115.2,110308,DB01327,Cefazolin
,6454387,clearance,"For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin.",Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),[ml] / [70·kg·min],75.9,110309,DB01327,Cefazolin
,6454387,volume of distribution,"For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin.",Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),[ml] / [70·kg·min],75.9,110310,DB01327,Cefazolin
,6454387,volume of distribution,"For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin.",Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),[l] / [kg],0.44,110311,DB01327,Cefazolin
,6454387,volume of distribution,"For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin.",Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),[l] / [kg],0.19,110312,DB01327,Cefazolin
,6454387,t1/2beta,"For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin.",Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),h,3.47,110313,DB01327,Cefazolin
,6454387,t1/2beta,"For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin.",Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),h,2.18,110314,DB01327,Cefazolin
,6454387,area under the curve,"For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin.",Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),[h·mg] / [ml],151,110315,DB01327,Cefazolin
,6454387,area under the curve,"For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin.",Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),[h·mg] / [ml],236,110316,DB01327,Cefazolin
,6454387,Urinary recovery,Urinary recovery was essentially identical for both drugs: 55 to 75% in 8 h.,Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6454387/),%,55 to 75,110317,DB01327,Cefazolin
less,2097715,MIC90s,MIC90s were less than or equal to 0.25 mg/l for Enterobacteriaceae and streptococci.,Pharmacodynamics of cefepime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097715/),[mg] / [l],0.25,112322,DB01327,Cefazolin
,2097715,serum concentrations,Mean serum concentrations in patients were 62.5 +/- 2.7 mg/l (end infusion) and 1.1 +/- 0.8 mg/l (at 12 h) with an elimination half-life 2.72 +/- 0.59 h.,Pharmacodynamics of cefepime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097715/),[mg] / [l],62.5,112323,DB01327,Cefazolin
,2097715,serum concentrations,Mean serum concentrations in patients were 62.5 +/- 2.7 mg/l (end infusion) and 1.1 +/- 0.8 mg/l (at 12 h) with an elimination half-life 2.72 +/- 0.59 h.,Pharmacodynamics of cefepime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097715/),[mg] / [l],1.1,112324,DB01327,Cefazolin
,2097715,elimination half-life,Mean serum concentrations in patients were 62.5 +/- 2.7 mg/l (end infusion) and 1.1 +/- 0.8 mg/l (at 12 h) with an elimination half-life 2.72 +/- 0.59 h.,Pharmacodynamics of cefepime. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2097715/),h,2.72,112325,DB01327,Cefazolin
,7389424,serum half-life,The mean serum half-life of ceftezole was 0.64 h in patients with normal renal function and was prolonged to 10.7 h in patients with severely impaired renal function (creatinine clearance: 0-2.6 ml/min.).,Pharmacokinetics of ceftezole in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389424/),h,0.64,112549,DB01327,Cefazolin
,7389424,serum half-life,The mean serum half-life of ceftezole was 0.64 h in patients with normal renal function and was prolonged to 10.7 h in patients with severely impaired renal function (creatinine clearance: 0-2.6 ml/min.).,Pharmacokinetics of ceftezole in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389424/),h,10.7,112550,DB01327,Cefazolin
exceeded,26764340,bioavailability,"The median bioavailability for both antibiotics exceeded 92%, but other pharmacokinetic parameters varied markedly between antibiotics.",Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26764340/),%,92,118484,DB01327,Cefazolin
,26764340,volume of distribution,"Cefazolin had a smaller volume of distribution compared with cefalothin (14 vs 40 L, p = 0.003).",Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26764340/),l,14,118485,DB01327,Cefazolin
,26764340,volume of distribution,"Cefazolin had a smaller volume of distribution compared with cefalothin (14 vs 40 L, p = 0.003).",Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26764340/),l,40,118486,DB01327,Cefazolin
,26764340,trough total plasma antibiotic concentration,"The median trough total plasma antibiotic concentration for cefazolin and cefalothin during the dwell differed (plasma 56 vs 13 mg/L, p < 0.0001) despite a similar concentration in PD effluent (37 vs 38 mg/L, p = 0.58).",Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26764340/),[mg] / [l],56,118487,DB01327,Cefazolin
,26764340,trough total plasma antibiotic concentration,"The median trough total plasma antibiotic concentration for cefazolin and cefalothin during the dwell differed (plasma 56 vs 13 mg/L, p < 0.0001) despite a similar concentration in PD effluent (37 vs 38 mg/L, p = 0.58).",Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26764340/),[mg] / [l],13,118488,DB01327,Cefazolin
,26764340,trough total plasma antibiotic concentration,"The median trough total plasma antibiotic concentration for cefazolin and cefalothin during the dwell differed (plasma 56 vs 13 mg/L, p < 0.0001) despite a similar concentration in PD effluent (37 vs 38 mg/L, p = 0.58).",Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26764340/),[mg] / [l],37,118489,DB01327,Cefazolin
,26764340,trough total plasma antibiotic concentration,"The median trough total plasma antibiotic concentration for cefazolin and cefalothin during the dwell differed (plasma 56 vs 13 mg/L, p < 0.0001) despite a similar concentration in PD effluent (37 vs 38 mg/L, p = 0.58).",Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26764340/),[mg] / [l],38,118490,DB01327,Cefazolin
,25527166,peak cefazolin,"First mean peak cefazolin and linezolid plasma concentrations were 273 ± 92 µg/ml and 22.1 ± 8.9 µg/ml, respectively.",Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25527166/),[μg] / [ml],273,119442,DB01327,Cefazolin
,25527166,plasma concentrations,"First mean peak cefazolin and linezolid plasma concentrations were 273 ± 92 µg/ml and 22.1 ± 8.9 µg/ml, respectively.",Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25527166/),[μg] / [ml],22.1,119443,DB01327,Cefazolin
,25527166,peak concentrations,"Mean peak concentrations of antibiotics in sternal cancellous bone on the left and right sternal side were 112 ± 59 µg/ml and 159 ± 118 µg/ml for cefazolin and 10.9 ± 4.0 µg/ml and 12.6 ± 6.1 µg/ml for linezolid, respectively.",Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25527166/),[μg] / [ml],112,119444,DB01327,Cefazolin
,25527166,peak concentrations,"Mean peak concentrations of antibiotics in sternal cancellous bone on the left and right sternal side were 112 ± 59 µg/ml and 159 ± 118 µg/ml for cefazolin and 10.9 ± 4.0 µg/ml and 12.6 ± 6.1 µg/ml for linezolid, respectively.",Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25527166/),[μg] / [ml],159,119445,DB01327,Cefazolin
,25527166,peak concentrations,"Mean peak concentrations of antibiotics in sternal cancellous bone on the left and right sternal side were 112 ± 59 µg/ml and 159 ± 118 µg/ml for cefazolin and 10.9 ± 4.0 µg/ml and 12.6 ± 6.1 µg/ml for linezolid, respectively.",Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25527166/),[μg] / [ml],10.9,119446,DB01327,Cefazolin
,25527166,peak concentrations,"Mean peak concentrations of antibiotics in sternal cancellous bone on the left and right sternal side were 112 ± 59 µg/ml and 159 ± 118 µg/ml for cefazolin and 10.9 ± 4.0 µg/ml and 12.6 ± 6.1 µg/ml for linezolid, respectively.",Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25527166/),[μg] / [ml],12.6,119447,DB01327,Cefazolin
,1936061,Peak serum concentrations,Peak serum concentrations of cefazolin ranged from 85.8-269.4 mcg/ml.,Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936061/),[mcg] / [ml],85.8-269.4,126329,DB01327,Cefazolin
,1936061,Total clearance,"Total clearance, apparent distribution volume, and elimination half-life of cefazolin were 1.43 +/- 0.54 ml/min/kg, 0.08 +/- 0.03 l/kg, and 1.68 +/- 0.55 h respectively.",Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936061/),[ml] / [kg·min],1.43,126330,DB01327,Cefazolin
,1936061,apparent distribution volume,"Total clearance, apparent distribution volume, and elimination half-life of cefazolin were 1.43 +/- 0.54 ml/min/kg, 0.08 +/- 0.03 l/kg, and 1.68 +/- 0.55 h respectively.",Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936061/),[l] / [kg],0.08,126331,DB01327,Cefazolin
,1936061,elimination half-life,"Total clearance, apparent distribution volume, and elimination half-life of cefazolin were 1.43 +/- 0.54 ml/min/kg, 0.08 +/- 0.03 l/kg, and 1.68 +/- 0.55 h respectively.",Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936061/),h,1.68,126332,DB01327,Cefazolin
more,9861908,peak concentrations,"All peak concentrations were more than 40 micrograms/mL, while trough concentrations were all above the MIC90 of the expected pathogens: median, 3.2 micrograms/mL (range: 0.4-18.5 micrograms/mL).",Home-based treatment of cellulitis with twice-daily cefazolin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861908/),[μg] / [ml],40,127738,DB01327,Cefazolin
,9861908,trough concentrations,"All peak concentrations were more than 40 micrograms/mL, while trough concentrations were all above the MIC90 of the expected pathogens: median, 3.2 micrograms/mL (range: 0.4-18.5 micrograms/mL).",Home-based treatment of cellulitis with twice-daily cefazolin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861908/),[μg] / [ml],3.2,127739,DB01327,Cefazolin
,9861908,MIC90,"All peak concentrations were more than 40 micrograms/mL, while trough concentrations were all above the MIC90 of the expected pathogens: median, 3.2 micrograms/mL (range: 0.4-18.5 micrograms/mL).",Home-based treatment of cellulitis with twice-daily cefazolin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861908/),[μg] / [ml],3.2,127740,DB01327,Cefazolin
less,6301776,minimum inhibitory concentrations,"The minimum inhibitory concentrations of cefmenoxime against 179 isolates of respiratory pathogens (Streptococcus pneumoniae 53, Haemophilus influenzae 64, Klebsiella pneumoniae 43, Escherichia coli 9, Enterobacter spp. 10) were less than 0.20 micrograms/ml, and 43 (73%) of 60 Pseudomonas aeruginosa were inhibited by 12.5 micrograms/ml.",Laboratory evaluation of cefmenoxime: a new cephalosporin. In vitro and in vivo antibacterial activities and pharmacokinetic properties. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6301776/),[μg] / [ml],0.20,128674,DB01327,Cefazolin
,6644585,renal clearance of unbound drug,The renal clearance of unbound drug was 0.82 ml/min with a reabsorption ratio (R) of 0.22.,Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644585/),[ml] / [min],0.82,129996,DB01327,Cefazolin
,6644585,reabsorption ratio (R),The renal clearance of unbound drug was 0.82 ml/min with a reabsorption ratio (R) of 0.22.,Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644585/),,0.22,129997,DB01327,Cefazolin
,33969405,Cmax,"In obese patients (BMI 39.5-69.3 kg/m2) compared with non-obese patients (BMI 18.7-29.8 kg/m2), mean Cmax of total cefazolin in plasma was lower (115 versus 174 mg/L) and Vss was higher (19.4 versus 14.2 L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[mg] / [l],115,132999,DB01327,Cefazolin
,33969405,Cmax,"In obese patients (BMI 39.5-69.3 kg/m2) compared with non-obese patients (BMI 18.7-29.8 kg/m2), mean Cmax of total cefazolin in plasma was lower (115 versus 174 mg/L) and Vss was higher (19.4 versus 14.2 L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[mg] / [l],174,133000,DB01327,Cefazolin
,33969405,Vss,"In obese patients (BMI 39.5-69.3 kg/m2) compared with non-obese patients (BMI 18.7-29.8 kg/m2), mean Cmax of total cefazolin in plasma was lower (115 versus 174 mg/L) and Vss was higher (19.4 versus 14.2 L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),l,19.4,133001,DB01327,Cefazolin
,33969405,Vss,"In obese patients (BMI 39.5-69.3 kg/m2) compared with non-obese patients (BMI 18.7-29.8 kg/m2), mean Cmax of total cefazolin in plasma was lower (115 versus 174 mg/L) and Vss was higher (19.4 versus 14.2 L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),l,14.2,133002,DB01327,Cefazolin
,33969405,t½,"The mean differences in t½ (2.7 versus 2.4 h), CL (5.14 versus 4.63 L/h) and AUC∞ (402 versus 450 mg·h/L) were not significant.",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),h,2.7,133003,DB01327,Cefazolin
,33969405,t½,"The mean differences in t½ (2.7 versus 2.4 h), CL (5.14 versus 4.63 L/h) and AUC∞ (402 versus 450 mg·h/L) were not significant.",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),h,2.4,133004,DB01327,Cefazolin
,33969405,CL,"The mean differences in t½ (2.7 versus 2.4 h), CL (5.14 versus 4.63 L/h) and AUC∞ (402 versus 450 mg·h/L) were not significant.",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[l] / [h],5.14,133005,DB01327,Cefazolin
,33969405,CL,"The mean differences in t½ (2.7 versus 2.4 h), CL (5.14 versus 4.63 L/h) and AUC∞ (402 versus 450 mg·h/L) were not significant.",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[l] / [h],4.63,133006,DB01327,Cefazolin
,33969405,AUC∞,"The mean differences in t½ (2.7 versus 2.4 h), CL (5.14 versus 4.63 L/h) and AUC∞ (402 versus 450 mg·h/L) were not significant.",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[h·mg] / [l],402,133007,DB01327,Cefazolin
,33969405,AUC∞,"The mean differences in t½ (2.7 versus 2.4 h), CL (5.14 versus 4.63 L/h) and AUC∞ (402 versus 450 mg·h/L) were not significant.",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[h·mg] / [l],450,133008,DB01327,Cefazolin
,33969405,Cmax,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[mg] / [l],8.99,133009,DB01327,Cefazolin
,33969405,Cmax,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[mg] / [l],14.7,133010,DB01327,Cefazolin
,33969405,Vss,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),l,73.9,133011,DB01327,Cefazolin
,33969405,Vss,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),l,51.8,133012,DB01327,Cefazolin
,33969405,t½,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),h,11.9,133013,DB01327,Cefazolin
,33969405,t½,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),h,9.1,133014,DB01327,Cefazolin
,33969405,CL,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[l] / [h],4.62,133015,DB01327,Cefazolin
,33969405,CL,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[l] / [h],4.13,133016,DB01327,Cefazolin
,33969405,AUC∞,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[h·mg] / [l],116,133017,DB01327,Cefazolin
,33969405,AUC∞,"The influence of obesity on the pharmacokinetics of metronidazole was similar (Cmax 8.99 versus 14.7 mg/L, Vss 73.9 versus 51.8 L, t½ 11.9 versus 9.1 h, CL 4.62 versus 4.13 L/h, AUC∞ 116 versus 127 mg·h/L).",Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33969405/),[h·mg] / [l],127,133018,DB01327,Cefazolin
,17954069,plasma concentration,"Cefazolin plasma concentration rose to a peak of 443 microg/mL (range, 169 to 802 microg/mL) within 20 minutes (range, 20 to 40 minutes).",In vivo microdialysis to measure antibiotic penetration into soft tissue during cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17954069/),[μg] / [ml],443,134104,DB01327,Cefazolin
,14703199,clinical response rate,The clinical response rate to the empiric regimen was 90%.,Pharmacokinetics of ceftazidime in CAPD-related peritonitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703199/),%,90,136923,DB01327,Cefazolin
,22316145,fT>MIC,The protective duration of each cefazolin dose was assessed using the pharmacodynamic target for fT>MIC of 70%.,Cefazolin dosing for surgical prophylaxis in morbidly obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22316145/),%,70,137434,DB01327,Cefazolin
,22316145,half-life,The half-life ranged from 2.3 to 3.6 h and was unaffected by administration method.,Cefazolin dosing for surgical prophylaxis in morbidly obese patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22316145/),h,2.3 to 3.6,137435,DB01327,Cefazolin
,6091484,serum half-life,The serum half-life of ceftriaxone was approximately 15.7 hours.,Comparison of ceftriaxone and cefazolin prophylaxis against infection in open heart surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6091484/),h,15.7,137483,DB01327,Cefazolin
,2746854,half-life,The average half-life of SBT was 1.03 hours and that of ABPC was 0.83 hour.,"[Pharmacokinetic, bacteriological and clinical evaluation of sulbactam/ampicillin in pediatrics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746854/),h,1.03,153310,DB01327,Cefazolin
,2746854,half-life,The average half-life of SBT was 1.03 hours and that of ABPC was 0.83 hour.,"[Pharmacokinetic, bacteriological and clinical evaluation of sulbactam/ampicillin in pediatrics]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746854/),h,0.83,153311,DB01327,Cefazolin
,2746854,eradication rate,The bacteriological eradication rate was 80% (8/10).,"[Pharmacokinetic, bacteriological and clinical evaluation of sulbactam/ampicillin in pediatrics]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746854/),%,80,153312,DB01327,Cefazolin
,19006783,clearance,Cefazolin clearance and distribution estimates were 7.44 L/h and 12.04 L without gestational age-dependent trends in maternal plasma.,Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19006783/),[l] / [h],7.44,159141,DB01327,Cefazolin
,19006783,distribution,Cefazolin clearance and distribution estimates were 7.44 L/h and 12.04 L without gestational age-dependent trends in maternal plasma.,Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19006783/),l,12.04,159142,DB01327,Cefazolin
,19006783,half-life (T(eq)),"The equilibration half-life (T(eq)) between plasma and amniotic fluid at term gestational age was 4.4 hours, increased with decreasing gestational age, and was 9.09 times longer in patients with polyhydramnios.",Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19006783/),h,4.4,159143,DB01327,Cefazolin
<,27209020,minimal inhibitory concentrations,"More than 90% of bacteria on sternal skin were sensitive to cefazolin, indicating minimal inhibitory concentrations <8 mg/L.",Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209020/),[mg] / [l],8,159818,DB01327,Cefazolin
,27209020,clearance (CL),Pharmacokinetic modeling in a 1-compartment model predicted a population mean clearance (CL) of 5.23 L/h and a volume of distribution (Vd) of 15.8 L.,Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209020/),[l] / [h],5.23,159819,DB01327,Cefazolin
,27209020,volume of distribution (Vd),Pharmacokinetic modeling in a 1-compartment model predicted a population mean clearance (CL) of 5.23 L/h and a volume of distribution (Vd) of 15.8 L.,Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209020/),l,15.8,159820,DB01327,Cefazolin
,27209020,Vd,CPB increased Vd from 14.4 L to 22.1 L with a consecutive reduction to 18 L after the end of extracorporeal circulation.,Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209020/),l,14.4,159821,DB01327,Cefazolin
,27209020,Vd,CPB increased Vd from 14.4 L to 22.1 L with a consecutive reduction to 18 L after the end of extracorporeal circulation.,Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209020/),l,22.1,159822,DB01327,Cefazolin
,27209020,Vd,CPB increased Vd from 14.4 L to 22.1 L with a consecutive reduction to 18 L after the end of extracorporeal circulation.,Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209020/),l,18,159823,DB01327,Cefazolin
,2271755,elimination constant,"The elimination constant had a value of 0.832 +/- 0.821 h-1 (mean +/- S.D.), which is higher than the release constant of the derivative (0.109 +/- 0.072 h-1) (mean +/- S.D.).",Pharmacokinetics of dibenzylamine administered in a sustained drug delivery system with cefazolin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271755/),1/[h],0.832,162118,DB01327,Cefazolin
,2271755,release constant,"The elimination constant had a value of 0.832 +/- 0.821 h-1 (mean +/- S.D.), which is higher than the release constant of the derivative (0.109 +/- 0.072 h-1) (mean +/- S.D.).",Pharmacokinetics of dibenzylamine administered in a sustained drug delivery system with cefazolin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271755/),1/[h],0.109,162119,DB01327,Cefazolin
,2271755,excreted,Only a small amount of dibenzylamine is excreted in urine unchanged 3.43 +/- 3.28 per cent (mean +/- S.D.).,Pharmacokinetics of dibenzylamine administered in a sustained drug delivery system with cefazolin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271755/),%,3.43,162120,DB01327,Cefazolin
,2271755,accumulation factor,The accumulation factor was 1.09.,Pharmacokinetics of dibenzylamine administered in a sustained drug delivery system with cefazolin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271755/),,1.09,162121,DB01327,Cefazolin
,836007,retention time,"Cefazolin chromatographed without interference from ultraviolet-absorbing components of serum, with a retention time of 3.1 min.",Rapid analysis of cefazolin in serum by high-pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/836007/),min,3.1,162144,DB01327,Cefazolin
less,2751283,Protein binding,Protein binding of cefazolin and gentamicin in sera and wound fluids was low (less than or equal to 29 +/- 9%) in this canine model.,Penetration of antibiotics into the surgical wound in a canine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751283/),%,29,162637,DB01327,Cefazolin
lower,11783768,peak serum gentamicin levels,"The peak serum gentamicin levels were lower than the suggested values of 4 microg/mL, whereas the trough serum gentamicin levels were higher than the minimal toxic concentrations (2 microg/mL).",Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11783768/),[μg] / [ml],4,162795,DB01327,Cefazolin
,11783768,minimal toxic concentrations,"The peak serum gentamicin levels were lower than the suggested values of 4 microg/mL, whereas the trough serum gentamicin levels were higher than the minimal toxic concentrations (2 microg/mL).",Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11783768/),[μg] / [ml],2,162796,DB01327,Cefazolin
,20484555,K(m),Cephalexin uptake by human MATE1-expressing human embryonic kidney 293 cells exhibited saturable kinetics (K(m) = 5.9 +/- 0.5 mM) and a bell-shaped pH profile with a maximum at pH 7.0.,Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484555/),mM,5.9,163679,DB01327,Cefazolin
,30356800,percentage of,The percentage of cefazolin binding to serum protein was 36.2 ± 5.3%.,Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30356800/),%,36.2,165492,DB01327,Cefazolin
,30356800,binding to,The percentage of cefazolin binding to serum protein was 36.2 ± 5.3%.,Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30356800/),%,36.2,165493,DB01327,Cefazolin
,30356800,V1,"Population primary parameter estimates V1, V2, CL, and Q were (typical value ± SE) 0.116 ± 0.013 L/kg, 0.177 ± 0.011 L/kg, 0.0037 ± 0.0002 L/kg/min, and 0.0103 ± 0.0013 L/kg/min, respectively.",Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30356800/),[l] / [kg],0.116,165494,DB01327,Cefazolin
,30356800,V2,"Population primary parameter estimates V1, V2, CL, and Q were (typical value ± SE) 0.116 ± 0.013 L/kg, 0.177 ± 0.011 L/kg, 0.0037 ± 0.0002 L/kg/min, and 0.0103 ± 0.0013 L/kg/min, respectively.",Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30356800/),[l] / [kg],0.177,165495,DB01327,Cefazolin
,30356800,Q,"Population primary parameter estimates V1, V2, CL, and Q were (typical value ± SE) 0.116 ± 0.013 L/kg, 0.177 ± 0.011 L/kg, 0.0037 ± 0.0002 L/kg/min, and 0.0103 ± 0.0013 L/kg/min, respectively.",Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30356800/),[l] / [kg·min],0.0103,165496,DB01327,Cefazolin
,30356800,distribution,"Cefazolin presented rapid distribution and elimination half-lives (mean ± SE) 4.17 ± 0.77 min and 57.93 ± 3.11 min, respectively.",Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30356800/),min,4.17,165497,DB01327,Cefazolin
,30356800,elimination half-lives,"Cefazolin presented rapid distribution and elimination half-lives (mean ± SE) 4.17 ± 0.77 min and 57.93 ± 3.11 min, respectively.",Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30356800/),min,57.93,165498,DB01327,Cefazolin
≤,30356800,MIC,"In conclusion, cefazolin administered prophylactically in surgical dogs at 25 mg/kg IV every 6 h was deemed effective against pathogens with a MIC value ≤ 2 mg/L and from a PK/PD perspective, can be recommended in a wide range of canine patient populations with no necessary dose adjustment for special dog subpopulations.",Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30356800/),[mg] / [l],2,165499,DB01327,Cefazolin
,721712,Plasma levels at peak,"Plasma levels at peak were 134 microgram SK&F 75073/ml (half-life, 1.9 hours) and 72 microgram cefazolin/ml (half-life, 0.75 hours).","Distribution in normal and inflammatory tissue of a new semisynthetic cephalosporin, SK&F 75073. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721712/),μg,134,168620,DB01327,Cefazolin
,721712,half-life,"Plasma levels at peak were 134 microgram SK&F 75073/ml (half-life, 1.9 hours) and 72 microgram cefazolin/ml (half-life, 0.75 hours).","Distribution in normal and inflammatory tissue of a new semisynthetic cephalosporin, SK&F 75073. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721712/),h,1.9,168621,DB01327,Cefazolin
,721712,half-life,"Plasma levels at peak were 134 microgram SK&F 75073/ml (half-life, 1.9 hours) and 72 microgram cefazolin/ml (half-life, 0.75 hours).","Distribution in normal and inflammatory tissue of a new semisynthetic cephalosporin, SK&F 75073. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721712/),h,0.75,168622,DB01327,Cefazolin
,721712,Serum protein binding,Serum protein binding ranged from 96 approximately 98% for SK&F 75073 and 34 approximately 69% for cefazolin.,"Distribution in normal and inflammatory tissue of a new semisynthetic cephalosporin, SK&F 75073. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721712/),%,96 approximately 98,168623,DB01327,Cefazolin
,721712,Serum protein binding,Serum protein binding ranged from 96 approximately 98% for SK&F 75073 and 34 approximately 69% for cefazolin.,"Distribution in normal and inflammatory tissue of a new semisynthetic cephalosporin, SK&F 75073. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721712/),%,34 approximately 69,168624,DB01327,Cefazolin
,27999040,Clearance,"Clearance (1.56 L/h), central volume (1.93 L) and peripheral volume (2.39 L) were allometrically scaled by body weight.","Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999040/),[l] / [h],1.56,169581,DB01327,Cefazolin
,27999040,central volume,"Clearance (1.56 L/h), central volume (1.93 L) and peripheral volume (2.39 L) were allometrically scaled by body weight.","Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999040/),l,1.93,169582,DB01327,Cefazolin
,27999040,peripheral volume,"Clearance (1.56 L/h), central volume (1.93 L) and peripheral volume (2.39 L) were allometrically scaled by body weight.","Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999040/),l,2.39,169583,DB01327,Cefazolin
,19050530,wound drainage concentrations (peak,"These patients also demonstrated wound drainage concentrations (peak, 22.49 microg/ml) for approximately 4 to 5 hours.",Pharmacokinetics of topical and intravenous cefazolin in patients with clean surgical wounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19050530/),[μg] / [ml],22.49,172351,DB01327,Cefazolin
above,19050530,minimum therapeutic concentration,Measured concentrations were above the minimum therapeutic concentration (8 microg/ml) for Staphylococcus aureus.,Pharmacokinetics of topical and intravenous cefazolin in patients with clean surgical wounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19050530/),[μg] / [ml],8,172352,DB01327,Cefazolin
,19050530,peak,"In addition, these patients' wound drain fluid demonstrated very high cefazolin concentrations (peak, 4185.93 microg/ml), which remained high for 24 hours.",Pharmacokinetics of topical and intravenous cefazolin in patients with clean surgical wounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19050530/),[μg] / [ml],4185.93,172353,DB01327,Cefazolin
,33341979,MIC90,"For both CET and CEZ, the MIC90 against S. zooepidemicus was 0.12 mg/L and against S. aureus was 0.5 mg/L.",Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33341979/),[mg] / [l],0.12,173498,DB01327,Cefazolin
,33341979,MIC90,"For both CET and CEZ, the MIC90 against S. zooepidemicus was 0.12 mg/L and against S. aureus was 0.5 mg/L.",Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33341979/),[mg] / [l],0.5,173499,DB01327,Cefazolin
,6448233,number of binding sites,"The extent of protein binding, the number of binding sites and the association constant to human serum albumin were 90.4%, 0.87 and 2.16 X 10(4) in T-1551, and 89.2%, 0.78 and 2.46 X 10(4) in CEZ, respectively.",Studies on protein binding of antibiotics. I. Effect of cefazolin on protein binding and pharmacokinetics of cefoperazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6448233/),,0.87,174407,DB01327,Cefazolin
,6448233,number of binding sites,"The extent of protein binding, the number of binding sites and the association constant to human serum albumin were 90.4%, 0.87 and 2.16 X 10(4) in T-1551, and 89.2%, 0.78 and 2.46 X 10(4) in CEZ, respectively.",Studies on protein binding of antibiotics. I. Effect of cefazolin on protein binding and pharmacokinetics of cefoperazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6448233/),,2.16,174408,DB01327,Cefazolin
,6448233,number of binding sites,"The extent of protein binding, the number of binding sites and the association constant to human serum albumin were 90.4%, 0.87 and 2.16 X 10(4) in T-1551, and 89.2%, 0.78 and 2.46 X 10(4) in CEZ, respectively.",Studies on protein binding of antibiotics. I. Effect of cefazolin on protein binding and pharmacokinetics of cefoperazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6448233/),%,89,174409,DB01327,Cefazolin
,6448233,number of binding sites,"The extent of protein binding, the number of binding sites and the association constant to human serum albumin were 90.4%, 0.87 and 2.16 X 10(4) in T-1551, and 89.2%, 0.78 and 2.46 X 10(4) in CEZ, respectively.",Studies on protein binding of antibiotics. I. Effect of cefazolin on protein binding and pharmacokinetics of cefoperazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6448233/),,0.78,174410,DB01327,Cefazolin
,6448233,number of binding sites,"The extent of protein binding, the number of binding sites and the association constant to human serum albumin were 90.4%, 0.87 and 2.16 X 10(4) in T-1551, and 89.2%, 0.78 and 2.46 X 10(4) in CEZ, respectively.",Studies on protein binding of antibiotics. I. Effect of cefazolin on protein binding and pharmacokinetics of cefoperazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6448233/),,2.46,174411,DB01327,Cefazolin
,6448233,association constant,"The extent of protein binding, the number of binding sites and the association constant to human serum albumin were 90.4%, 0.87 and 2.16 X 10(4) in T-1551, and 89.2%, 0.78 and 2.46 X 10(4) in CEZ, respectively.",Studies on protein binding of antibiotics. I. Effect of cefazolin on protein binding and pharmacokinetics of cefoperazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6448233/),,2.16,174412,DB01327,Cefazolin
,6448233,association constant,"The extent of protein binding, the number of binding sites and the association constant to human serum albumin were 90.4%, 0.87 and 2.16 X 10(4) in T-1551, and 89.2%, 0.78 and 2.46 X 10(4) in CEZ, respectively.",Studies on protein binding of antibiotics. I. Effect of cefazolin on protein binding and pharmacokinetics of cefoperazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6448233/),,2.46,174413,DB01327,Cefazolin
,6310788,Apparent volumes,Apparent volumes of distribution vary little from the mean volume which is 0.30 liter per kg body weight.,[Comparative pharmacokinetics of moxalactam and other cephalosporins]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6310788/),[l] / [kg],0.30,176488,DB01327,Cefazolin
,6310788,apparent elimination half-lifes,"Conversely, apparent elimination half-lifes show significant differences, with values ranging from 0.52 h (cephalotin) and 0.75 h (cefotaxim) to 2.74 h (Moxalactam) and 3.07 h (cefazolin).",[Comparative pharmacokinetics of moxalactam and other cephalosporins]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6310788/),h,0.52,176489,DB01327,Cefazolin
,6310788,apparent elimination half-lifes,"Conversely, apparent elimination half-lifes show significant differences, with values ranging from 0.52 h (cephalotin) and 0.75 h (cefotaxim) to 2.74 h (Moxalactam) and 3.07 h (cefazolin).",[Comparative pharmacokinetics of moxalactam and other cephalosporins]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6310788/),h,0.75,176490,DB01327,Cefazolin
,6310788,apparent elimination half-lifes,"Conversely, apparent elimination half-lifes show significant differences, with values ranging from 0.52 h (cephalotin) and 0.75 h (cefotaxim) to 2.74 h (Moxalactam) and 3.07 h (cefazolin).",[Comparative pharmacokinetics of moxalactam and other cephalosporins]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6310788/),h,2.74,176491,DB01327,Cefazolin
,6310788,apparent elimination half-lifes,"Conversely, apparent elimination half-lifes show significant differences, with values ranging from 0.52 h (cephalotin) and 0.75 h (cefotaxim) to 2.74 h (Moxalactam) and 3.07 h (cefazolin).",[Comparative pharmacokinetics of moxalactam and other cephalosporins]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6310788/),h,3.07,176492,DB01327,Cefazolin
,8836706,lipophilicity (log k'w),"In our experimental conditions, the ideal lipophilicity (log k'w) range for diffusion of cephalosporins from plasma into CSF was between 1.6 and 1.8.",Influence of lipophilicity on the diffusion of cephalosporins into the cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836706/),,1.6 and 1.8,177348,DB01327,Cefazolin
,33905919,time interval,"The mean time interval between drug administration and incision did not differ between the two groups (18 ± 10 min vs. 11 ± 10 min, respectively, p = .0.25).",Cefazolin prophylaxis in minimally invasive gynecologic surgery - are dosage and timing appropriate? Prospective study using resampling simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33905919/),min,18,180257,DB01327,Cefazolin
,33905919,time interval,"The mean time interval between drug administration and incision did not differ between the two groups (18 ± 10 min vs. 11 ± 10 min, respectively, p = .0.25).",Cefazolin prophylaxis in minimally invasive gynecologic surgery - are dosage and timing appropriate? Prospective study using resampling simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33905919/),min,11,180258,DB01327,Cefazolin
,582722,serum elimination half-life,"In particular, it must be noted that cefazedone has a relatively long serum elimination half-life (1.64 +/- 0.23 h after i.v. and 1.85 +/- 0.51 h after i.m. administration) and that cefazedone exhibits, in comparison with cefazolin, a more favourable concentration ratio of central vs. peripheral (= tissue) compartment (1:2).","Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. Pharmacokinetics in comparison with cefazolin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/582722/),h,1.64,183874,DB01327,Cefazolin
,582722,serum elimination half-life,"In particular, it must be noted that cefazedone has a relatively long serum elimination half-life (1.64 +/- 0.23 h after i.v. and 1.85 +/- 0.51 h after i.m. administration) and that cefazedone exhibits, in comparison with cefazolin, a more favourable concentration ratio of central vs. peripheral (= tissue) compartment (1:2).","Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. Pharmacokinetics in comparison with cefazolin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/582722/),h,1.85,183875,DB01327,Cefazolin
,10820176,bioavailability,"The bioavailability was found to be 77.9 +/- 3.1%, volume of distribution 0.20 +/- 0.05 L/kg, and plasma half-life 39.9 +/- 25.4 h.",Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820176/),%,77.9,185574,DB01327,Cefazolin
,10820176,volume of distribution,"The bioavailability was found to be 77.9 +/- 3.1%, volume of distribution 0.20 +/- 0.05 L/kg, and plasma half-life 39.9 +/- 25.4 h.",Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820176/),[l] / [kg],0.20,185575,DB01327,Cefazolin
,10820176,plasma half-life,"The bioavailability was found to be 77.9 +/- 3.1%, volume of distribution 0.20 +/- 0.05 L/kg, and plasma half-life 39.9 +/- 25.4 h.",Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820176/),h,39.9,185576,DB01327,Cefazolin
,10820176,total,"Mean total, renal, and peritoneal clearances were 4.5 +/- 2.3, 1. 4 +/- 1.1, and 3.5 +/- 1.8 ml/min, respectively.",Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820176/),[ml] / [min],4.5,185577,DB01327,Cefazolin
,10820176,peritoneal clearances,"Mean total, renal, and peritoneal clearances were 4.5 +/- 2.3, 1. 4 +/- 1.1, and 3.5 +/- 1.8 ml/min, respectively.",Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820176/),[ml] / [min],3.5,185578,DB01327,Cefazolin
,30345801,interdialysis clearance,"Median interdialysis clearance was 0.16 L/h (interquartile range [IQR]: 0.11-0.21 L/h), and median intradialysis clearance was 1.95 L/h (IQR: 1.66-2.45 L/h).",Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30345801/),[l] / [h],0.16,186024,DB01327,Cefazolin
,30345801,intradialysis clearance,"Median interdialysis clearance was 0.16 L/h (interquartile range [IQR]: 0.11-0.21 L/h), and median intradialysis clearance was 1.95 L/h (IQR: 1.66-2.45 L/h).",Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30345801/),[l] / [h],1.95,186025,DB01327,Cefazolin
,30345801,inter,Median interdialysis half-life was 28.2 hours (IQR: 23.5-59.3 hours) as compared with a median intradialysis half-life of 2.3 hours (IQR: 1.7-2.7 hours).,Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30345801/),h,28.2,186026,DB01327,Cefazolin
,30345801,half-life,Median interdialysis half-life was 28.2 hours (IQR: 23.5-59.3 hours) as compared with a median intradialysis half-life of 2.3 hours (IQR: 1.7-2.7 hours).,Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30345801/),h,2.3,186027,DB01327,Cefazolin
,30345801,percentage removal,The median percentage removal of cefazolin during dialysis was 41% (IQR: 35%-53%).,Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30345801/),%,41,186028,DB01327,Cefazolin
greater,30345801,total serum drug concentrations,"Current dosing recommendations of 1 g IV post-SDHD achieve total serum drug concentrations greater than 40 mg/L in all patients, which is the total drug concentration required for bactericidal activity against Staphylococcus species.",Pharmacokinetic Study of Cefazolin in Short Daily Hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30345801/),[mg] / [l],40,186029,DB01327,Cefazolin
,29506833,Maximum serum concentrations,Maximum serum concentrations of cefazolin were achieved 42.6 ± 2.0 min after the time of injection and were found to be 18.8 ± 7.4 μg/mL.,Subcutaneous cefazolin to reduce surgical site infections in a porcine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29506833/),min,42,187349,DB01327,Cefazolin
,29506833,Maximum serum concentrations,Maximum serum concentrations of cefazolin were achieved 42.6 ± 2.0 min after the time of injection and were found to be 18.8 ± 7.4 μg/mL.,Subcutaneous cefazolin to reduce surgical site infections in a porcine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29506833/),[μg] / [ml],18.8,187350,DB01327,Cefazolin
,29506833,elimination rate constant,The elimination rate constant was 0.0033 ± 0.0016 min-1 and the half-life was 266 ± 149 min.,Subcutaneous cefazolin to reduce surgical site infections in a porcine model. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29506833/),1/[min],0.0033,187351,DB01327,Cefazolin
,29506833,half-life,The elimination rate constant was 0.0033 ± 0.0016 min-1 and the half-life was 266 ± 149 min.,Subcutaneous cefazolin to reduce surgical site infections in a porcine model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29506833/),min,266,187352,DB01327,Cefazolin
,29506833,area under the curve,The area under the curve was 4940 ± 1030 μg × min/mL.,Subcutaneous cefazolin to reduce surgical site infections in a porcine model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29506833/),[min·μg] / [ml],4940,187353,DB01327,Cefazolin
,29506833,relative bioavailability,The relative bioavailability of subcutaneous injection was 95% +5%/-20%.,Subcutaneous cefazolin to reduce surgical site infections in a porcine model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29506833/),%,95,187354,DB01327,Cefazolin
,318227,bioavailability,The bioavailability of intramuscularly administered cefoxitin is equivalent to that of intravenously administered cefoxitin and is 90% complete within 3-4 hr after the dose is given.,Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/318227/),,90,192253,DB01327,Cefazolin
,2762224,Vss,The Vss value of cefazolin was predicted to be 0.3 . (predicted Vss of tobramycin) + 0.052 . total body weight (kg).,Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762224/),,0.3,192663,DB01327,Cefazolin
,2131868,minimum inhibitory concentration (MIC),"During the postoperative period, cefazolin levels were consistently greater than the minimum inhibitory concentration (MIC) for sensitive bacteria (4 micrograms/mL); average netilmicin levels were greater than MIC of sensitive bacteria (2 micrograms/mL) for 2 hours after antibiotic infusion.",Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2131868/),[μg] / [ml],4,194535,DB01327,Cefazolin
,2131868,MIC,"During the postoperative period, cefazolin levels were consistently greater than the minimum inhibitory concentration (MIC) for sensitive bacteria (4 micrograms/mL); average netilmicin levels were greater than MIC of sensitive bacteria (2 micrograms/mL) for 2 hours after antibiotic infusion.",Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2131868/),[μg] / [ml],2,194536,DB01327,Cefazolin
,2131868,trough levels,The netilmicin trough levels were 0.6 +/- 0.5 micrograms/mL.,Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2131868/),[μg] / [ml],0.6,194537,DB01327,Cefazolin
,2131868,elimination half-life,"Pharmacokinetic parameters were determined using a model-independent method, and gave the following results during surgery: cefazolin--elimination half-life, 231 minutes, total body clearance, 1.05 mL/kg/min, and steady-state volume of distribution, 243 mL/kg.",Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2131868/),min,231,194538,DB01327,Cefazolin
,2131868,total body clearance,"Pharmacokinetic parameters were determined using a model-independent method, and gave the following results during surgery: cefazolin--elimination half-life, 231 minutes, total body clearance, 1.05 mL/kg/min, and steady-state volume of distribution, 243 mL/kg.",Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2131868/),[ml] / [kg·min],1.05,194539,DB01327,Cefazolin
,2131868,steady-state volume of distribution,"Pharmacokinetic parameters were determined using a model-independent method, and gave the following results during surgery: cefazolin--elimination half-life, 231 minutes, total body clearance, 1.05 mL/kg/min, and steady-state volume of distribution, 243 mL/kg.",Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2131868/),[ml] / [kg],243,194540,DB01327,Cefazolin
,2131868,elimination half-life,"Postoperatively there were no significant changes in the disposition of cefazolin, but the elimination half-life of netilmicin was shorter (124 minutes, P less than 0.01) and the total body clearance greater (3.58 mL/kg/min, P less than 0.01) than during surgery.",Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2131868/),min,124,194541,DB01327,Cefazolin
,2131868,total body clearance,"Postoperatively there were no significant changes in the disposition of cefazolin, but the elimination half-life of netilmicin was shorter (124 minutes, P less than 0.01) and the total body clearance greater (3.58 mL/kg/min, P less than 0.01) than during surgery.",Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2131868/),[ml] / [kg·min],3.58,194542,DB01327,Cefazolin
,6283194,peak tissue levels,The mean peak tissue levels of CZX after 1 g dose by intravenous drip infusion for 1 hour were 14.3 micrograms/g (n = 5) in gingiva and 8.5 micrograms/g (n = 2) in bone marrow at the end of intravenous drip infusion.,[Experimental and clinical studies on ceftizoxime in the field of oral surgery (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6283194/),[μg] / [g],14.3,195860,DB01327,Cefazolin
,6283194,peak tissue levels,The mean peak tissue levels of CZX after 1 g dose by intravenous drip infusion for 1 hour were 14.3 micrograms/g (n = 5) in gingiva and 8.5 micrograms/g (n = 2) in bone marrow at the end of intravenous drip infusion.,[Experimental and clinical studies on ceftizoxime in the field of oral surgery (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6283194/),[μg] / [g],8.5,195861,DB01327,Cefazolin
,6283194,rate of effectiveness,The final rate of effectiveness was 88.2%.,[Experimental and clinical studies on ceftizoxime in the field of oral surgery (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6283194/),%,88.2,195862,DB01327,Cefazolin
,11765153,half-lives,"The vitreal half-lives of cephalexin, cefazolin, and cephalothin were 185.38 +/- 27.25 min, 111.40 +/- 17.17 min, and 146.68 +/- 47.52 min, respectively.",Ocular pharmacokinetics of cephalosporins using microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765153/),min,185.38,198381,DB01327,Cefazolin
,11765153,half-lives,"The vitreal half-lives of cephalexin, cefazolin, and cephalothin were 185.38 +/- 27.25 min, 111.40 +/- 17.17 min, and 146.68 +/- 47.52 min, respectively.",Ocular pharmacokinetics of cephalosporins using microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765153/),min,111.40,198382,DB01327,Cefazolin
,11765153,half-lives,"The vitreal half-lives of cephalexin, cefazolin, and cephalothin were 185.38 +/- 27.25 min, 111.40 +/- 17.17 min, and 146.68 +/- 47.52 min, respectively.",Ocular pharmacokinetics of cephalosporins using microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765153/),min,146.68,198383,DB01327,Cefazolin
,11765153,AUC,"The pharmacokinetic parameters of cephalexin in the presence of gly-pro, i.e., AUC (44452.06 +/- 3326.55 microg x min/ml), clearance (0.0013 +/- 0.0004 ml/min) and vitreal half-life (825.12 +/- 499.95 min) were different from that of the control (14612.83 +/- 4036.47 microg x min/ml, 0.0036 +/- 0.0011 ml/min, and 187.96 +/- 65.12 min, respectively).",Ocular pharmacokinetics of cephalosporins using microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765153/),[min·μg] / [ml],44452.06,198384,DB01327,Cefazolin
,11765153,clearance,"The pharmacokinetic parameters of cephalexin in the presence of gly-pro, i.e., AUC (44452.06 +/- 3326.55 microg x min/ml), clearance (0.0013 +/- 0.0004 ml/min) and vitreal half-life (825.12 +/- 499.95 min) were different from that of the control (14612.83 +/- 4036.47 microg x min/ml, 0.0036 +/- 0.0011 ml/min, and 187.96 +/- 65.12 min, respectively).",Ocular pharmacokinetics of cephalosporins using microdialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765153/),[ml] / [min],0.0013,198385,DB01327,Cefazolin
,11765153,half-life,"The pharmacokinetic parameters of cephalexin in the presence of gly-pro, i.e., AUC (44452.06 +/- 3326.55 microg x min/ml), clearance (0.0013 +/- 0.0004 ml/min) and vitreal half-life (825.12 +/- 499.95 min) were different from that of the control (14612.83 +/- 4036.47 microg x min/ml, 0.0036 +/- 0.0011 ml/min, and 187.96 +/- 65.12 min, respectively).",Ocular pharmacokinetics of cephalosporins using microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765153/),min,825.12,198386,DB01327,Cefazolin
,11765153,half-life,"The pharmacokinetic parameters of cephalexin in the presence of gly-pro, i.e., AUC (44452.06 +/- 3326.55 microg x min/ml), clearance (0.0013 +/- 0.0004 ml/min) and vitreal half-life (825.12 +/- 499.95 min) were different from that of the control (14612.83 +/- 4036.47 microg x min/ml, 0.0036 +/- 0.0011 ml/min, and 187.96 +/- 65.12 min, respectively).",Ocular pharmacokinetics of cephalosporins using microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765153/),min,187.96,198387,DB01327,Cefazolin
,30336498,QBL,"Median QBL was 630 mL (interquartile range [IQR]: 473-818) and 1,160 mL (IQR: 1,000-1,560) in the low and high QBL groups, respectively.",The Effect of Blood Loss on Cefazolin Levels in Women Undergoing Cesarean Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336498/),ml,630,198815,DB01327,Cefazolin
,30336498,QBL,"Median QBL was 630 mL (interquartile range [IQR]: 473-818) and 1,160 mL (IQR: 1,000-1,560) in the low and high QBL groups, respectively.",The Effect of Blood Loss on Cefazolin Levels in Women Undergoing Cesarean Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336498/),ml,"1,160",198816,DB01327,Cefazolin
greater,3512862,TC/MIC ratio,Cefoxitin and moxalactam failed to achieve an effective therapeutic TC/MIC ratio (greater than 10) for S. aureus and S. albus in all the tissues studied whereas cefoxitin and cefamandole were above therapeutic levels.,Antibiotic prophylaxis in vascular surgery: pharmacokinetic study of four commonly used cephalosporins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512862/),,10,199808,DB01327,Cefazolin
,15487653,half-life,Zinc levels in the plasma declined in a steady fashion (half-life = 7.6 d).,Diagnosis and treatment of zinc poisoning in a dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487653/),d,7.6,201996,DB01327,Cefazolin
,31610538,Protein binding,Protein binding was ∼60%.,Pharmacokinetics of Total and Unbound Cefazolin during Veno-Arterial Extracorporeal Membrane Oxygenation: A Case Report. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31610538/),%,∼60,204288,DB01327,Cefazolin
,27246239,plasma unbound cefazolin,The median plasma unbound cefazolin peak level (immediately after cefazolin administration) was 36.6 mg/L (IQR 23.7-54.1) and the level at the time of cyst fluid aspiration was 16.1 mg/L (IQR 13.0-20.1).,Hepatic cyst penetration of cefazolin in patients receiving aspiration sclerotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27246239/),[mg] / [l],36.6,205335,DB01327,Cefazolin
,27246239,peak level,The median plasma unbound cefazolin peak level (immediately after cefazolin administration) was 36.6 mg/L (IQR 23.7-54.1) and the level at the time of cyst fluid aspiration was 16.1 mg/L (IQR 13.0-20.1).,Hepatic cyst penetration of cefazolin in patients receiving aspiration sclerotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27246239/),[mg] / [l],36.6,205336,DB01327,Cefazolin
,27246239,peak level,The median plasma unbound cefazolin peak level (immediately after cefazolin administration) was 36.6 mg/L (IQR 23.7-54.1) and the level at the time of cyst fluid aspiration was 16.1 mg/L (IQR 13.0-20.1).,Hepatic cyst penetration of cefazolin in patients receiving aspiration sclerotherapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27246239/),[mg] / [l],16.1,205337,DB01327,Cefazolin
,27246239,hepatic cyst penetration,"In total, the hepatic cyst penetration of free cefazolin was only 2.2% (IQR 0.7-5.2).",Hepatic cyst penetration of cefazolin in patients receiving aspiration sclerotherapy. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27246239/),%,2.2,205338,DB01327,Cefazolin
<,11772242,MIC90,"Ertapenem has a broad antibacterial spectrum with MIC90 values < 0.5 mg/l for penicillin-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella spp., Serratia spp., Proteus spp., Clostridium perfringens, Fusobacterium spp.",Ertapenem: a new carbapenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),[mg] / [l],0.5,205734,DB01327,Cefazolin
,11772242,PAE,Ertapenem exhibits a bactericidal mode of action as shown by time-killing curves and exhibits a short PAE of 1.4 - 2.6 h against the Gram-positive strains but no PAE against Gram-negative strains.,Ertapenem: a new carbapenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),h,1.4 - 2.6,205735,DB01327,Cefazolin
,11772242,half-life,"In comparison to other available carbapenems, ertapenem has a long half-life of 4.5 h and is developed as a single daily dose carbapenem.",Ertapenem: a new carbapenem. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),h,4.5,205736,DB01327,Cefazolin
,11772242,protein binding,The protein binding is dose-dependent and is estimated to 94% at concentrations under 100 mg/l and approximately 85% at 300 mg/l.,Ertapenem: a new carbapenem. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),%,94,205737,DB01327,Cefazolin
,11772242,protein binding,The protein binding is dose-dependent and is estimated to 94% at concentrations under 100 mg/l and approximately 85% at 300 mg/l.,Ertapenem: a new carbapenem. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),%,85,205738,DB01327,Cefazolin
,11772242,Cmax,Cmax after a dose of 1 g in healthy volunteers has been estimated to 190 mg/l.,Ertapenem: a new carbapenem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),[mg] / [l],190,205739,DB01327,Cefazolin
,11772242,MIC,"For pathogens with a MIC of 0.5 mg/l, the estimated T > MIC will be 50% (of 24 h) and for pathogens with a MIC of 1 mg/l 31%.",Ertapenem: a new carbapenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),[mg] / [l],0.5,205740,DB01327,Cefazolin
,11772242,T > MIC,"For pathogens with a MIC of 0.5 mg/l, the estimated T > MIC will be 50% (of 24 h) and for pathogens with a MIC of 1 mg/l 31%.",Ertapenem: a new carbapenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),%,50,205741,DB01327,Cefazolin
,11772242,T > MIC,"For pathogens with a MIC of 0.5 mg/l, the estimated T > MIC will be 50% (of 24 h) and for pathogens with a MIC of 1 mg/l 31%.",Ertapenem: a new carbapenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),h,24,205742,DB01327,Cefazolin
,11772242,MIC,"For pathogens with a MIC of 0.5 mg/l, the estimated T > MIC will be 50% (of 24 h) and for pathogens with a MIC of 1 mg/l 31%.",Ertapenem: a new carbapenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),[mg] / [l],1,205743,DB01327,Cefazolin
,11772242,MIC,"For pathogens with a MIC of 0.5 mg/l, the estimated T > MIC will be 50% (of 24 h) and for pathogens with a MIC of 1 mg/l 31%.",Ertapenem: a new carbapenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),%,31,205744,DB01327,Cefazolin
,11772242,MIC,"For anaerobic bacteria with MIC values between 1-2 mg/l, the T > MIC may not be sufficient for bacterial eradication.",Ertapenem: a new carbapenem. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11772242/),[mg] / [l],1-2,205745,DB01327,Cefazolin
greater,311356,peak concentrations,"Following subconjunctival injection of 12.5 mg into infected eyes (S. aureus endophthalmitis) of pigmented rabbits, both drugs reached peak concentrations greater than 100 microgram/gm in cornea, sclera, and choroid-retina.",Intraocular levels of cefamandole compared with cefazolin after subconjunctival injection in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311356/),[μg] / [gm],100,210270,DB01327,Cefazolin
,311356,peak concentrations,Levels in the vitreous humor were exceedingly low with both drugs; mean peak concentrations were 0.24 microgram/ml after the 12.5 mg dosage of cefamandole and less than 1.6 microgram/ml after the 100 mg dose of cefazolin.,Intraocular levels of cefamandole compared with cefazolin after subconjunctival injection in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311356/),[μg] / [ml],0.24,210271,DB01327,Cefazolin
less,311356,peak concentrations,Levels in the vitreous humor were exceedingly low with both drugs; mean peak concentrations were 0.24 microgram/ml after the 12.5 mg dosage of cefamandole and less than 1.6 microgram/ml after the 100 mg dose of cefazolin.,Intraocular levels of cefamandole compared with cefazolin after subconjunctival injection in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/311356/),[μg] / [ml],1.6,210272,DB01327,Cefazolin
,4793878,Peak serum concentrations,"Peak serum concentrations averaged 36 mug/ml, about four times as high as with the same doses of cephalothin, twice as high as with cephaloridine, and slightly lower than with cefazolin.",Pharmacokinetics of cephanone in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4793878/),[μg] / [ml],36,211037,DB01327,Cefazolin
,4793878,steady-state serum concentration,"With a constant intravenous infusion of 100 mg/h, a steady-state serum concentration of 31 mug/ml was attained in four volunteers.",Pharmacokinetics of cephanone in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4793878/),[μg] / [ml],31,211038,DB01327,Cefazolin
,4793878,serum half-life,"The serum half-life was similar for the intramuscular and intravenous studies, 2.4 and 2.6 h, respectively.",Pharmacokinetics of cephanone in healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4793878/),h,2.4,211039,DB01327,Cefazolin
,4793878,serum half-life,"The serum half-life was similar for the intramuscular and intravenous studies, 2.4 and 2.6 h, respectively.",Pharmacokinetics of cephanone in healthy adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4793878/),h,2.6,211040,DB01327,Cefazolin
,4793878,renal clearance,The factor mainly responsible for the higher and more sustained serum concentrations of cephanone was its low renal clearance of 47 ml per min per 1.73 m(2).,Pharmacokinetics of cephanone in healthy adult volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4793878/),[1.73·min·ml] / [m(2],47,211041,DB01327,Cefazolin
,4793878,serum protein binding,"Cephanone has a small apparent volume of distribution, probably related to its high serum protein binding of 88%.",Pharmacokinetics of cephanone in healthy adult volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4793878/),%,88,211042,DB01327,Cefazolin
,16211531,minimum inhibitory concentrations,Serum cefazolin and ceftazidime levels exceeded the minimum inhibitory concentrations for susceptible organisms (8 mg/L) throughout the 20 hour study period.,Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[mg] / [l],8,211086,DB01327,Cefazolin
,16211531,bioavailability,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),%,71,211087,DB01327,Cefazolin
,16211531,bioavailability,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),%,63,211088,DB01327,Cefazolin
,16211531,elimination rate constant,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),-1·h,0.031,211089,DB01327,Cefazolin
,16211531,elimination rate constant,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),-1·h,0.045,211090,DB01327,Cefazolin
,16211531,total clearance,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[ml] / [min],5.8,211091,DB01327,Cefazolin
,16211531,total clearance,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[ml] / [min],16.0,211092,DB01327,Cefazolin
,16211531,peritoneal clearance,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[ml] / [min],1.6,211093,DB01327,Cefazolin
,16211531,peritoneal clearance,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[ml] / [min],3.9,211094,DB01327,Cefazolin
,16211531,renal clearance,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[ml] / [min],2.3,211095,DB01327,Cefazolin
,16211531,renal clearance,"Mean cefazolin and ceftazidime PK parameters included: bioavailability, 71% and 63%; elimination rate constant, 0.031 and 0.045 h -1 ; total clearance, 5.8 and 16.0 ml/min; peritoneal clearance, 1.6 and 3.9 ml/min; renal clearance, 2.3 and 3.9 ml/min, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[ml] / [min],3.9,211096,DB01327,Cefazolin
,16211531,steady-state trough serum cefazolin,"Predictive equations suggest that 1000 mg IP of cefazolin and of ceftazidime every 24 hours would produce average steady-state trough serum cefazolin and ceftazidime concentrations of 70 +/- 52 mg/L and 17 +/- 7 mg/L, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[mg] / [l],70,211097,DB01327,Cefazolin
,16211531,steady-state trough serum cefazolin,"Predictive equations suggest that 1000 mg IP of cefazolin and of ceftazidime every 24 hours would produce average steady-state trough serum cefazolin and ceftazidime concentrations of 70 +/- 52 mg/L and 17 +/- 7 mg/L, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[mg] / [l],17,211098,DB01327,Cefazolin
,16211531,concentrations,"Predictive equations suggest that 1000 mg IP of cefazolin and of ceftazidime every 24 hours would produce average steady-state trough serum cefazolin and ceftazidime concentrations of 70 +/- 52 mg/L and 17 +/- 7 mg/L, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[mg] / [l],70,211099,DB01327,Cefazolin
,16211531,concentrations,"Predictive equations suggest that 1000 mg IP of cefazolin and of ceftazidime every 24 hours would produce average steady-state trough serum cefazolin and ceftazidime concentrations of 70 +/- 52 mg/L and 17 +/- 7 mg/L, respectively.",Pharmacokinetics of intraperitoneal cefazolin and ceftazidime coadministered to CAPD patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16211531/),[mg] / [l],17,211100,DB01327,Cefazolin
,27925657,MIC,"AT concentrations for 5000 overweight and obese patients receiving 1-, 2-, and 3-g cefazolin regimens were simulated to calculate the probability that free drug concentrations remained above an MIC of 2 μg/mL at 1, 1.5, and 2 hours after administration.",Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27925657/),[μg] / [ml],2,211213,DB01327,Cefazolin
,27925657,clearance,"Final model parameters were clearance 7.38 ± 5.34 L/h, volume of central compartment 11.8±9.36 L, and AT volume of distribution 80.12 ± 55.47 L.",Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27925657/),[l] / [h],7.38,211214,DB01327,Cefazolin
,27925657,volume of central compartment,"Final model parameters were clearance 7.38 ± 5.34 L/h, volume of central compartment 11.8±9.36 L, and AT volume of distribution 80.12 ± 55.47 L.",Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27925657/),l,11.8,211215,DB01327,Cefazolin
,27925657,volume of distribution,"Final model parameters were clearance 7.38 ± 5.34 L/h, volume of central compartment 11.8±9.36 L, and AT volume of distribution 80.12 ± 55.47 L.",Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27925657/),l,80.12,211216,DB01327,Cefazolin
,27925657,penetration ratio,The mean±SD (median) penetration ratio of cefazolin into AT was 0.81 ± 2.06 (0.62).,Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27925657/),,0.81,211217,DB01327,Cefazolin
,27925657,penetration ratio,The mean±SD (median) penetration ratio of cefazolin into AT was 0.81 ± 2.06 (0.62).,Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27925657/),,0.62,211218,DB01327,Cefazolin
,526003,Half-life (t((1/2)),"Half-life (t((1/2)), 2.8 h), plasma clearance (Cl(p), 48 ml/min per 1.73 m(2)), and renal clearance (Cl(0-12h) (r), 47 ml/min per 1.73 m(2); tubular secretion, 44%, and glomerular filtration, 56%) did not change with increased dose or on multiple dosing.",Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526003/),h,2.8,215530,DB01327,Cefazolin
,526003,plasma clearance (Cl(p),"Half-life (t((1/2)), 2.8 h), plasma clearance (Cl(p), 48 ml/min per 1.73 m(2)), and renal clearance (Cl(0-12h) (r), 47 ml/min per 1.73 m(2); tubular secretion, 44%, and glomerular filtration, 56%) did not change with increased dose or on multiple dosing.",Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526003/),[1.73·min·ml] / [m(2],48,215531,DB01327,Cefazolin
,526003,renal clearance (Cl(0-12h),"Half-life (t((1/2)), 2.8 h), plasma clearance (Cl(p), 48 ml/min per 1.73 m(2)), and renal clearance (Cl(0-12h) (r), 47 ml/min per 1.73 m(2); tubular secretion, 44%, and glomerular filtration, 56%) did not change with increased dose or on multiple dosing.",Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526003/),[1.73·min·ml] / [m(2],47,215532,DB01327,Cefazolin
,526003,t((1/2)),"No significant change was observed in t((1/2)) (1.9 h), area under the plasma concentration-time curve, Cl(r) (60 ml/min per 1.73 m(2); tubular secretion, 80%, and glomerular filtration, 20%), or Cl(p) (75 ml/min per 1.73 m(2)) for 4-g single doses compared with twice-daily administration of cefazolin.",Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526003/),h,1.9,215533,DB01327,Cefazolin
,526003,"area under the plasma concentration-time curve, Cl(r)","No significant change was observed in t((1/2)) (1.9 h), area under the plasma concentration-time curve, Cl(r) (60 ml/min per 1.73 m(2); tubular secretion, 80%, and glomerular filtration, 20%), or Cl(p) (75 ml/min per 1.73 m(2)) for 4-g single doses compared with twice-daily administration of cefazolin.",Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526003/),[1.73·min·ml] / [m(2],60,215534,DB01327,Cefazolin
,526003,Cl(p),"No significant change was observed in t((1/2)) (1.9 h), area under the plasma concentration-time curve, Cl(r) (60 ml/min per 1.73 m(2); tubular secretion, 80%, and glomerular filtration, 20%), or Cl(p) (75 ml/min per 1.73 m(2)) for 4-g single doses compared with twice-daily administration of cefazolin.",Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526003/),[1.73·min·ml] / [m(2],75,215535,DB01327,Cefazolin
,657874,protein binding,Reported values for protein binding range from 6% for cephradine to 92% for cefazolin.,Pharmacokinetics of cephalosporin antibiotics: protein-binding considerations. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657874/),%,6,218141,DB01327,Cefazolin
,657874,protein binding,Reported values for protein binding range from 6% for cephradine to 92% for cefazolin.,Pharmacokinetics of cephalosporin antibiotics: protein-binding considerations. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/657874/),%,92,218142,DB01327,Cefazolin
,3207857,time,"The time of cefazolin at levels greater than 1 microgram ml-1 was 16.03 +/- 2.51 and 47.76 +/- 14.18 h-1 after administration of the standard formulation and the DDS, respectively.",Pharmacokinetics of cefazolin administered as a new drug delivery system in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207857/),1/[h],16.03,219173,DB01327,Cefazolin
,3207857,time,"The time of cefazolin at levels greater than 1 microgram ml-1 was 16.03 +/- 2.51 and 47.76 +/- 14.18 h-1 after administration of the standard formulation and the DDS, respectively.",Pharmacokinetics of cefazolin administered as a new drug delivery system in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207857/),1/[h],47.76,219174,DB01327,Cefazolin
,33526489,MIC,The pharmacodynamic index target value obtained from our results indicates the probability of maintaining CFZ trough and hip joint capsule concentrations exceeding the MIC of 1 mg/liter to account for methicillin-susceptible S. aureus (MSSA).,Population Pharmacokinetic and Pharmacodynamic Target Attainment Analysis of Cefazolin in the Serum and Hip Joint Capsule of Patients Undergoing Total Hip Arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33526489/),[mg] / [l],1,221794,DB01327,Cefazolin
,33526489,volume of distribution of the central compartment (Vc),"The estimated population pharmacokinetic parameters were as follows: clearance (CL) (liters/h) = 1.46 × (creatinine clearance [CLcr] [ml/min]/77)0.891, volume of distribution of the central compartment (Vc) (liters) = 7.5, central-hip joint capsule compartment clearance (Q) (liters/h) = 3.38, and volume of distribution in the hip joint capsule compartment (VJC) (liters) = 36.1.",Population Pharmacokinetic and Pharmacodynamic Target Attainment Analysis of Cefazolin in the Serum and Hip Joint Capsule of Patients Undergoing Total Hip Arthroplasty. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33526489/),l,7.5,221795,DB01327,Cefazolin
,33526489,central-hip joint capsule compartment clearance (Q),"The estimated population pharmacokinetic parameters were as follows: clearance (CL) (liters/h) = 1.46 × (creatinine clearance [CLcr] [ml/min]/77)0.891, volume of distribution of the central compartment (Vc) (liters) = 7.5, central-hip joint capsule compartment clearance (Q) (liters/h) = 3.38, and volume of distribution in the hip joint capsule compartment (VJC) (liters) = 36.1.",Population Pharmacokinetic and Pharmacodynamic Target Attainment Analysis of Cefazolin in the Serum and Hip Joint Capsule of Patients Undergoing Total Hip Arthroplasty. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33526489/),[l] / [h],3.38,221796,DB01327,Cefazolin
,33526489,volume of distribution in the hip joint capsule compartment (VJC),"The estimated population pharmacokinetic parameters were as follows: clearance (CL) (liters/h) = 1.46 × (creatinine clearance [CLcr] [ml/min]/77)0.891, volume of distribution of the central compartment (Vc) (liters) = 7.5, central-hip joint capsule compartment clearance (Q) (liters/h) = 3.38, and volume of distribution in the hip joint capsule compartment (VJC) (liters) = 36.1.",Population Pharmacokinetic and Pharmacodynamic Target Attainment Analysis of Cefazolin in the Serum and Hip Joint Capsule of Patients Undergoing Total Hip Arthroplasty. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33526489/),l,36.1,221797,DB01327,Cefazolin
,650006,peak concentration,"The mean peak concentration in serum after intramuscular (im) injection of 1 g of cefamandole was 20 microgram/ml at 0.5 hr, whereas the level at 6 hr was 1 microgram/ml.",Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),[μg] / [ml],20,223075,DB01327,Cefazolin
,650006,peak concentration,"The mean peak concentration in serum after intramuscular (im) injection of 1 g of cefamandole was 20 microgram/ml at 0.5 hr, whereas the level at 6 hr was 1 microgram/ml.",Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),[μg] / [ml],1,223076,DB01327,Cefazolin
,650006,half-life (t1/2),The half-life (t1/2) of cefamandole after im injection ranged from 1 to 1.5 hr and from 0.45 to 1.2 hr after iv injection.,Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),h,1 to 1.5,223077,DB01327,Cefazolin
,650006,half-life (t1/2),The half-life (t1/2) of cefamandole after im injection ranged from 1 to 1.5 hr and from 0.45 to 1.2 hr after iv injection.,Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),h,0.45 to 1.2,223078,DB01327,Cefazolin
,650006,Rates of serum,Rates of serum and renal clearance of cefamandole ranged from 210 to 300 microliter/min per 1.73 m2.,Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),[μl] / [1.73·m2·min],210 to 300,223079,DB01327,Cefazolin
,650006,apparent volume of distribution,The apparent volume of distribution ranged from 12.4 to 17.9 liters/1.73 m2.,Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/650006/),[l] / [1.73·m2],12.4 to 17.9,223080,DB01327,Cefazolin
,1211920,Peak levels,"Peak levels of cefamandole ranged from 6.0 to 110 mug/ml in serum and levels ranged from 440 to 16,800 mug/ml in a 4- to 6-h collection of urine after a 500-mg or 1-g intramuscular dose (6.1 to 17.3 mg/kg) in patients with endogenous creatinine clearances of >/=31 ml/min.","In vitro activity and pharmacokinetics in patients of cefamandole, a new cephalsoporin antibiotic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1211920/),[μg] / [ml],6.0 to 110,223875,DB01327,Cefazolin
,1211920,Peak levels,"Peak levels of cefamandole ranged from 6.0 to 110 mug/ml in serum and levels ranged from 440 to 16,800 mug/ml in a 4- to 6-h collection of urine after a 500-mg or 1-g intramuscular dose (6.1 to 17.3 mg/kg) in patients with endogenous creatinine clearances of >/=31 ml/min.","In vitro activity and pharmacokinetics in patients of cefamandole, a new cephalsoporin antibiotic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1211920/),[μg] / [ml],"440 to 16,800",223876,DB01327,Cefazolin
,1211920,half-life,The half-life of cefamandole in serum was 49 to 126 min.,"In vitro activity and pharmacokinetics in patients of cefamandole, a new cephalsoporin antibiotic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1211920/),min,49 to 126,223877,DB01327,Cefazolin
,24827890,MIC,"Nine clinical isolates [five MSSA (cefazolin MIC range 0.5-2.0 mg/L), two Escherichia coli (cefazolin MICs 1.0 and 2.0 mg/L) and two Klebsiella pneumoniae (cefazolin MICs of 1.0 and 2.0 mg/L)] were evaluated with a starting inoculum (0 h) of 10(6) cfu/mL.",Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827890/),[mg] / [l],0.5-2.0,226675,DB01327,Cefazolin
,24827890,MICs,"Nine clinical isolates [five MSSA (cefazolin MIC range 0.5-2.0 mg/L), two Escherichia coli (cefazolin MICs 1.0 and 2.0 mg/L) and two Klebsiella pneumoniae (cefazolin MICs of 1.0 and 2.0 mg/L)] were evaluated with a starting inoculum (0 h) of 10(6) cfu/mL.",Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827890/),[mg] / [l],1.0,226676,DB01327,Cefazolin
,24827890,MICs,"Nine clinical isolates [five MSSA (cefazolin MIC range 0.5-2.0 mg/L), two Escherichia coli (cefazolin MICs 1.0 and 2.0 mg/L) and two Klebsiella pneumoniae (cefazolin MICs of 1.0 and 2.0 mg/L)] were evaluated with a starting inoculum (0 h) of 10(6) cfu/mL.",Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827890/),[mg] / [l],2.0,226677,DB01327,Cefazolin
,24827890,peak,"Cefazolin human simulated targets for peak, trough and half-life were 13.0 mg/L, 2.6 mg/L and 2.6 h, respectively.",Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827890/),[mg] / [l],13.0,226678,DB01327,Cefazolin
,24827890,trough,"Cefazolin human simulated targets for peak, trough and half-life were 13.0 mg/L, 2.6 mg/L and 2.6 h, respectively.",Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827890/),[mg] / [l],2.6,226679,DB01327,Cefazolin
,24827890,half-life,"Cefazolin human simulated targets for peak, trough and half-life were 13.0 mg/L, 2.6 mg/L and 2.6 h, respectively.",Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24827890/),h,2.6,226680,DB01327,Cefazolin
,6304364,maximum aqueous humor levels,"On the other hand, in case of 5 g SBPC or 2 g CEZ administration maximum aqueous humor levels were 12.5 micrograms/ml and 5.2 micrograms/ml respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),[μg] / [ml],12.5,231233,DB01327,Cefazolin
,6304364,maximum aqueous humor levels,"On the other hand, in case of 5 g SBPC or 2 g CEZ administration maximum aqueous humor levels were 12.5 micrograms/ml and 5.2 micrograms/ml respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),[μg] / [ml],5.2,231234,DB01327,Cefazolin
,6304364,Maximum aqueous humor levels,"Maximum aqueous humor levels of CFS, CTM, SBPC and CEZ were 2.9, 3.6, 11.4 micrograms/ml and 4.3 micrograms/ml and biological half life of gamma-phase were 2.57, 2.31, 2.77 hours and 2.24 hours respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),[μg] / [ml],2.9,231235,DB01327,Cefazolin
,6304364,Maximum aqueous humor levels,"Maximum aqueous humor levels of CFS, CTM, SBPC and CEZ were 2.9, 3.6, 11.4 micrograms/ml and 4.3 micrograms/ml and biological half life of gamma-phase were 2.57, 2.31, 2.77 hours and 2.24 hours respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),[μg] / [ml],3.6,231236,DB01327,Cefazolin
,6304364,Maximum aqueous humor levels,"Maximum aqueous humor levels of CFS, CTM, SBPC and CEZ were 2.9, 3.6, 11.4 micrograms/ml and 4.3 micrograms/ml and biological half life of gamma-phase were 2.57, 2.31, 2.77 hours and 2.24 hours respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),[μg] / [ml],11.4,231237,DB01327,Cefazolin
,6304364,Maximum aqueous humor levels,"Maximum aqueous humor levels of CFS, CTM, SBPC and CEZ were 2.9, 3.6, 11.4 micrograms/ml and 4.3 micrograms/ml and biological half life of gamma-phase were 2.57, 2.31, 2.77 hours and 2.24 hours respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),[μg] / [ml],4.3,231238,DB01327,Cefazolin
,6304364,biological half life of gamma-phase,"Maximum aqueous humor levels of CFS, CTM, SBPC and CEZ were 2.9, 3.6, 11.4 micrograms/ml and 4.3 micrograms/ml and biological half life of gamma-phase were 2.57, 2.31, 2.77 hours and 2.24 hours respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),h,2.57,231239,DB01327,Cefazolin
,6304364,biological half life of gamma-phase,"Maximum aqueous humor levels of CFS, CTM, SBPC and CEZ were 2.9, 3.6, 11.4 micrograms/ml and 4.3 micrograms/ml and biological half life of gamma-phase were 2.57, 2.31, 2.77 hours and 2.24 hours respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),h,2.31,231240,DB01327,Cefazolin
,6304364,biological half life of gamma-phase,"Maximum aqueous humor levels of CFS, CTM, SBPC and CEZ were 2.9, 3.6, 11.4 micrograms/ml and 4.3 micrograms/ml and biological half life of gamma-phase were 2.57, 2.31, 2.77 hours and 2.24 hours respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),h,2.77,231241,DB01327,Cefazolin
,6304364,biological half life of gamma-phase,"Maximum aqueous humor levels of CFS, CTM, SBPC and CEZ were 2.9, 3.6, 11.4 micrograms/ml and 4.3 micrograms/ml and biological half life of gamma-phase were 2.57, 2.31, 2.77 hours and 2.24 hours respectively.",[The studies on distributions of cefsulodin and cefotiam to human aqueous humor and cornea]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6304364/),h,2.24,231242,DB01327,Cefazolin
,15467657,resistance breakpoint,"Serum antimicrobial concentrations exceeded resistance breakpoint (32 microg/mL) in 73%, 68%, and 52% of BMI groups A, B, and C, respectively.",Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15467657/),[μg] / [ml],32,235194,DB01327,Cefazolin
,6654640,half-life,"The half-life values in the vitreous humor were: carbenicillin 10 hours, cefazolin 7 hours, and gentamicin 33 hours.","Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,10,240229,DB01327,Cefazolin
,6654640,half-life,"The half-life values in the vitreous humor were: carbenicillin 10 hours, cefazolin 7 hours, and gentamicin 33 hours.","Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,7,240230,DB01327,Cefazolin
,6654640,half-life,"The half-life values in the vitreous humor were: carbenicillin 10 hours, cefazolin 7 hours, and gentamicin 33 hours.","Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,33,240231,DB01327,Cefazolin
,6654640,half-life,Concomitant intraperitoneal administration of probenecid prolonged the vitreal half-life of carbenicillin to 20 hours and of cefazolin to 30 hours.,"Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,20,240232,DB01327,Cefazolin
,6654640,half-life,Concomitant intraperitoneal administration of probenecid prolonged the vitreal half-life of carbenicillin to 20 hours and of cefazolin to 30 hours.,"Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654640/),h,30,240233,DB01327,Cefazolin
,2287555,percentages of penetration,"The median percentages of penetration for soft tissue and bone at 5, 2, and 1 minute were 14.5% and 4.6%, 6.7% and 3.0%, and 5.9% and 4.6%, respectively.",The effect of tourniquet inflation on cefazolin tissue penetration during total knee arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287555/),%,14.5,241694,DB01327,Cefazolin
,2287555,percentages of penetration,"The median percentages of penetration for soft tissue and bone at 5, 2, and 1 minute were 14.5% and 4.6%, 6.7% and 3.0%, and 5.9% and 4.6%, respectively.",The effect of tourniquet inflation on cefazolin tissue penetration during total knee arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287555/),%,4.6,241695,DB01327,Cefazolin
,2287555,percentages of penetration,"The median percentages of penetration for soft tissue and bone at 5, 2, and 1 minute were 14.5% and 4.6%, 6.7% and 3.0%, and 5.9% and 4.6%, respectively.",The effect of tourniquet inflation on cefazolin tissue penetration during total knee arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287555/),%,6.7,241696,DB01327,Cefazolin
,2287555,percentages of penetration,"The median percentages of penetration for soft tissue and bone at 5, 2, and 1 minute were 14.5% and 4.6%, 6.7% and 3.0%, and 5.9% and 4.6%, respectively.",The effect of tourniquet inflation on cefazolin tissue penetration during total knee arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287555/),%,3.0,241697,DB01327,Cefazolin
,2287555,percentages of penetration,"The median percentages of penetration for soft tissue and bone at 5, 2, and 1 minute were 14.5% and 4.6%, 6.7% and 3.0%, and 5.9% and 4.6%, respectively.",The effect of tourniquet inflation on cefazolin tissue penetration during total knee arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2287555/),%,5.9,241698,DB01327,Cefazolin
,27520693,V d,"Since cefazolin is a water soluble antibiotic (V d = 0.2 L/Kg), penetration into adipose tissue is not V d not dose-dependent.",Optimal Cefazolin Prophylactic Dosing for Bariatric Surgery: No Need for Higher Doses or Intraoperative Redosing. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27520693/),[l] / [kg],0.2,243080,DB01327,Cefazolin
,27317707,concentrations,Skeletal muscle concentrations peaked at a median of 37.6 (IQR 26.8-40.0) µg ml(-1) within 30-60 min after the first cefazolin 30 mg kg(-1) dose.,Skeletal muscle and plasma concentrations of cefazolin during complex paediatric spinal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317707/),[μg] / [ml],37.6,244205,DB01327,Cefazolin
,27317707,peak concentrations,"For patients who received a second 30 mg kg(-1) dose, the peak concentrations reached a median of 40.5 (IQR 30.8-45.7) µg ml(-1) within 30-60 min.",Skeletal muscle and plasma concentrations of cefazolin during complex paediatric spinal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317707/),[μg] / [ml],40.5,244206,DB01327,Cefazolin
,10864588,half-lives,Cefazolin and tobramycin half-lives were markedly different on cycler than off cycler (cefazolin on cycler : 10.67 +/- 4.66 h; cefazolin off cycler : 23.09 +/- 5.6 h; P = 0.001; tobramycin on cycler : 14.27 +/- 4.53 h; tobramycin off cycler : 68. 5 +/- 26.47 h; P < 0.001).,Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864588/),h,10.67,246365,DB01327,Cefazolin
,10864588,half-lives,Cefazolin and tobramycin half-lives were markedly different on cycler than off cycler (cefazolin on cycler : 10.67 +/- 4.66 h; cefazolin off cycler : 23.09 +/- 5.6 h; P = 0.001; tobramycin on cycler : 14.27 +/- 4.53 h; tobramycin off cycler : 68. 5 +/- 26.47 h; P < 0.001).,Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864588/),h,23.09,246366,DB01327,Cefazolin
,10864588,half-lives,Cefazolin and tobramycin half-lives were markedly different on cycler than off cycler (cefazolin on cycler : 10.67 +/- 4.66 h; cefazolin off cycler : 23.09 +/- 5.6 h; P = 0.001; tobramycin on cycler : 14.27 +/- 4.53 h; tobramycin off cycler : 68. 5 +/- 26.47 h; P < 0.001).,Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864588/),h,14.27,246367,DB01327,Cefazolin
,10864588,half-lives,Cefazolin and tobramycin half-lives were markedly different on cycler than off cycler (cefazolin on cycler : 10.67 +/- 4.66 h; cefazolin off cycler : 23.09 +/- 5.6 h; P = 0.001; tobramycin on cycler : 14.27 +/- 4.53 h; tobramycin off cycler : 68. 5 +/- 26.47 h; P < 0.001).,Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864588/),h,68. 5,246368,DB01327,Cefazolin
,25941220,terminal elimination half-life,"The mean cefazolin terminal elimination half-life, clearance, and area under the concentration-time curve from time zero to infinity in this population were 1.95 h, 0.804 ml/min/kg, and 607 mg · h/liter, respectively.",Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25941220/),h,1.95,249321,DB01327,Cefazolin
,25941220,clearance,"The mean cefazolin terminal elimination half-life, clearance, and area under the concentration-time curve from time zero to infinity in this population were 1.95 h, 0.804 ml/min/kg, and 607 mg · h/liter, respectively.",Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25941220/),[ml] / [kg·min],0.804,249322,DB01327,Cefazolin
,25941220,area under the concentration-time curve from time zero to infinity,"The mean cefazolin terminal elimination half-life, clearance, and area under the concentration-time curve from time zero to infinity in this population were 1.95 h, 0.804 ml/min/kg, and 607 mg · h/liter, respectively.",Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25941220/),[h·mg] / [l],607,249323,DB01327,Cefazolin
,598929,microbiologically active concentration,"The mean microbiologically active concentration of cefazolin in serum five minutes after discontinuing the infusion was 410 microgram/ml, after 60 minutes 190 microgram/ml and after 8 hours 8.5 microgram/ml.",[Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598929/),[μg] / [ml],410,252678,DB01327,Cefazolin
,598929,microbiologically active concentration,"The mean microbiologically active concentration of cefazolin in serum five minutes after discontinuing the infusion was 410 microgram/ml, after 60 minutes 190 microgram/ml and after 8 hours 8.5 microgram/ml.",[Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598929/),[μg] / [ml],190,252679,DB01327,Cefazolin
,598929,microbiologically active concentration,"The mean microbiologically active concentration of cefazolin in serum five minutes after discontinuing the infusion was 410 microgram/ml, after 60 minutes 190 microgram/ml and after 8 hours 8.5 microgram/ml.",[Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598929/),[μg] / [ml],8.5,252680,DB01327,Cefazolin
,598929,serum half-life,"The mean serum half-life was 87.38 minutes in the one compartment model, and the volume of distribution 9.20 1.",[Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598929/),min,87.38,252681,DB01327,Cefazolin
,598929,volume of distribution,"The mean serum half-life was 87.38 minutes in the one compartment model, and the volume of distribution 9.20 1.",[Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598929/),1,9.20,252682,DB01327,Cefazolin
,598929,area under the curve,The area under the curve was 44626.15 microgram.min.ml-1.,[Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin (author's transl)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598929/),[min·μg] / [ml],44626.15,252683,DB01327,Cefazolin
,598929,clearance,The mean value for the clearance was 73.5 ml/min.,[Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598929/),[ml] / [min],73.5,252684,DB01327,Cefazolin
,24492261,MIC,Monte Carlo simulations were performed aiming for unbound concentrations above an MIC of 8 mg/L (>60% of the time) in all patients.,Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492261/),[mg] / [l],8,253028,DB01327,Cefazolin
,24492261,maximum protein binding (Bmax),A one-compartment pharmacokinetic model was developed in which total and unbound concentrations were linked by maximum protein binding (Bmax) of 136 mg/L and a dissociation constant (KD) for cefazolin protein binding of 46.5 mg/L.,Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492261/),[mg] / [l],136,253029,DB01327,Cefazolin
,24492261,dissociation constant (KD),A one-compartment pharmacokinetic model was developed in which total and unbound concentrations were linked by maximum protein binding (Bmax) of 136 mg/L and a dissociation constant (KD) for cefazolin protein binding of 46.5 mg/L.,Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492261/),[mg] / [l],46.5,253030,DB01327,Cefazolin
,15490984,serum half-life,"The pharmacokinetic parameters determined for ciprofloxacin were (mean +/- SEM) serum half-life 10.1 +/- 1.2 hours, maximum serum concentration 2.7 +/- 0.5 mg/L, time to maximum serum concentration 1.6 +/- 0.1 hours after the first dose, and peritoneal clearance 1.2% +/- 0.1% of the mean calculated total body clearance.",Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490984/),h,10.1,253668,DB01327,Cefazolin
,15490984,maximum serum concentration,"The pharmacokinetic parameters determined for ciprofloxacin were (mean +/- SEM) serum half-life 10.1 +/- 1.2 hours, maximum serum concentration 2.7 +/- 0.5 mg/L, time to maximum serum concentration 1.6 +/- 0.1 hours after the first dose, and peritoneal clearance 1.2% +/- 0.1% of the mean calculated total body clearance.",Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490984/),[mg] / [l],2.7,253669,DB01327,Cefazolin
,15490984,time to maximum serum concentration,"The pharmacokinetic parameters determined for ciprofloxacin were (mean +/- SEM) serum half-life 10.1 +/- 1.2 hours, maximum serum concentration 2.7 +/- 0.5 mg/L, time to maximum serum concentration 1.6 +/- 0.1 hours after the first dose, and peritoneal clearance 1.2% +/- 0.1% of the mean calculated total body clearance.",Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490984/),h,1.6,253670,DB01327,Cefazolin
>,15490984,serum area under the concentration-time curve:MIC,"While all patients achieved serum area under the concentration-time curve:MIC > 125 for Escherichia coli and Klebsiella species after the first dose, only 2 patients achieved this goal for Pseudomonas aeruginosa.",Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15490984/),,125,253671,DB01327,Cefazolin
,24041887,free area under the curve from 0 to 8 h (fAUC0-8),"The free area under the curve from 0 to 8 h (fAUC0-8) values for serum and wound were 48.0 ± 18.66 and 56.35 ± 41.17 μg · h/ml, respectively, for the patients receiving 1 g every 8 h.",Tissue pharmacokinetics of cefazolin in patients with lower limb infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041887/),[h·μg] / [ml],48.0,259026,DB01327,Cefazolin
,24041887,free area under the curve from 0 to 8 h (fAUC0-8),"The free area under the curve from 0 to 8 h (fAUC0-8) values for serum and wound were 48.0 ± 18.66 and 56.35 ± 41.17 μg · h/ml, respectively, for the patients receiving 1 g every 8 h.",Tissue pharmacokinetics of cefazolin in patients with lower limb infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041887/),[h·μg] / [ml],56.35,259027,DB01327,Cefazolin
,24041887,fAUC0-24,"The fAUC0-24 values for serum and wound were 1,326.1 and 253.9 μg · h/ml, respectively, for the single patient receiving 2 g every 24 h.",Tissue pharmacokinetics of cefazolin in patients with lower limb infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041887/),[h·μg] / [ml],"1,326.1",259028,DB01327,Cefazolin
,24041887,fAUC0-24,"The fAUC0-24 values for serum and wound were 1,326.1 and 253.9 μg · h/ml, respectively, for the single patient receiving 2 g every 24 h.",Tissue pharmacokinetics of cefazolin in patients with lower limb infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041887/),[h·μg] / [ml],253.9,259029,DB01327,Cefazolin
,24041887,tissue penetration ratio (tissue/serum fAUC ratio),The mean tissue penetration ratio (tissue/serum fAUC ratio) was 1.06.,Tissue pharmacokinetics of cefazolin in patients with lower limb infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041887/),,1.06,259030,DB01327,Cefazolin
,25947397,MICs,The MICs were between 0.25 and 1 mg/L.,A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25947397/),[mg] / [l],0.25 and 1,259870,DB01327,Cefazolin
,25947397,C max,The main PK parameters were C max 175.22 ± 36.28 mg/L; T½ 1.52 ± 0.23 h; AUC (0-∞) 280.51 ± 68.17 mg·L -1·h -1 ; CL 7.37 ± 1.84 L/h; Vd 16.06 ± 4.42 L.,A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25947397/),[mg] / [l],175.22,259871,DB01327,Cefazolin
,25947397,T½,The main PK parameters were C max 175.22 ± 36.28 mg/L; T½ 1.52 ± 0.23 h; AUC (0-∞) 280.51 ± 68.17 mg·L -1·h -1 ; CL 7.37 ± 1.84 L/h; Vd 16.06 ± 4.42 L.,A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25947397/),h,1.52,259872,DB01327,Cefazolin
,25947397,AUC (0-∞),The main PK parameters were C max 175.22 ± 36.28 mg/L; T½ 1.52 ± 0.23 h; AUC (0-∞) 280.51 ± 68.17 mg·L -1·h -1 ; CL 7.37 ± 1.84 L/h; Vd 16.06 ± 4.42 L.,A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25947397/),-1·-1·h·l·mg,280.51,259873,DB01327,Cefazolin
,25947397,CL,The main PK parameters were C max 175.22 ± 36.28 mg/L; T½ 1.52 ± 0.23 h; AUC (0-∞) 280.51 ± 68.17 mg·L -1·h -1 ; CL 7.37 ± 1.84 L/h; Vd 16.06 ± 4.42 L.,A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25947397/),[l] / [h],7.37,259874,DB01327,Cefazolin
,25947397,Vd,The main PK parameters were C max 175.22 ± 36.28 mg/L; T½ 1.52 ± 0.23 h; AUC (0-∞) 280.51 ± 68.17 mg·L -1·h -1 ; CL 7.37 ± 1.84 L/h; Vd 16.06 ± 4.42 L.,A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25947397/),l,16.06,259875,DB01327,Cefazolin
,25947397,ƒT > MIC,The average ƒT > MIC was 55.45 ± 8.12%.,A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25947397/),%,55.45,259876,DB01327,Cefazolin
,21499760,clearance,Cefazolin clearance was 4.2 ± 1.0 L h(-1) (mean ± standard deviation) and showed a negative correlation with age (p = 0.003) but not with bodyweight measures (p > 0.05).,Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499760/),[l] / [h],4.2,261362,DB01327,Cefazolin
,21499760,Volume of distribution,Volume of distribution was 13.0 ± 3.1 L and correlated positively with bodyweight measures (p ≤ 0.001).,Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499760/),l,13.0,261363,DB01327,Cefazolin
,21499760,protein binding,"Saturable protein binding was observed with a median protein binding of 79% (interquartile range 74-82), which proved similar to reported protein binding in non-obese patients.",Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499760/),%,79,261364,DB01327,Cefazolin
above,21499760,minimal inhibitory concentration for 90% (MIC(90)),"In all patients, unbound cefazolin concentrations remained above 1 mg L(-1) (minimal inhibitory concentration for 90% (MIC(90)) of methicillin-sensitive isolates of Staphylococcus aureus in Europe) until 4 h post-dosing.",Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499760/),[mg] / [l],1,261365,DB01327,Cefazolin
above,21499760,unbound plasma cefazolin concentrations,"However, as in all patients with bodyweights up to 260 kg, unbound plasma cefazolin concentrations remained above 1 mg L(-1) until 4 h after the intravenous administration of a 2-g dose.",Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21499760/),[mg] / [l],1,261366,DB01327,Cefazolin
>,33211137,minimum inhibitory concentrations (MICs),The simulation studies suggested that the current dosing protocols are insufficient for attaining PTA > 0.9 throughout surgery against pathogens with minimum inhibitory concentrations (MICs) >8 mg/L.,"Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33211137/),[mg] / [l],8,262946,DB01327,Cefazolin
>,33211137,PTA,A new dosing protocol that achieves a PTA > 0.9 for pathogens with a MIC of 16 mg/L was proposed.,"Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33211137/),,0,262947,DB01327,Cefazolin
,33211137,MIC,A new dosing protocol that achieves a PTA > 0.9 for pathogens with a MIC of 16 mg/L was proposed.,"Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33211137/),[mg] / [l],16,262948,DB01327,Cefazolin
,8911256,volume of distribution,"The volume of distribution of cefazolin was normal (ie, 12.5 L), while the volume of distribution of gentamicin was 5-fold greater than expected.",Does intraoperative blood loss affect antibiotic serum and tissue concentrations? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911256/),l,12.5,264621,DB01327,Cefazolin
less,3464778,peak MIC,"The peak MIC of MK-0787 was less than or equal to 0.024 micrograms/ml against S. aureus, which were sensitive or resistant to CEZ, 0.10 micrograms/ml against E. coli, P. mirabilis, or K. pneumoniae, 0.39 micrograms/ml against S. marcescens and 1.56 micrograms/ml against P. aeruginosa.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],0.024,268583,DB01327,Cefazolin
,3464778,peak MIC,"The peak MIC of MK-0787 was less than or equal to 0.024 micrograms/ml against S. aureus, which were sensitive or resistant to CEZ, 0.10 micrograms/ml against E. coli, P. mirabilis, or K. pneumoniae, 0.39 micrograms/ml against S. marcescens and 1.56 micrograms/ml against P. aeruginosa.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],0.10,268584,DB01327,Cefazolin
,3464778,peak MIC,"The peak MIC of MK-0787 was less than or equal to 0.024 micrograms/ml against S. aureus, which were sensitive or resistant to CEZ, 0.10 micrograms/ml against E. coli, P. mirabilis, or K. pneumoniae, 0.39 micrograms/ml against S. marcescens and 1.56 micrograms/ml against P. aeruginosa.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],0.39,268585,DB01327,Cefazolin
,3464778,peak MIC,"The peak MIC of MK-0787 was less than or equal to 0.024 micrograms/ml against S. aureus, which were sensitive or resistant to CEZ, 0.10 micrograms/ml against E. coli, P. mirabilis, or K. pneumoniae, 0.39 micrograms/ml against S. marcescens and 1.56 micrograms/ml against P. aeruginosa.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],1.56,268586,DB01327,Cefazolin
,3464778,Maximum serum levels,"Maximum serum levels of MK-0787, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg were 41.6 micrograms/ml and 72.9 micrograms/ml, respectively, at the end of infusion and 0.1 micrograms/ml at 6 hours, respectively, after drip infusion.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],41.6,268587,DB01327,Cefazolin
,3464778,Maximum serum levels,"Maximum serum levels of MK-0787, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg were 41.6 micrograms/ml and 72.9 micrograms/ml, respectively, at the end of infusion and 0.1 micrograms/ml at 6 hours, respectively, after drip infusion.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],72.9,268588,DB01327,Cefazolin
,3464778,Maximum serum levels,"Maximum serum levels of MK-0787, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg were 41.6 micrograms/ml and 72.9 micrograms/ml, respectively, at the end of infusion and 0.1 micrograms/ml at 6 hours, respectively, after drip infusion.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],0.1,268589,DB01327,Cefazolin
,3464778,half-life,The half-life of both dose levels was 0.9 hour.,[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),h,0.9,268590,DB01327,Cefazolin
,3464778,peak serum levels,"Mean peak serum levels of MK-0791, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 49.7 micrograms/ml and 87.0 micrograms/ml, respectively, with half-life of 1.1 and 0.6 hour, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],49.7,268591,DB01327,Cefazolin
,3464778,peak serum levels,"Mean peak serum levels of MK-0791, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 49.7 micrograms/ml and 87.0 micrograms/ml, respectively, with half-life of 1.1 and 0.6 hour, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),[μg] / [ml],87.0,268592,DB01327,Cefazolin
,3464778,half-life,"Mean peak serum levels of MK-0791, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 49.7 micrograms/ml and 87.0 micrograms/ml, respectively, with half-life of 1.1 and 0.6 hour, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),h,1.1,268593,DB01327,Cefazolin
,3464778,half-life,"Mean peak serum levels of MK-0791, at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 49.7 micrograms/ml and 87.0 micrograms/ml, respectively, with half-life of 1.1 and 0.6 hour, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),h,0.6,268594,DB01327,Cefazolin
,3464778,Urinary recovery rates,"Urinary recovery rates of MK-0787 for 6 hours at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 47.8-82.7% and 25.5-78.0%, respectively, and of MK-0791 for 6 hours were 51.7-93.4% and 40.3-94.4%, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),%,47.8-82.7,268595,DB01327,Cefazolin
,3464778,Urinary recovery rates,"Urinary recovery rates of MK-0787 for 6 hours at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 47.8-82.7% and 25.5-78.0%, respectively, and of MK-0791 for 6 hours were 51.7-93.4% and 40.3-94.4%, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),%,25.5-78.0,268596,DB01327,Cefazolin
,3464778,Urinary recovery rates,"Urinary recovery rates of MK-0787 for 6 hours at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 47.8-82.7% and 25.5-78.0%, respectively, and of MK-0791 for 6 hours were 51.7-93.4% and 40.3-94.4%, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),%,51.7-93.4,268597,DB01327,Cefazolin
,3464778,Urinary recovery rates,"Urinary recovery rates of MK-0787 for 6 hours at dose levels of 10 mg/10 mg/kg and 20 mg/20 mg/kg, were 47.8-82.7% and 25.5-78.0%, respectively, and of MK-0791 for 6 hours were 51.7-93.4% and 40.3-94.4%, respectively.",[Fundamental and clinical studies on imipenem/cilastatin sodium in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3464778/),%,40.3-94.4,268598,DB01327,Cefazolin
,3613097,T 1/2,Median T 1/2 was 0.96 hour.,[Studies on cefuzoname in the field of pediatrics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3613097/),h,0.96,271720,DB01327,Cefazolin
,3613097,CSF,"In the case of pneumonia the CSF concentration of CZON was 0.272 microgram/ml after 45 minutes, in the case of meningitis they were 0.155 microgram/ml after 5 hours.",[Studies on cefuzoname in the field of pediatrics]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3613097/),[μg] / [ml],0.272,271721,DB01327,Cefazolin
,3613097,CSF,"In the case of pneumonia the CSF concentration of CZON was 0.272 microgram/ml after 45 minutes, in the case of meningitis they were 0.155 microgram/ml after 5 hours.",[Studies on cefuzoname in the field of pediatrics]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3613097/),[μg] / [ml],0.155,271722,DB01327,Cefazolin
,3613097,concentration,"In the case of pneumonia the CSF concentration of CZON was 0.272 microgram/ml after 45 minutes, in the case of meningitis they were 0.155 microgram/ml after 5 hours.",[Studies on cefuzoname in the field of pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3613097/),[μg] / [ml],0.272,271723,DB01327,Cefazolin
,3613097,concentration,"In the case of pneumonia the CSF concentration of CZON was 0.272 microgram/ml after 45 minutes, in the case of meningitis they were 0.155 microgram/ml after 5 hours.",[Studies on cefuzoname in the field of pediatrics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3613097/),[μg] / [ml],0.155,271724,DB01327,Cefazolin
,3613097,MIC,Both of these values were higher than MIC of 0.025 microgram/ml against Haemophilus influenzae which was isolated from a case of bacterial meningitis.,[Studies on cefuzoname in the field of pediatrics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3613097/),[μg] / [ml],0.025,271725,DB01327,Cefazolin
,6357074,maximum drug concentration,"The mean (+/- standard deviation) maximum drug concentration in serum at the end of the 20-min infusion (day 1) was 185.5 +/- 28.5 micrograms/ml, decreasing to 0.8 +/- 0.4 microgram/ml after 12 h.",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),[μg] / [ml],185.5,271925,DB01327,Cefazolin
,6357074,maximum drug concentration,"The mean (+/- standard deviation) maximum drug concentration in serum at the end of the 20-min infusion (day 1) was 185.5 +/- 28.5 micrograms/ml, decreasing to 0.8 +/- 0.4 microgram/ml after 12 h.",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),[μg] / [ml],0.8,271926,DB01327,Cefazolin
,6357074,recovery of drug in urine,The mean recovery of drug in urine at 12 h was 71.5 +/- 12.2%.,Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),%,71.5,271927,DB01327,Cefazolin
,6357074,elimination half-life,"Pharmacokinetic parameters calculated on the basis of a two-compartment model were as follows: elimination half-life, 110.5 +/- 15.2 min; volume of distribution at steady state, 21.2 +/- 2.6 liters/100 kg; volume of distribution by the area method, 26.2 +/- 4.0 liters/100 kg; area under the serum concentration-time curve, 293.3 +/- 47.8 micrograms X h/ml; total body clearance, 116.4 +/- 20.3 ml/min per 70 kg; renal clearance, 82.2 +/- 15.1 ml/min per 70 kg.",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),min,110.5,271928,DB01327,Cefazolin
,6357074,volume of distribution at steady state,"Pharmacokinetic parameters calculated on the basis of a two-compartment model were as follows: elimination half-life, 110.5 +/- 15.2 min; volume of distribution at steady state, 21.2 +/- 2.6 liters/100 kg; volume of distribution by the area method, 26.2 +/- 4.0 liters/100 kg; area under the serum concentration-time curve, 293.3 +/- 47.8 micrograms X h/ml; total body clearance, 116.4 +/- 20.3 ml/min per 70 kg; renal clearance, 82.2 +/- 15.1 ml/min per 70 kg.",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),[l] / [100·kg],21.2,271929,DB01327,Cefazolin
,6357074,volume of distribution by the area method,"Pharmacokinetic parameters calculated on the basis of a two-compartment model were as follows: elimination half-life, 110.5 +/- 15.2 min; volume of distribution at steady state, 21.2 +/- 2.6 liters/100 kg; volume of distribution by the area method, 26.2 +/- 4.0 liters/100 kg; area under the serum concentration-time curve, 293.3 +/- 47.8 micrograms X h/ml; total body clearance, 116.4 +/- 20.3 ml/min per 70 kg; renal clearance, 82.2 +/- 15.1 ml/min per 70 kg.",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),[l] / [100·kg],26.2,271930,DB01327,Cefazolin
,6357074,area under the serum concentration-time curve,"Pharmacokinetic parameters calculated on the basis of a two-compartment model were as follows: elimination half-life, 110.5 +/- 15.2 min; volume of distribution at steady state, 21.2 +/- 2.6 liters/100 kg; volume of distribution by the area method, 26.2 +/- 4.0 liters/100 kg; area under the serum concentration-time curve, 293.3 +/- 47.8 micrograms X h/ml; total body clearance, 116.4 +/- 20.3 ml/min per 70 kg; renal clearance, 82.2 +/- 15.1 ml/min per 70 kg.",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),[h·μg] / [ml],293.3,271931,DB01327,Cefazolin
,6357074,total body clearance,"Pharmacokinetic parameters calculated on the basis of a two-compartment model were as follows: elimination half-life, 110.5 +/- 15.2 min; volume of distribution at steady state, 21.2 +/- 2.6 liters/100 kg; volume of distribution by the area method, 26.2 +/- 4.0 liters/100 kg; area under the serum concentration-time curve, 293.3 +/- 47.8 micrograms X h/ml; total body clearance, 116.4 +/- 20.3 ml/min per 70 kg; renal clearance, 82.2 +/- 15.1 ml/min per 70 kg.",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),[ml] / [70·kg·min],116.4,271932,DB01327,Cefazolin
,6357074,renal clearance,"Pharmacokinetic parameters calculated on the basis of a two-compartment model were as follows: elimination half-life, 110.5 +/- 15.2 min; volume of distribution at steady state, 21.2 +/- 2.6 liters/100 kg; volume of distribution by the area method, 26.2 +/- 4.0 liters/100 kg; area under the serum concentration-time curve, 293.3 +/- 47.8 micrograms X h/ml; total body clearance, 116.4 +/- 20.3 ml/min per 70 kg; renal clearance, 82.2 +/- 15.1 ml/min per 70 kg.",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),[ml] / [70·kg·min],82.2,271933,DB01327,Cefazolin
,6357074,maximum drug levels,"Mean maximum drug levels in serum were 185.5 to 214.5 micrograms/ml, and mean trough levels were 0.8 to 1.1 micrograms/ml (days 1 to 8).",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),[μg] / [ml],185.5 to 214.5,271934,DB01327,Cefazolin
,6357074,trough levels,"Mean maximum drug levels in serum were 185.5 to 214.5 micrograms/ml, and mean trough levels were 0.8 to 1.1 micrograms/ml (days 1 to 8).",Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6357074/),[μg] / [ml],0.8 to 1.1,271935,DB01327,Cefazolin
,24214905,penetration ratio (fAUC(tissue)/fAUC(plasma)),The unbound (free) cefazolin ISF penetration ratio (fAUC(tissue)/fAUC(plasma)) was 0.70 (range 0.68-0.83) in morbidly obese patients versus 1.02 (range 0.85-1.41) in non-obese patients (P < 0.05).,Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24214905/),,0.70,273479,DB01327,Cefazolin
,24214905,penetration ratio (fAUC(tissue)/fAUC(plasma)),The unbound (free) cefazolin ISF penetration ratio (fAUC(tissue)/fAUC(plasma)) was 0.70 (range 0.68-0.83) in morbidly obese patients versus 1.02 (range 0.85-1.41) in non-obese patients (P < 0.05).,Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24214905/),,1.02,273480,DB01327,Cefazolin
,24214905,MIC,Monte Carlo simulations showed reduced probability of target attainment for morbidly obese versus non-obese patients for MIC values of 2 and 4 mg/L.,Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24214905/),[mg] / [l],2,273481,DB01327,Cefazolin
,24214905,MIC,Monte Carlo simulations showed reduced probability of target attainment for morbidly obese versus non-obese patients for MIC values of 2 and 4 mg/L.,Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24214905/),[mg] / [l],4,273482,DB01327,Cefazolin
,6214989,peak serum level,"After a 1,000-mg intramuscular injection of moxalactam, a mean peak serum level of 49 +/- 10 micrograms/ml was achieved at 30 to 60 min which was equivalent to the level achieved with 0.5 g of cefazolin.",Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6214989/),[μg] / [ml],49,273867,DB01327,Cefazolin
,6214989,half-life,The half-life of moxalactam was 2.3 h.,Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6214989/),h,2.3,273868,DB01327,Cefazolin
,6214989,half-life,"The half-life of moxalactam was 2.3 h, similar to that of cefazolin.",Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6214989/),h,2.3,273869,DB01327,Cefazolin
,6214989,Urinary recovery,"Urinary recovery of the drug was 76% after intramuscular injection and 74% after intravenous infusion, with the majority of the drug having been excreted in the first 4 h after administration.",Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6214989/),%,76,273870,DB01327,Cefazolin
,6214989,Urinary recovery,"Urinary recovery of the drug was 76% after intramuscular injection and 74% after intravenous infusion, with the majority of the drug having been excreted in the first 4 h after administration.",Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6214989/),%,74,273871,DB01327,Cefazolin
,6214989,Urinary recovery,Urinary recovery of cefazolin was 85%.,Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6214989/),%,85,273872,DB01327,Cefazolin
